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The incidence of allergic diseases such as asthma, allergic rhinitis, atopic dermatitis 
and hayfever is increasing over the past few decades. Current treatments for these 
diseases still mainly provided symptomatic relief. Allergen gene immunization and 
cytokine gene immunization are novel approaches that have been explored as 
alternative treatments for allergic diseases. Studies carried out using murine models 
have shown that allergen gene immunization approach is very effective for anti-
allergic reactions; however the major drawback of this approach in human clinical 
trials is its low immunogenicity. 
 
The first part of the study aimed at enhancing and evaluating the immunogenicity and 
efficacy of DNA vaccines by the incorporation of additional human CpG motifs (D 
and K type, designated as DTKT) into the pVAX plasmid backbone. cDNA encoding 
for a major allergen from the Blomia tropicalis mite, Blo t 5, was cloned into the 
pVAX vector. CpG-modified and unmodified DNA constructs were designated as 
pVAXBlot5-DTKT and pVAXBlot5 respectively. Blo t 5 was used as the model 
allergen in this study and the immunogenicity of DNA constructs was evaluated in the 
Blo t 5-induced murine allergy model. The modified pVAXBlot5-DTKT elicited a 
higher level of Blo t 5-specific IFN-γ when compared to pVAXBlot5. Both 
pVAXBlot5-DTKT and pVAXBlot5 attenuated Blo t 5-specific IgE, in addition 
pVAXBlot5-DTKT elicited higher levels of IgG2c than pVAXBlot5. In addition, 
allergen gene vaccination also suppressed Blo t 5 specific IFN-γ, IL-17, IL-5, IL-13 
and IL-6 induced by intraperitoneal immunization with rBlo t 5 protein adjuvanted 
with aluminium hydroxide. In vitro evaluation of plasmid constructs was carried out 
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using human peripheral blood mononuclear cells (PBMCs). Co-culture of PBMCs 
with plasmid DNA revealed that pVAXBlot5-DTKT elicited higher levels of pro-
inflammatory cytokines and chemokines such as IL-6, MIP-1α and MIP-1β when 
compared to pVAXBlot5 and DTKT oligonucleotides stimulation. In addition, 
pVAXBlot5-DTKT induced up-regulation of the release of chemotactic chemokines 
and mediators for the inflammatory response such as PDGF-AA, GRO-α, NT-4, 
osteoprotegerin, VEGF-D, GM-CSF, IL-1β, MCP-1 and ENA-78 from PBMC when 
compared to pVAXBlot5 at an early time point. In vivo evaluation of the various 
plasmids in rhesus macaques showed that monkeys immunized with both pVAXBlot5 
and pVAXBlot5-DTKT showed suppression in Blo t 5-specific IgE when compared 
to monkeys immunized with the pVAX control. In addition, monkeys immunized 
with pVAXBlot5-DTKT also produced higher levels of Blo t 5-specific IgG when 
compared to those immunized with pVAXBlot5. Furthermore, the frequencies of IFN-
γ producing cells in response to stimulation with Blo t 5 peptide pools were higher 
from monkeys immunized with pVAXBlot5-DTKT as compared to those immunized 
with pVAXBlot5 in the ELISPOT assay. 
 
The second part of the thesis aimed to explore the use of the IL-35 encoding gene 
immunization approach for the treatment of allergic diseases. IL-35 is a novel 
cytokine that is produced by Foxp3+ regulatory T cells and has been reported to have 
suppressive functions. However the therapeutic role of IL-35 in Th2 mediated allergic 
diseases has not been evaluated. Hence in this study, cDNA encoding a single chain 
IL-35 was cloned into the pVAX vector, designated as pVAX-IL-35, and the 
suppressive effect of IL-35 was evaluated in two murine models. Firstly, the 
effectiveness of pVAX-IL-35 was evaluated in the eosinophilic lung inflammation 
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model induced by a Blo t 5-specific Th2 cell line. Intra-tracheal administration of 
pVAX-IL-35 was found to be able to attenuate the Blo t 5-specific Th2 cell line 
induced total cellular infiltration as well as eosinophil, lymphocyte and neutrophil 
counts in the bronchial alveolar lavage fluids (BALF). In addition, Th2 cytokines IL-4, 
IL-5 and IL-13 as well as chemotactic chemokines CCL2/MCP-1, CXCL1/KC, 
CXCL5/LIX, CXCL9/MIG and CXCL10/IP-10 were significantly attenuated in the 
BALF from the experimental group of mice received pVAX-IL-35 as compared to 
that from the control pVAX group. Systemic administration of pVAX-IL-35 via the 
intramuscular injection elicited a long-term suppression of Blo t 5-specific humoral 
responses in mice upon intranasal Blo t 5 instillation. Mice received pVAX-IL-35 
injection produced lower titres of Blo t 5-specific IgE and persistently suppressed Blo 
t 5-specific IgE and IgG1 production. The long-term suppression by the pVAX-IL-35 
injection was also found on the production of total serum IgE in mice which received 
the Blo t 5 specific Th2 cell transfer and intranasal Blo t 5 challenges. In contrast, 
there was no difference in the total serum IgM, IgA, IgG1 and IgG2c between mice 
that received pVAX or pVAX-IL-35. These results indicated that systemic 
administration of IL-35 by the DNA immunization did not exert a pan 
immunosuppressive effect on B cells. 
 
Secondly, the effectiveness of pVAX-IL-35 was evaluated in a neutrophilic lung 
inflammation model induced in Blo t 5-specific T cell receptor (TCR) transgenic mice 
upon intranasal Blo t 5 sensitization. Intra-tracheal administration of pVAX-IL-35 
was also found to effectively reduce total cellular infiltration as well as neutrophil and 
lymphocyte infiltration in Blo t 5-specfic TCR transgenic mice upon intranasal Blo t 5 
instillation. In addition, pro-inflammatory cytokines and chemotactic chemokines 
XIII 
 
such as IFN-γ, IL-1α, IL-6, IL-17, GCSF, LIF, MIP-1α/CCL3, MIP-1β/CCL4, 
RANTES/CCL5, CXCL1/KC, CXCL9/MIG and CXCL10/IP-10 were significantly 
attenuated in the BALF from mice in the experimental pVAX-IL-35 group as 
compared to that from the control pVAX group. These data showed that IL-35 could 
be a promising therapeutic tool against allergic and neutrophilic airway inflammation. 
Taken together, the new findings from this thesis will make valuable contributions to 
the development of efficacious approaches in allergen gene as well as cytokine gene 
deliveries for the control of allergic diseases. 
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Chapter 1 .Literature Review 
 
1.1 Allergic airway inflammation 
1.1.1 Epidemiology, prevalence and risk factors 
The incidence of allergic diseases such as asthma, allergic rhinitis, atopic dermatitis 
and hayfever had increased over the past few years. Population based studies reported 
the variation in the prevalence of allergic diseases in Asia and rising prevalence of 
allergic diseases mainly occurred in low and mid-income countries (Bjorksten et al., 
2008; Pearce et al., 2007). The major risk factor for asthma and allergic rhinitis was 
allergic sensitization and it had been estimated that about 300 million people 
worldwide suffer from asthma (Pawankar et al., 2009). Other risk factors for allergic 
asthma included environmental, occupational and genetic factors. In atopic 
individuals, inappropriate immune responses were mounted against otherwise 
harmless antigens. Although there were differences in the aeroallergens that triggered 
allergy and asthma in various areas of Asia Pacific, the important source of allergens 
in Asia was from house dust mites followed by pollens, insects, molds and fungi 
(Daengsuwan et al., 2003). It was estimated that about 10% of the general population 
and 90% of asthmatic people developed sensitivity to house dust mites (Chew et al., 
1999a). 
 
1.1.2 House dust mites 
The main allergenic components from household dust were house dust mites and 
these mites were complex organisms that secreted a variety of different proteins and 
other macromolecules. In the temperate regions, Dermatophagoides pteronyssinus 
and Dermatophagoides farinae were the predominant species while in the tropics 
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Dermatophagoides pteronyssinus and Blomia tropicalis were the major allergen 
sources (Fernandez-Caldas, 1997; van Hage-Hamsten, 1995). Highly diverse 
allergens had been identified from dust mites with more than 20 groups of allergens 
been characterized, out of which group 1, 2, 3, 9, 11, 14 and 15 allergens had been 
reported to have strong IgE binding (Thomas et al., 2002). The group 1 and 2 
allergens constituted the greatest proportion of allergenicities in Dermatophagoides 
pteronyssinus (Der p) and Dermatophagoides farinae, besides that they also 
constituted the major allergens in dustmite extracts (Chapman and Platts-Mills, 1980; 
Custovic et al., 1996; Lind and Lowenstein, 1983; Platts-Mills and Chapman, 1987). 
 
Blomia tropicalis group 5 allergen (Blo t 5) was the first major allergen from the 
Blomia tropicalis group and was cloned and expressed as a fusion protein with 
glutathione-S-transferase (Arruda et al., 1997; Caraballo et al., 1996). The 14 kDa Blo 
t 5 was a very important allergen among the eight allergens evaluated in Blomia 
tropicalis, Blo t 1, Blo t 2, Blo t 3, Blo t 5, Blo t 10, Blo t 11, Blo t 12 and Blo t 13, as 
it had IgE reactivity of up to 70% in allergic subjects as reflected by skin prick tests 
and in vitro IgE binding assays. In addition, 40-60% of individuals allergic to Blomia. 
tropicalis have Blo t 5 specific IgE (Tsai et al., 2003). Despite sharing a 43% identity 
in their amino acid sequences, Blo t 5 had been demonstrated via in vitro and in vivo 
assays to exhibit low levels of IgE cross-reactivity with its homologue, Der p 5 (Chew 
et al., 1999b; Kuo et al., 2003; Simpson et al., 2003). Blo t 5 consisted of a 17-
residues signal peptide and a 117-residues mature protein in comparison to the 
homologous Der p 5 that contained a 19-residues signal peptide and a 113-residues 
mature protein (Arruda et al., 1997; Liaw et al., 2001). The nuclear magnetic 
resonance structure and IgE epitopes of Blo t 5 had been determined that showed Blo 
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t 5 to be made up of a helical bundle consisting of three anti-parallel helices (Naik et 
al., 2008). Four charged residues, Glu76, Asp81, Glu86 and Glu91 had been identified 
to be located on a major putative linear IgE epitope of Blo t 5 from residues 76-91 and 
it consisted of the sequence ELKRTDLNILERFNYE (Chan et al., 2008). 
 
1.2 DNA vaccines 
DNA vaccines were a promising therapeutic tool as it conferred many advantages 
over other vaccine approaches.  DNA vaccines were inexpensive and easier to purify 
in large amounts, in addition, there was sustained antigen expression, a cold chain was 
not required and it was relatively safe. Limitations of major class histocompatibility 
complex (MHC) restrictions were circumvented as many potential class I and II 
epitopes were provided by having full length-cDNA (Hirschhorn-Cymerman and 
Perales). Unlike immunization with protein vaccines, synthesis of proteins encoded by 
plasmids in host cells resulted in the antigen likely to be correctly glycosylated, folded 
in the native confirmation and correct post translational modifications which induced 
the formation of correct neutralizing antibodies. Immunization with plasmid DNA 
allowed the continued synthesis of protein in the host cells compared to protein 
vaccines which may be degraded with time. In addition, another interesting feature of 
DNA vaccine was that it could be engineered to target many diseases by 
modifications to the plasmid DNA. Genetic immunization involved injecting a DNA 
plasmid encoding the gene of interest into the muscle or skin of the host whereby it 
entered the host cells and directed the synthesis of the antigen. The antigen was in 
turn processed and presented by the host cells or antigen presenting cells (APCs) and 
an immune response against the antigen was mounted. DNA vaccines had been 
known to be able to induce both humoral and T cell responses in various animal 
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models and to be able to mount strong immune responses against infectious diseases 
such as tuberculosis, Ebola virus and malaria (Hoffman et al., 1997; Lowrie et al., 
1997; Strugnell et al., 1997; Wang et al., 1998; Xu et al., 1998). 
 
Immunization with DNA vaccines could manipulate the balance of T helper type 1 
(Th1) and T helper type 2 (Th2)  immune responses, hence it could be used for the 
therapy and prevention of many diseases such as cancer, autoimmunity and allergic 
diseases. Studies had shown that DNA vaccines were able to induce Th1 responses 
and suppress Th2 responses in immunoglobulin E mediated allergic responses (Hartl 
et al., 1999; Hsu et al., 1996; Raz et al., 1996). Besides skewing the immune 
responses to that of a Th1, DNA vaccines were also able to induce Th2 responses to 
protect against experimental autoimmune encephalitis (Ramshaw et al., 1997). DNA 
vaccines had been tested and proved to be safe in both small and large animals. HIV-1 
encoding DNA plasmid when administered to pregnant, adult and infant chimpanzees 
had proved to be safe and well tolerated (Bagarazzi et al., 1998). In addition, DNA 
vaccines for HIV-1 had already entered human clinical trials (Boyer et al., 1999; 
MacGregor et al., 1998). The safety of DNA vaccine was further emphasized in 
another study whereby intramuscular administration of a malaria DNA vaccine of up 
to 2500 g plasmid DNA was also well tolerated (Le et al., 2000). 
 
The treatment for allergic asthma by pharmaceutical drugs was still mainly 
asymptomatic (Katial et al., 2011). An alternative treatment for allergy was 
immunotherapy that could cure allergic asthma, however it consisted of many 
applications of allergen extracts at increasing dosage over the course of a few years 
(Edlmayr et al., 2011). More work had to be done to address the issue on the 
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underlying immunological mechanisms of immunotherapy. However due to the long 
course of this therapy, it was inconvenient and there were many cases of patient 
noncompliance. In addition it had the potential to induce anaphylaxis thus requiring 
close monitoring by clinicians (Bernstein and Epstein, 2011). As such, there was a 
need for an alternative treatment. DNA-based immunization was a potential candidate 
to solve this problem in the future. 
 
1.2.1 Optimisation Strategies 
However the main disadvantage of DNA vaccines was its low immunogenicity, hence 
many approaches to enhance the potency of DNA vaccines had been used over the 
years such as improvement of promoter efficiency by modifying the plasmid 
backbone, use of more efficient leader sequences (Ulmer et al., 2006), co-delivery of 
cytokine genes (Chattergoon et al., 2004; Chow et al., 1998; Kim et al., 1997), 
ubiquitination of the allergen protein (Bauer et al., 2006), incorporating localization 
and secretory signals (Jiang et al., 2002), use of chemical adjuvants (Jin et al., 2004), 
increased gene expression (Baldwin et al., 1999; Jiang et al., 2002) and incorporation 
of immunostimulatory sequences in the plasmid backbone (Kojima et al., 2002; 
Zhang et al., 2005). Much attention had been placed on the incorporation of 
immunostimulatory sequences such as CpG motifs into the plasmid backbone. 
 
1.2.2 LAMP-1 targeting sequence 
The targeting sequence of the lysosome associated membrane protein-1 (LAMP-1), 
had been extensively reported to be able to enhance the delivery of antigen to MHC 
class II rich compartment of APCs by targeting endogenously synthesized protein to 
the lysosomal/endosomal vesicular pathway in transfected APCs (Chen et al., 1988; 
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Chen et al., 1985; Wu et al., 1995). The processed antigen would be loaded onto 
MHC class II molecules, thus enhancing CD4+T cells mediated responses, in contrast, 
cytoplasmic antigens that lacked the LAMP-1 targeting sequence would be processed 
and loaded onto MHC class I, hence had less efficacy in inducing CD4+T cells 
mediated responses (de Arruda et al., 2004). In addition, DNA vaccines that employed 
the use of LAMP-1 targeting sequence had also been reported to induce robust Th1 
responses (de Arruda et al., 2004; Kim et al., 2003; Marques et al., 2003). Besides that, 
the use of lysosomal targeting approach had been highlighted in another study 
whereby mice immunized with DNA constructs encoding a mite allergen with signal 
peptide and lysosomal-targeting sequence showed strong and exclusive Th1 responses 
(Tan et al., 2006). In contrast, mice immunized with DNA constructs encoding the 
mite allergen with signal peptide and without lysosomal-targeting sequence showed a 
mixed Th1/Th2 phenotype, strong IgE production and a large amount of circulating 
allergen protein encoded by the DNA construct (Tan et al., 2006). This was 
potentially dangerous as Th2-skewed immune responses may be induced, hence 
lysosomal-targeting sequences could improve the safety and efficacy of DNA 
vaccines. 
 
1.2.3 Different Routes of DNA Immunization 
The common methods of delivering DNA vaccines had been needle injection into skin 
or muscles and the use of a gene gun to propel gold particles covered by plasmid 
DNA using helium or carbon dioxide pressure into tissues (Williams et al., 1991). 
Gene gun delivery required far lesser quantities of DNA than intramuscular (i.m) 
injection using needle. Muscle was a preferred route for the delivery of DNA vaccines 
as it was more efficient in the uptake and expression of plasmid DNA encoded 
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proteins. Plasmid DNA and encoded proteins had been detected as late as 19 months 
post injection in the muscle (Wolff et al., 1992). Electroporation had been shown to 
enhance uptake efficiency of plasmid DNA (Bachy et al., 2001). A study had reported 
that in muscles injected with DNA, MHC class II positive cells accumulated near 
transfected mononuclear cells and such accumulation might facilitate antigen transfer 
to APCs and result in antigen presentation and activation of T cells (Gronevik et al., 
2003). 
 
The different sites of DNA immunization also influenced the Th bias of the immune 
response generated. It had been shown by many studies that intramuscular injection 
elicited Th1-like responses while DNA administration to the skin elicited more Th2-
like immune responses (Fan et al., 1999; Fuller and Haynes, 1994; Sin et al., 1999). 
Injection into the muscle transfected mainly myocytes while intradermal injection 
resulted in the transfection of mainly keratinocytes and skin fibroblasts. Delivery of 
DNA vaccine intradermally and using the gene gun targeted the skin where there were 
two populations of dendritic cells (DC), namely the interstitial dendritic cells and the 
epidermal Langerhans cells (Banchereau and Steinman, 1998). However i.m injection 
targeted the muscle where there were no Langerhans cells. In addition there were 
fewer dendritic cells as compared to the skin. Both needle injections as well as the use 
of gene gun were physical injuries that caused local irritation and elicited danger 
signals which would result in the recruitment of APCs. 
 
Muscle cells may not be as inert as previously thought. Increasing evidence had shed 
light on the possible role of muscle cells as APCs. Myoblasts had been shown to be 
capable of presenting antigen and stimulating secretion of IL-2 by T cell hybridomas 
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using class I and class II MHC transfectant clones of myoblast cell line (Rock and 
Shen, 2005). The presentation of both exogenous and endogenous antigen by 
myoblasts stimulated antigen specific CD4+ T cells (Goebels et al., 1992; Rock and 
Shen, 2005). Another study also showed that in vivo plasmid transfected myocytes 
could present peptides to CD4+ T cells and that i.m injection of unmethylated CpG 
motifs induced expression of chemokines such as monocyte chemotactic protein 1 
(MCP-1) and MHC class II on myocytes (Stan et al., 2001). In addition, muscle cells 
served as factories for antigen synthesis to provide the antigen to boost Th1 skewed 
immune response. Using green fluorescent protein, it had been shown that encoded 
proteins were synthesized within transfected muscle cells (Gronevik et al., 2003). 
 
1.3 Immune responses 
1.3.1 Mechanism of activation of CD4+ and CD8+ T cells / MHC class I and II 
The immunogenicity of DNA vaccines was mediated by both CD4+ and CD8+ T cells. 
CD4+ T cells gave help to B cells to produce antibodies while CD8+ T cells were 
involved in cytotoxicity. It had been found that in addition to CD4+ cells, CD8+ cells 
induced by allergen gene immunization played an important role in conferring 
protective immunity against allergic responses and also in enhancing the immune 
response (Hsu et al., 1996). Hence in order to enhance the immunogenicity of DNA 
vaccines, it was important to target and prime both the CD4+ and CD8+ T cells. The 
two main classes of MHC were known as MHC class I and MHC class II. MHC class 
I presented peptides to CD8+ T cells while MHC class II presented peptides to CD4+ 
T cells. Almost all somatic cells expressed MHC class I while mainly APCs expressed 
MHC class II. It was commonly known that MHC class I presented epitopes from 
endogenous proteins while MHC class II presented epitopes from exogenous proteins. 
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When a virus or bacteria infected the host, the antigens were processed within the cell 
and the proteasome broke down the full length proteins to peptides which were moved 
via the transporter associated with antigen processing (TAP) into the endoplasmic 
reticulum (ER). The peptides associated with MHC class I molecules and 2-
microglobulin in the ER and this complex was transported to cell surface whereby it 
would bind to and activate antigen-specific CD8+ T cells. However a phenomenon 
termed cross priming or cross presentation had enabled some APCs to accept 
extracellular proteins into the MHC class I pathway (Rodriguez et al., 1999; Watts, 
1997). Extracellular antigen in turn was taken up into the lysosomal compartment of 
professional APCs whereby it was broken down into peptides and bound to MHC 
class II molecules. This complex moved to the surface of the APCs whereby it bound 
to and activated CD4+ T helper cells. The activated CD4+ T helper cells then provided 
help to B cells, resulting in class-switching. 
 
1.3.2 Possible mechanisms for generation of immune responses via genetic 
immunization 
There were three possible mechanisms for the generation of immune responses via 
genetic immunization. In the first mechanism, genetic immunization would transfect a 
cell (eg myocyte or keratinocyte) and protein production occured in the cells. The 
protein would be broken down and peptides would bind to and be presented on MHC 
class I molecules, stimulating CD8+ T cells. Soluble protein released  by transfected 
cells might be taken up by bone marrow derived APCs such as dendritic cells, 
monocytes, macrophages which would process the protein and present it in the 
context of MHC class II, hence activating CD4+ T cells. In the second mechanism, 
genetic immunization might directly transfect bone marrow derived APCs residing in 
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the target tissue hence activating CD8+ T cells. Soluble protein produced by 
transfected APCs or transfected tissue cells would activate CD4+ T cells. However the 
second mechanism might not correctly reflect the immune mechanism generated after 
intramuscular immunization as the muscle environment was relatively devoid of 
APCs. In the third mechanism, bone marrow APCs infiltrated the muscle after 
immunization and they took up antigens that were produced by transfected tissue cells 
such as myocytes or keratinocytes. Some of these antigen after internalization were 
able to cross over to the MHC class I pathway, hence activating both CD4+ and CD8+ 
T cells (Cohen et al., 1998). 
 
1.3.3 Cross-Presentation and Cross-priming 
Cross presentation/cross priming was the phenomenon whereby extracellular antigens 
were taken up by APCs and were presented on MHC class I instead of on MHC class 
II molecules. There were two main pathways by which cross-priming could occur. I.m 
injection led to transfection of myocytes, resulting in subsequent protein synthesis. 
Myocytes might serve as a reservoir of antigen for professional APCs via antigen 
transfer which was shown by a study (Fu et al., 1997). Cross priming usually occurred 
in specialized APCs such as dendritic cells (DCs) (Heath et al., 2004; Heath and 
Carbone, 2001). DCs had been found to play a vital role in cross presenting antigen in 
vivo, hence priming CD8+ T cell responses. Ablation of CD8+ T cell responses had 
been found in mice whereby CD11c+ DCs were depleted (Jung et al., 2002). In 
agreement to this, another group used parentalF1 bone marrow chimeric mice to 
show that bone marrow derived APCs were required for induction of MHC class I-
restricted CTLs after i.m vaccination (Corr et al., 1996). Professional APCs were 
sparse in the muscle environment and APCs such as macrophages and immature DCs 
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were normally recruited to muscle after danger signals were elicited by injection. 
Professional APCs such as dendritic cells would uptake the plasmid DNA by 
phagocytosis or pinocytosis and express the protein which was  presented on MHC 
class I molecules, hence priming CD8+ T cells (Condon et al., 1996). Transfer of 
protein, processed peptide and uptake of apoptotic cells by professional APCs could 
also lead to cross priming of CD8+ T cells. 
 
There were two pathways of cross-presentation, in the first pathway, the extracellular 
antigen was uptaken into the phagosome and transported into the cytosol where it was 
broken down into oligopeptides by proteasomes. These oligopeptides were then 
transported by TAP to the ER or phagosomes where they bound to MHC class I 
molecules. In the second pathway, endosomal proteases such as cathepsin S cleaved 
the antigen that had been taken up by phagosomes into peptides and these peptides 
bound to MHC class I molecules in the endocytic compartment. Cross-presentation 
led to the priming of CD8+ T cells (Rock and Shen, 2005). There were studies that 
reported that cross priming may be the main mechanism that induced CD8+ T cell 
responses (Cho et al., 2001; Corr et al., 1999). Supporting evidence for the importance 
of cross priming came from studies in which DNA vaccines were found to be less 
effective in mice that were deficient in receptors for type I interferons as vital role of 
type I interferons had been highlighted for cross priming (Le Bon et al., 2003; Van 
Uden et al., 2001). 
 
1.3.4 Strategies to induce CD4+  T cells 
CD4+ T cells were important in the induction of immune responses as they not only 
activated B cells to produce antibodies, they also activated CD8+ T cells via the 
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cytokines they secreted. It had been shown that addition of a LAMP-1 targeting 
sequence could prime CD4+ T cells and increase safety and efficacy of DNA vaccines 
(Tan et al., 2006). Another group used lysosomal integral membrane protein-II 
(LIMP-II) to target proteins directly to the lysosomes from the ER (Vega et al., 1991). 
Besides using targeting sequences to the lysosomal and endosomal pathway, other 
groups had looked at the fusion of invariant chain to proteins as invariant chain 
blocked the binding of MHC class II molecules to peptides in the ER that had entered 
via TAP. MHC class II molecule, being attached to the invariant chain then left ER 
and subsequently fused with endosomes whereby it bound to peptides and presented 
the epitopes at the cell surface (Malcherek et al., 1998; Sanderson et al., 1995). 
 
1.3.5 Strategies to induce CD8+ T cells 
There were two main pathways to induce CD8+ T cells, the first pathway was via the 
conventional MHC class I pathway whereby peptides in the ER bound to MHC class I 
molecules with the subsequent activation of CD8+ T cells via the interaction of MHC 
class I/peptide complexes at the cell surface. The second pathway was via cross-
priming whereby protein was taken in by the phagosomes into the cytosol, broken 
down by the proteasome and lastly entered the ER via the TAP. In this way, 
exogenous proteins were taken in by the cell and crossed over to the MHC class I 
pathway. Methods to increase the activation or induction of CD8+ T cells include 
enhancing protein degradation by ubiquitination and enhancing delivery to the 
proteasome or proteasome rich cellular compartment (Barry et al., 1995; Fu et al., 
1998; Hung et al., 2003; Rodriguez et al., 1997). Other groups had used the minigene 
approach that encoded a single T cell epitope in DNA vaccines and protection against 
virus had been induced (Del Val et al., 1991). Cytosolic peptides were normally 
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generated by ubiquitinaton and degradation of endogenous proteins that entered the 
ER via TAP. In the ER, the degraded peptides bound to MHC class I, hence minigene 
enhanced MHC class I presentation by the means of having a small translation peptide 
that facilitated entry into ER via TAP. In addition, attachment of a signal peptide 
could also boost the immunogenicity of T cell epitopes by directly targeting it to the 
ER, hence bypassing the need for TAP (Bacik et al., 1994). Besides targeting at the 
conventional MHC class I pathway, there were other groups that had shifted their 
focus to target at the MHC class I cross-priming pathway as cross-priming had been 
speculated to be the main mechanism of activation of CD8+ T cells. Some studies had 
showed that heat shock proteins could induce CD8+ T cell responses by being 
molecular chaperones that transport immunogenic peptides into APCs (Blachere et al., 
1997). Activation of CD8+ T cell responses could also be brought about by the 
binding of heat shock proteins to DCs receptors as well as by targeting proteins to T 
helper secretory pathway (Oran and Robinson, 2003; Qiu et al., 2000; Singh-Jasuja et 
al., 2000; Todryk et al., 1999). 
 
1.4 Cells associated with allergic responses 
1.4.1 T lymphocytes 
The origin of all T cells was from haematopoietic stem cells in the bone marrow, 
maturation of T cells took place in the thymus and the initial thymocytes did not 
express CD4 or CD8. These double negative cells then developed to become 
CD4+CD8+ double positive cells and eventually to single positive thymocytes that 
migrated from the thymus to peripheral tissues. Generally, there were three 
subpopulations of T cells, namely the T helper (Th), T-cytotoxic and T regulatory cell 
(Treg) cells. Activation of Th cells occured when APCs presented peptide antigens 
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via the MHC class II molecules that were expressed on the surface of APCs. 
Activated Th cells differentiated into one of several subtypes such as Th1, Th2, Th17 
and Th9 which produced different cytokine profiles to induce diverse immune 
responses. CD4+ T cells were generally Th cells that recognized MHC class II bound 
to peptides while CD8+ T cells were generally T-cytotoxic cells that recognized MHC 
class I bound to peptides.  Development of Treg cells occured in the thymus from 
CD4+ thymocytes and they were referred to as natural Treg, in addition, naïve CD4+ T 
cells could also convert in the periphery to induced Treg under the effect of certain 
tolerogenic stimuli. Specific Treg markers were CD4 and CD25 and they were 
involved in the maintenance of tolerance of immune response (Kong et al., 1989; 
Sakaguchi et al., 1995; Sakaguchi et al., 2008). 
 
1.4.2 T helper 1 and T helper 2 cells 
Two functional subsets of TH clones termed TH1 and TH2 in mouse had been 
described more than 2 decades ago (Mosmann et al., 1986). These two distinct 
effector cells were divided by virtue of their cellular functions and lymphokine 
profiles. Th1 cells produced IFN-, IL-2 and lymphotoxin while Th2 cells produced 
IL-4, IL-5, IL-9 and IL-13. Besides distinct cytokine profiles, Th1 cells were usually 
associated with the induction of IgG2a or IgG2c antibodies in mice while Th2 cells 
usually induced the production of IgE antibodies. The type of immune response 
induced was dependent on the routes of administration of the DNA vaccine (reviewed 
earlier) and also on the nature of the encoded antigen. T helper lineage fates of Th1 or 
Th2 were determined by differential transcription factors’ activation and expression. 
The lineage related transcription factor would induce characteristic cytokine secretion 
while at the same time suppressing cytokine secretion of other lineages. T-box 
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transcription factor (T-bet) was the master regulator of the Th1 lineage and it was 
highly expressed in polarized Th1 cells and NK cells and expression of T-bet 
correlated with IFN-γ expression (Lighvani et al., 2001). Expression of IFN-γ also 
induced expression of T-bet in an autocrine loop (Lighvani et al., 2001). Besides that, 
Th2 cells’ cytokine profile also changed to that of a Th1 with IFN-γ production and 
suppression of IL-4 and IL-5 expression when there is overexpression of T-bet 
(Lighvani et al., 2001). Induction of T-bet expression and activity was mediated by 
IL-12 via STAT4 or by IFN-γ via signal transducer and activator of transcription-1 
(STAT1) (Lighvani et al., 2001). Transcription factor GATA binding protein 3 
(GATA-3) was the Th2 master regulator. IL-4 producing Th2 cells’ differentiation 
was driven by IL-4 via STAT6 although GATA-3 was also capable of inducing its 
expression via an autocrine loop independently of STAT6 (Scheinman and Avni, 
2009; Zhu et al., 2001). Polarity of Th1 cells was switched to a Th2 phenotype when 
GATA3 was overexpressed in Th1 cells. Similarly, cells tend to adopt a Th1 
phenotype in the absence of polarizing cytokines when GATA-3 was deleted in 
peripheral CD4+ T cells. Regulation of T cell lineage commitment was brought about 
by crosstalk between T-bet and GATA-3 that exerted opposing effect on the 
transcription of a number of common genes, hence affecting the ultimate commitment 
to either Th1 or Th2 lineage. 
 
1.4.3 Role of T helper 2 cells in allergic inflammation 
Allergic asthma had been associated with activation of TH2 cells in the airways since 
two decades ago. Canonical Th2 cytokines included IL-4, IL-5 and IL-13 that were 
involved in the allergic inflammation, eosinophilia as well as in the mediation of IgE 
responses. IL-4, IL-5 and IL-13 were clustered with GM-CSF in close proximity on 
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chromosome 5q and the expression of these cytokines was well coordinated in murine 
and human TH2 cells (Cousins et al., 2002; Locksley, 2009). IL-4 played a vital role in 
Th2 polarization, in addition other Th2-polarizing factors such as MCP-1 and OX40 
ligand had been described (Ohshima et al., 1998). Upregulation of IL-4 production 
had been shown to be brought about by OX40 ligation and this in turn promoted Th2 
polarization with the subsequent production of IL-4, IL-5 and IL-13 (Ohshima et al., 
1998). IL-13 and IL-4 were both capable of inducing class switch of B cells to IgE 
production, activating macrophages and monocytes and increasing mucus production 
in the airways via globlet cell hyperplasia (Wills-Karp, 2004). IL-4 and IL-13 also 
played a vital role by increasing the expression of cell adhesion molecules in vascular 
endothelial cells which facilitated the migration of eosinophils (Meager, 1999). The 
role of IL-13 as a key regulator of the extracellular matrix had been pointed out in 
studies that reported IL-13 to mediate tissue fibrosis in asthma, besides that, the 
expression of MHC class II on monocytes was also upregulated by IL-13 (Wynn, 
2003). 
 
IL-5 was the key cytokine that was involved in the recruitment of eosinophils to the 
lung from the bone marrow, In addition, IL-5 also played a vital role in the 
proliferation, differentiation of eosinophils as well as the release of eosinophils from 
the bone marrow (Broide, 2002; Cho et al., 2004; Lopez et al., 1988; Rothenberg, 
1998). The importance of IL-5 was highlighted in a study using IL-5-deficient mice 
where peribronchial fibrosis was markedly reduced upon sensitization and repetitive 
challenge with ovalbumin compared to wild type mice (Cho et al., 2004). Previous 
studies had reported that in a placebo controlled human study, the expression of 
extracellular matrix proteins such as procollagen III, lumican and tenascin in 
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bronchial mucosal reticular basement membrane of mild atopic asthmatic patients was 
significantly decreased upon the administration of anti-IL-5 antibody when compared 
to placebo group (Flood-Page et al., 2003). In addition, eosinophilia, TGF-β1 mRNA 
expressing eosinophils and levels of TGF-β in bronchoalveolar lavage fluid were also 
reduced with the administration of anti-IL-5 antibody (Flood-Page et al., 2003). The 
evidence stated above clearly highlighted the association between IL-5 and 
eosinophilia and demostrate the detrimental role of IL-5 and eosinophilia in allergic 
asthma. 
 
Recently, thymic stromal lymphopoietin, IL-25 and IL-33 were innate immune 
cytokines that were discovered to have potent Th2 inducing abilities and important 
mediators in the immunopathogenesis of allergy and asthma. Thymic stromal 
lymphopoietin was secreted from epithelial cells in the presence of allergens and it 
had been found to activate DCs resulting in the upregulation of surface OX40 ligand 
and subsequent Th2 differentiation (Ito et al., 2005; Liu, 2007). The elevation of 
thymic stromal lymphopoietin in asthma that activated DCs to induce Th2 
inflammatory responses had been described in humans and also in murine models 
whereby inflammation and airway hyperresponsiveness had been reduced by blocking 
thymic stromal lymphopoietin (Kato et al., 2007; Liu, 2007; Ray et al., 1996). IL-25 
also known as IL-17E had been associated with the Th2 type immunity regulation as 
airway hyperresponsiveness (AHR) and inflammation were attenuated in murine 
models of allergic asthma when IL-25 was blocked (Ballantyne et al., 2007; Wang et 
al., 2007). IL-25 was described to be produced by Th2 cells, mast cells, epithelial 
cells in mouse and by eosinophils, basophils in humans (Wang et al., 2007). The 
actions of IL-33 were diverse, firstly IL-33 induced production of type 2 cytokines 
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from eosinophils and T cells, next IL-33 also stimulated type 2 cytokines release from 
basophils and mast cells via the activation of both IgE-dependent and independent 
pathways. Eosinophil-mediated differentiation of airway macrophages in the airways 
towards the alternatively activated macrophage phenotype was also enhanced by IL-
33 in an IL-13 dependent manner (Kondo et al., 2008; Kurowska-Stolarska et al., 
2008; Stolarski et al., 2010). IL-33 had also been found to induce eosinophils to 
produce IL-13, chemokine (C-C motif) ligand -17 (CCL-17) and TGF-β (Stolarski et 
al.). Differentiation of CD117+ progenitors to eosinophils was found to be a result of 
IL-33 in an IL-5 dependent manner (Stolarski et al., 2010). 
 
1.4.4 T helper 17 cells 
IL-17-producing T cells were first reported by Infante-Duarte et al to be another Th 
population besides the classical Th1 and Th2 populations (Infante-Duarte et al., 2000). 
Differentiation of Th17 was reported to be dependent on STAT3 as Stat3-deficient 
CD4+ T cells was found to have a reduced expression of IL-17 and increased 
expression of IFN-γ (Yang et al., 2007). Hence Th17 was a distinct subset from the 
Th1 and Th2 subsets as its’ differentiation had been found to be not regulated by T-
bet, STAT1, STAT4 and STAT6 which were transcription factors of the Th1 and Th2 
subsets (Harrington et al., 2005; Park et al., 2005). The IL-17 family consisted of IL-
17A, B, C, D and E (Kolls and Linden, 2004). Besides the production of IL-17A and 
IL-17F, IL-21 and IL-22 were also produced by Th17 cells (Korn et al., 2007; Liang 
et al., 2006; Nurieva et al., 2007; Zheng et al., 2007; Zhou et al., 2007). IL-17 was not 
exclusively produced by Th17 cells, CD8+ T cells, NK T cells and γδ T cells also 
secreted IL-17 (Ivanov and Linden, 2009; Lockhart et al., 2006; Michel et al., 2008). 
Not only do Th17 cells produced IL-21, member of the IL-2 family, in large quantities, 
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ICOS+CXCR5+CCR7+ T follicular helper cells were also capable of releasing IL-21 
(Chtanova et al., 2004). IL-17 receptor family consisted of IL-17RA, IL-17RB, IL-
17RC, IL-17RD and IL-17RE (Gaffen, 2009). IL17A and IL17F could form 
homodimers, besides that they could also form heterodimer IL17F/IL17A which 
signaled through the receptor that was made up of IL17RA and IL17RC in humans 
(Toy et al., 2006; Wright et al., 2008). The first transcription factor for the 
differentiation of Th17 cell had been identified to be retinoic-related orphan receptor 
γt (RORγt) (Ivanov et al., 2006) while the human homologue had been identified to be 
RORC2 (Ivanov et al., 2007). Recently, another nuclear receptor RORα had also been 
found to be highly expressed by Th17 cells (Yang et al., 2008b). Expression of both 
RORγt and RORα had been reported to be regulated by STAT3 (Laurence et al., 2007; 
Yang et al., 2007; Yang et al., 2008b). Overexpression of RORα had been found to 
upregulate the mRNA expression of IL-17, IL-17F and IL-23R, in addition Th17 
differentiation had been enhanced by the overexpression of RORα in RORγ-deficient 
cells (Yang et al., 2008b). RORγ and RORα double deficiency blocked the 
differentiation of Th17 and onset of experimental autoimmune encephalomyelitis 
disease (Yang et al., 2008b). It was known that IL-6 downstream signaling activated 
both STAT3 and STAT1 (Ihle and Kerr, 1995), however in Th17 cells, STAT1 
activation was suppressed while STAT3 was activated (Kimura et al., 2007). 
 
TGF-β and IL-6 had been reported to be the prerequisites for Th17 cell differentiation 
in mouse (Veldhoen et al., 2006) and commitment to the Th17 lineage was reinforced 
by IL-23 (Yang et al., 2007). Antigen presenting cells like DCs and macrophages 
upon activation produced IL-23. The receptor for IL-23 was heterodimeric and 
consisted of IL-12Rβ1 and IL-23R (Kastelein et al., 2007). In vitro experiments had 
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revealed that IL-23 was required for Th17 to secrete high levels of IL-22, which 
might hint that IL-22 was an effector cytokine produced by Th17 cells that were 
commited to the Th17 lineage and were fully differentiated (Bettelli et al., 2008; 
Liang et al., 2006; Zheng et al., 2007). TGF-β, despite playing a vital role in the 
generation of murine Th17 cells, was not a necessary factor in driving human Th17 
differentiation. Differentiation of human Th17 cells was driven by IL-6 and other 
cytokines IL-1, IL-21 or IL-23 (Acosta-Rodriguez et al., 2007a; Wilson et al., 2007). 
IL-1β had been shown to be crucial in early differentiation of Th17 cells in both 
human and mouse, in addition conversion of Foxp3+ T cells into IL-17 producing 
cells was also reported to be dependent on IL-1β (Acosta-Rodriguez et al., 2007a; 
Chung et al., 2009). IL-17 had been found to be involved in the activation of nuclear 
factor-κB (NFκB) and mitogen-activated protein kinase pathways (Gaffen, 2008). It 
had been proposed that differentiation of Th17 followed a three-step model whereby 
induction of differentiation of Th17 was first brought about by the action of both 
TGF-β and IL-6, the frequency of Th17 cells was then enhanced by IL-21 while IL-23 
ensured that differentiated Th17 cells were stabilized and committed to their lineage 
(Bettelli et al., 2008). STAT4 might play an important role in the expansion of Th17 
cells driven by IL-23 (Mathur et al., 2007). Human IL-17 producing cells could be 
identified by the co-expression of both C-C chemokine receptor 4 (CCR4) and CCR6 
or by expression of CCR2 and absence of CCR5 (Acosta-Rodriguez et al., 2007b; 
Sato et al., 2007). Expression of TGF-βR1, IL-6R, IL-23R and chemokine receptors, 
CCR4 and CCR6, on the cell surface of Th17 cells was reported and the chemokine 




TGF-β had been reported to play a role in the generation of Treg cells via increasing 
the expression of Forkhead box p3 (Foxp3) (Chen et al., 2003). However, the addition 
of IL-6 in an environment of TGF- β had been found to stimulate the differentiation of 
Th17, at the same time impairing Treg generation via the suppression of Foxp3 
expression (Bettelli et al., 2006). The reciprocal relationship between Treg and Th17 
had been emphasized by reports of retinoic acid, a factor not only involved in the 
induction of Treg cells, but also capable of inhibiting IL-6 induced generation of Th17 
cells (Mucida et al., 2007). Consistent with earlier reports, Foxp3 had also been 
shown to impair the function of RORγt thus inhibiting IL-17 production, this 
inhibition was brought about by higher concentrations of TGF-β (Zhou et al., 2008). 
Direct interaction of Foxp3 and RORγt had also been reported to result in inhibition 
of IL-17A mRNA transcription (Ichiyama et al., 2008). Foxp3 protein was also being 
reported to hinder physically the association between RORγt and IL-17 promoter 
(Zhang et al., 2008; Zhou et al., 2008). 
 
Besides the antagonistic action between Treg and Th17, Th1 and Th2 were also 
implicated in suppressing the differentiation of the Th17 lineage. Studies had reported 
that T-bet, a Th1 transcription factor as well as master regulator, abolished and 
inhibited Th17 differentiation (Guo et al., 2009; Yang et al., 2008c). Other reports had 
shown that GATA3, a Th2 transcription factor, downregulated STAT3, STAT4 and 
RORγt, all of which were Th17 directing transcription factors, hence inhibiting the 
production of IL-17 (van Hamburg et al., 2008). In addition, IL-27, a member of the 
IL-12 family, was also reported to inhibit Th17 differentiation and was supported by 
observations that development of Th17 cells was suppressed in vitro when naïve 
primary T cells were treated with IL-27 (Stumhofer et al., 2006). Mice deficient in the 
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IL-27 receptor also exhibited a robust Th17 response with fatal CD4+T cell- mediated 
pathology when chronically infected with Toxoplasma gondii (Stumhofer et al., 2006). 
In comparison, Th1 cytokine such as IL-2 was more efficient than Th2 cytokines such 
as IL-4 in antagonizing Th17 differentiation (van Hamburg et al., 2008). While the 
aforementioned factors were inhibitors of Th17 development, interferon-regulatory 
factor 4 and dioxin, a ligand of aryl hydrocarbon receptor, were positive regulators of 
Th17 differentiation (Brustle et al., 2007; Kimura et al., 2008; Quintana et al., 2008; 
Veldhoen et al., 2008). 
 
1.4.5 Role of T helper 17 cells in allergic inflammation 
Allergic diseases conventionally had been thought to be only Th2 mediated with the 
characteristic infiltration of increased numbers of eosinophils, Th2 lymphocytes, 
activated mast cells and airway remodeling (Bousquet et al., 2000; Pascual and Peters, 
2005). However, asthma was not only characterized by eosinophilia, neutrophilia was 
also a characteristic feature of another subtype of asthma. Studies on neutrophilic 
asthma had shed light on the involvement of IL-17, the hallmark cytokine produced 
by Th17 cells (Hellings et al., 2003). Another study also reported the increase in 
neutrophils and keratinocyte derived chemokine (KC) protein and mRNA when anti-
IL17 antibody was used (Park et al.).Th17 cell numbers were also increased in the 
lungs of mice that had house dust mite allergy (McGee et al., 2010). IL-17 cytokine, 
IL-25, also had been reported to initiate and enhance Th2 responses (Angkasekwinai 
et al., 2007; Ballantyne et al., 2007; Tamachi et al., 2006). The association of IL-17 
with asthma had been strengthened with reports of IL-17 being upregulated in the 
bronchoalveolar lavage fluid (BALF), lung cells, sputum and peripheral blood of 
asthmatic patients (Barczyk et al., 2003; Molet et al., 2001). Studies on hIL-17 had 
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also reported that hIL-17 could stimulate synovial fibroblasts, human bronchial 
fibroblasts and bronchial epithelial cells to produce cytokines such as IL-6, IL-8, 
GCSF resulting in neutrophil hematopoiesis and granulopoiesis (Fossiez et al., 1996; 
Louten et al., 2009; Molet et al., 2001; Park and Lee). Other studies also showed that 
the neutrophil attracting function of IL-17 was mediated via the increased production 
of IL-8 (Cannons et al.) by lung structural cells (Laan et al., 1999; Park and Lee; Ye et 
al., 2001).All this evidence suggested that IL-17 played a major role in the 
recruitment and activation of neutrophils during an inflammatory response via the 
induction of chemokines and cytokines. 
 
1.4.6 Protective effect of T helper 17 cells 
Protective effect of Th17 immune responses had been described for defense against 
fungal infection and supported by evidence whereby IL-17RA deficient mice were 
more susceptible to infection by Candida albicans which could be due to the delay in 
the recruitment and activation of neutrophils in the infected organs (Huang et al., 
2004). IL-17 had been reported to play a vital role in the clearance of pathogens such 
as Candida albicans and Toxoplasma gondii (Huang et al., 2004; Kelly et al., 2005). 
Candida albicans specific IL-17A producing CD4 memory T cells were also 
identified in human subjects (Acosta-Rodriguez et al., 2007a). Th17 cells also helped 
to control M.tuberculosis infections by the induction of chemokines such as 
chemokine (C-X-C motif) ligand 9 (CXCL9), CXCL10 and CXCL11 that served as a 
chemoattractant for Th1 cells that were rapidly recruited into the lung tissue and 
infection was controlled (Khader et al., 2007). Hence Th17 cells were proposed to be 
able to link innate and adaptive immunity via the induction of chemokines that helped 
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to recruit other Th cells to the infected areas, hence helping to control the infection 
(Bettelli et al., 2008). 
 
Although many have normally associated production of IL-17 with Th17 cells, the 
main lymphocyte subset that produced IL-17 in naïve mice at a steady state was the γδ 
T cells (Stark et al., 2005). Although Th17 had been suggested to be involved in the 
pathogenesis of proinflammatory diseases, they were not the main IL-17 producers 
during allergic airway disease, instead IL-17 producing γδT cells were found to be the 
main producers of IL-17 which was vital and essential in the amelioration of allergic 
airway inflammation (Murdoch and Lloyd). This shedded new light on the importance 
of IL-17 in allergic diseases, hence IL-17 might not necessarily be harmful, the cell 
type that produced IL-17 might actually determine if IL-17 exert a harmful or 
protective effect. Besides, the importance of γδT cells in maintaining normal airway 
tone was highlighted in another study (Lahn et al., 1999). γδT cells were a prominent 
cell type at mucosal surfaces such as the airway epithelium and other studies had 
suggested that γδT cells were capable of immunoregulation and preventing host tissue 
from incurring damage during immune responses (Born et al., 2000; Wands et al., 
2005). In addition, in murine models of OVA-induced allergic asthma, airway 
hyperresponsiveness (AHR) was upregulated in the absence of γδT cells (Lahn et al., 
1999). 
 
Besides that, the role of IL-17 in allergic asthma had also been highlighted in the 
development of allergic asthma (Schnyder-Candrian et al., 2006). Surprisingly, 
coadministration of recombinant murine IL-17 with OVA during challenge reduced 
metacholine response significantly and this suppression was removed by the use of 
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IL-17 blocking antibody (Schnyder-Candrian et al., 2006). Besides that, pulmonary 
CC-chemokine expression and eosinophilia were also reduced by IL-17 (Schnyder-
Candrian et al., 2006). This evidence showed that IL-17 may not only play a 
detrimental role in the initiation of allergic asthma, the protective role of IL-17 in the 
effector phase could not be underestimated. Other supporting evidence revealed that 
neutralization of IL-22, another cytokine produced by Th17 cells, resulted in 
increased eosinophilia (Schnyder et al.). It had also been shown that IL-17A and IL-
22 exerted their effects on DCs as transfer of DCs preincubated with IL-22 and IL-
17A into naive mouse conferred protection against eosinophilia upon further OVA 
challenge (Schnyder et al.). 
 
1.4.7 Plasticity of T helper 17 cells 
Relationship between Th17 and Th1 had been ambiguous and had been supported by 
studies in which IFN-γ and IL-17 double producing T cells were generated when 
CD4+T cells were subjected to a Th17 polarizing environment (Evans et al., 2007; 
Yang et al., 2009). In addition, other evidence had suggested that Th1 cell recruitment 
to inflammation sites was dependent on an early Th17 response and this Th17 
response also facilitated Th1 memory development (Khader et al., 2007). Consistent 
with the earlier reports, in vitro generated human Th17 cells consisted of IL-17+, IFN-
γ+(Th17-IFN-γ) and IL-17+/IFN-γ+ cells and these subsets also expressed IL-17F, IL-
22, CCL20, IL-26, lymphotoxin α and IL-1A transcripts at higher levels at Th1-IFN-
γ+ cells (Boniface et al.). Surprisingly, IL-17 and IFN-γ double producing cells were 
unstable and had a tendency to convert to IFN-γ single producing cells (Boniface et 
al.). Plasticity of Th17 cells was also highlighted whereby IL-12 skewed Th17 cell 
subsets to become “Th1-like” IFN-y+ cells, in contrast Th1 cells remained stable even 
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under Th17 promoting environment (Boniface et al.). Another study had reported that 
the adoptive cell transfer of a Th17 polarized population into mice could convert to 
IFN-γ producers that could produce either both IFN-γ and IL-17 or IFN-γ only in the 
lung (Ashino et al.). 
 
1.5 CpG oligonucleotides 
1.5.1 Distinct classes of CpG Oligonucleotides 
CpG dinucleotides were present at a frequency of 1 in every 16 dinucleotides in 
bacterial genomes while in vertebrate DNA, there was CG suppression and CpG 
dinucleotides were present at one-fourth the frequency in bacterial genome (Gardiner-
Garden and Frommer, 1987). Hence unmethylated CpG motifs were being regarded 
as “danger signals”. Impaired responses of Toll like receptor (TLR) 9 deficient mice 
to CpG DNA implied that TLR9 was essential for the recognition of CpG (Hemmi et 
al., 2000). CpG oligonucleotides (ODN) were known to bind to TLR9 and hence 
activated a series of signaling cascade that could lead to the differentiation, 
maturation, and proliferation of effector cells like T cells, NK cells, B cells and 
dendritic cells to secrete chemokine, cytokines and immunoglobulins (Ig) (Gursel et 
al., 2002; Klinman et al., 1996; Sparwasser et al., 1998; Stacey et al., 1996). As 
previously described by other groups, there existed two main structurally distinct 
classes of synthetic CpG ODN that could activate human immune cells which were 
namely, the D and K type (Gursel et al., 2002; Hartmann et al., 2003; Verthelyi et al., 
2001). “K” type ODN (also known as B type) consisted of phosphorotiorate backbone 
that encoded multiple CpG motifs such as TCGTT and/or the TCGTA motif and they 
were capable of inducing the differentiation of plasmacytoid dendritic cells (pDC) to 
produce TNF-α. B cells were also stimulated by “K” type ODN to proliferate and 
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secrete IgM (Hartmann and Krieg, 2000; Krug et al., 2001). “D” type ODNs (also 
known as “A”type) consisted of a purine/pyrimidine/CG/purine/pyrimidine motif, 
capped by a poly G tail at the 3’ end. “D” type ODNs could stimulate pDC to secrete 
IFN-α and induced the maturation of monocytes into mature dendritic cells (Coban et 
al., 2005). It had been proposed that the inability of “K” ODN to induce strong IFN-α 
secretion could be due to their strong ability of inducing the maturation of pDC 
(Verthelyi and Zeuner, 2003). Matured pDC tend to not produce high levels of IFN-α 
(Verthelyi and Zeuner, 2003). 
 
The immunomodulatory effects of CpG ODN varied across species and the optimal 
sequence motif, number of CpG motifs and flanking sequences might vary in different 
species which could be due to the evolutionary divergence in TLR9 molecules in 
different species (Rankin et al., 2001). As such, the optimal CpG motifs for mouse 
might not be effective in humans as the amino acid sequence of murine and human 
TLR9 differed by 24% (Hemmi et al., 2000). In humans, B cells and pDC were the 
major cell types that expressed TLR9 while in mice, TLR9 expression was on 
immune cells of the myeloiod lineage such as macrophages, myeloid dendritic cells 
(mDC). One of the earliest studies that involved the transfection of human monocytes 
with CpG-DNA showed that the immunogenicity of DNA vaccines could be 
enhanced by CpG motifs (Sato et al., 1996). Human CpG motifs had been inserted 
into plasmid backbone to increase its immunogenicity and the results had shown that 
CpG (“K” or “D”) modified plasmid DNA upregulated surface marker expression and 
increased the production of IL-6 from peripheral blood mononuclear cells (PBMC) 
(Coban et al., 2005). In addition, monocytes were also stimulated to develop into 
mature dendritic cells by CpG modified plasmid DNA. Interestingly, although other 
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groups had incorporated up to 90 CpG motifs, this group proved that insertion of as 
few as 3 to 5 human CpG motifs was adequate to boost the immunogenicity of 
plasmid DNA (Coban et al., 2005). Differences between free CpG ODN and “K”-
CpG modified plasmid DNA was also demonstrated whereby “K”-CpG modified 
plasmid DNA was a strong inducer of IFN-γ and IFN-α unlike “K” ODN. “D” ODN 
was a good inducer of IFN-γ and IFN-α unlike “D”-CpG modified plasmid DNA 
(Coban et al., 2005). 
 
The differential effects of “D” and ‘K” type ODN on human immune cells was 
investigated by another group that showed that uptake of “D” ODN was greater than 
that of “K” ODN (Gursel et al., 2002). “D” ODN was also found to occupy 
punctuated vesicles while “K” ODN had a more diffuse distribution. In agreement 
with previous reports, “K” ODN was found to activate CD19+ B cells, triggering 
proliferation and an increase in IgM and IL-6 production. “D” ODN, on the  contrary 
had a weaker activation of CD19+ B cells (Gursel et al., 2002). “D” type ODN 
activated NK cells and stimulated significant IFN-γ production  while “K” ODN did 
not induce any significant IFN-γ production despite a modest activation of NK cells 
(Gursel et al., 2002). The differential effects of “K” and “D” type ODN were also 
shown on purified monocytes while “K” ODN stimulated the proliferation of 
monocytes and production of IL-6, “D” ODN did not elicit such effects. Instead “D” 
but not “K” ODN induced the maturation of monocytes into CD83+/CD86+ DCs 
(Gursel et al., 2002). In addition, there appeared to be competitive effects between 




Differences in backbone modified CpG-DNA had been reported, CpG ODNs with 
phosphorothiorate backbone (PS-ODN) when injected intra-peritoneally into mice 
resulted in an increase in spleen weight and splenocytes based on the CG sequence 
(Kim et al., 2009). Migration of macrophages into the peritoneal cavity was also 
increased, hence although PS-ODN led to strong activation of immune responses and 
production of PS-ODN specific antibodies, but this could result in harmful side 
effects in vivo (Kim et al., 2009).In contrast, CpG ODNs with phosphodiester 
backbone did not cause any increase in spleen weights, cell number or IgM 
production hence it might be a more useful and safe tool to enhance innate immune 
responses (Kim et al., 2009). 
 
1.5.2 Factors affecting immunogenic effects of CpG oligodeoxynucleotides 
Structure of CpG ODN, route of administration of CpG ODN and time of 
administration of CpG ODN were factors that affected the immunogenic effect of 
CpG ODN. It had been demonstrated that conjugation of a large oligonucleotide to 
CpG DNA through 5’ends would decrease the immunostimulatory activity of CpG 
DNA. In comparison, a small oligonucleotide conjugated to 5’end of CpG DNA or 
oligonucleotide of any size linked to 3’ end of CpG DNA did not affect the 
immunostimulatory effect of CpG DNA (Kandimalla et al., 2002). Another group had 
shown that the type of antigen and mode of immunization affected the effect of CpG 
motifs in vivo. They had also reported that CpG ODN co-adminstered with DNA was 
better at downregulating Th2 responses that CpG ODN co-administered with protein 
(Hochreiter et al., 2001). It was also reported that CpG ODN when administered alone 
had decreased immunostimulatory effect. To achieve protective immune response, co-
administration of CpG ODN with the antigen was essential (Corral and Petray, 2000) 
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and this effect could be maximized by conjugation of CpG ODN and the allergen (Mo 
et al., 2006; Suzuki et al., 2007). It was frequently reported that gene gun 
bombardment induced a Th2 response while intramuscular immunization induced a 
Th1 response. However another study had reported that addition of CpG ODN to a 
vaccine could induce a Th1 response and upregulate IL-12 mRNA in draining lymph 
nodes regardless of the mode of immunization (Liu et al., 2005). The timely 
administration of CpG ODN was emphasized by another group. They reported that 
mice immunized with CpG ODN followed by HSV-2 glycoprotein D vaccine exhibit 
decreased Th1 response. In contrast, when CpG ODN was administered 48h after 
immunization with vaccine, there was an induction of strong Th1 response 
characterized by elevated IgG2c and IFN-γ (Tengvall et al., 2005). 
 
1.5.3 Applications of CpG oligodeoxynucleotides 
CpG ODN had been shown by many groups to be able to cause a strong adjuvant 
effect and to induce a Th1 type immune response against different antigens in 
different animal models via different routes of administration (summarized in table 1). 
In addition, CpG ODN was also used as treatment tools to reduce airway remodeling 
and to reverse established Th2 responses in murine models (Jain et al., 2002; 
Weeratna et al., 2001). CpG ODN also showed promising results against parasites 
(Zimmermann et al., 2008). CpG ODN not only showed promising results in small 
animals but also in large animals. CpG ODN were added to Hepatitis B surface 
antigen with alum and immunized into orang utans. The rate of seroconversion rose to 
100% after the second administration of the vaccine and protective antibody titres 
were also significantly enhanced (Davis et al., 2000). Despite such promising results, 
there were also groups that had negated the usefulness of CpG ODN. A group showed 
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that while a strong Th1 immune response was induced in mice co-immunized with 
Toxoplasma gondii soluble antigen and CpG ODN but the mice were not protected 
when challenged with the virulent strain (Saavedra et al., 2004). This finding was in 
agreement with another study which reported that although the addition of CpG ODN 
to vaccines enhanced the production of IFN-γ by lymph nodes but it did not help in 
the reduction of bacteria load in the lungs or improve histopathology after challenge 
(Hsieh et al., 2004). However CpG ODN had proven to be effective in humans as they 
had already entered clinical trials. CpG ODN 7909 had been tested in clinical trials. 
Melanoma patients were vaccinated with CpG7909 co-administered with melanoma 
antigen A, analog peptide and incomplete Freund’s adjuvant and they showed strong 
antigen-specific T cell responses (Speiser et al., 2005). This finding was supported by 
another study in which CpG7909 also showed promising results as an adjuvant in 
melanoma patients (Molenkamp et al., 2007). Similarly, another phase I study had 
reported that another CpG ODN, 1018 ISS was a strong adjuvant that induced 
elevated antibody levels when co-administered with vaccines against hepatitis B virus 
(Halperin et al., 2003). 
 
Safety of CpG ODN had been demonstrated by some groups. “A” type (also known as 
“D”) CpG ODN was used in a phase I/IIa clinical trial as an adjuvant in allergen-
specific immunotherapy in humans. The results of the clinical trial showed that “A” 
type CpG ODN together with house dust mite allergen when administered 
subcutaneously was safe with 100% of patients having complete alleviation of allergy 
symptoms after ten weeks of immunotherapy (Senti et al., 2009). In rhesus macaques, 
co-administration of CpG ODN with anthrax vaccine adsorbed increased the speed, 
avidity and immune response than anthrax vaccine alone (Klinman et al., 2004). 
32 
 
Protective IgG anti-PA antibodies were also increased in macaques immunized with 
the CpG ODN and anthrax vaccine and these serum antibodies, when passively 
transferred to mice, also conferred protection in nearly half of recipient mice against 
anthrax challenge (Klinman et al., 2004). In addition, CpG ODN co-adminstration 
with anthrax vaccines were well tolerated in macaques with no serious local or 
systemic adverse effects reported (Klinman et al., 2004). 
 
1.5.4 CpG oligonucleotides and Toll like receptor 9 
The TLR family provided an important line of defense against pathogens in innate 
immunity. Toll-like receptor consisted of leucine-rich repeats, a transmembrane 
domain and a cytoplasmic Toll/interleukin-1 receptor (TIR) homology domain. The 
TLR family encoded 11 members. While there were TLRs that resided at the cell 
surface such as TLR2, TLR4, TLR5, and TLR11 that detected lipopolysaccharide, 
flagellin and profilin respectively, other receptors that detected single stranded DNA 
such as TLR9 was localized primarily in the endoplasmic reticulum, endosome and 
lysosome (Akira and Takeda, 2004; Latz et al., 2004; Wagner, 2004). TLR 
dimerization upon ligand ligation activated two pathways, one that involved myeloid 
differentiation primary response gene 88 (MyD88) and resulted in the production of 
type I interferons and proinflammatory cytokines due to activation of NFkB. The 
other pathway encompassed TIR domain containing adaptor inducing beta interferon 
(TRIF), with the subsequent production of type I interferons (Wagner and Bauer, 
2006). 
 
The intracellular signalling pathway of TLR9 had been debated upon. While it had 
been suggested that in the translocation of TLR9 from the ER to the early endosomes, 
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the golgi complex had been bypassed (Latz et al., 2004), other evidence had shown 
that TLR9 did not bypass the golgi complex, instead golgi export was critical for 
TLR9 signalling (Chockalingam et al., 2009). TLR9 had been found to be subjected to 
the action of golgi-resident protease furin during intracellular movement 
(Chockalingam et al., 2009). Confocal microscopy studies had revealed that 
colocalization of TLR9, MyD88 and CpG ODN occurred in late endosomes and 
maturation of endosomes was essential for signaling (Ahmad-Nejad et al., 2002; 
Takeshita et al., 2001). Endosomal acidification had been reported to be vital for 
TLR9 signalling. Low pH might constitute a preferred environment for the binding of 
TLR9 to some DNA as TLR9 signalling had been reported to be hindered with 
endosomal acidification blockers. CpG ODN localization in the endosome mediated 
the recognition by TLR9 and upon CpG-ODN binding in the endolysomes, TLR9 had 
been reported to undergo conformational change (Hacker et al., 1998; Latz et al., 
2007; Rutz et al., 2004; Yi et al., 1998). TLR9 movement from the endoplasmic 
reticulum to endolysosomal compartments was subjected to the control of a 12 
membrane spanning endoplasmic reticulum protein known as UNC93B via direct 
interaction with TLR9 (Tabeta et al., 2006). pDC could uptake CpG DNA via 
clathrin-dependent endocytic pathways that subsequently bound to TLR9 present in 
lysosomal compartments (Sasai et al., 2010). Upon binding of CpG DNA to TLR9, 
MyD88 adaptor molecule with the TIR domain and death domain would be recruited 
with the subsequent activation of IL-1R associated kinase 1 (IRAK1), IRAK4 and 
interferon regulatory factor 7. Tumor necrosis factor receptor associated factor 6 was 
then recruited and transforming growth factor β-activated kinase 1, mitogen-activated 
protein kinase, and eventually NF-κB pathway was activated (Krieg, 2002). 
Activation of the innate immune system upon CpG DNA binding to TLR9 brought 
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about maturation of dendritic cells, proliferation of B cells, induction of 
proinflammatory cytokines, chemokines and immunoglobulins. TLR9 activity had 
also recently been found to be regulated by rapamycin sensitive PI(3)k-mTOR-p70S6 
pathway. 
 
K” ODN had been reported to bind to TLR9(Takeshita et al., 2001; Verthelyi et al., 
2001). In contrast to  “K” ODNs, “D” ODNs appeared not to bind to TLR9, another 
receptor was believed to be involved in the transportation of “D” ODNs to endosomes 
(Gursel et al., 2002). As “D” type ODN had poly G tail, scavenger receptor A had 
been proposed to play a role in the binding of “D” ODN as it had been to be able to 
bind poly G stretches. In addition ligands of the scavenger receptor A were found to 
decrease the activity of poly G containing CpG ODN on splenic dendritic cells (Lee et 
al., 2000). Recently, scavenger B1 receptor had been reported to be the mediator for 
CpG-induced calcium mobilization in B cells but a negative regulator for TLR9 
dependent B cell activation, production of IL-6, IL-10 and IgM were downregulated 
(Zhu et al., 2009). CpG DNA had been reported by earlier studies to bind to TLR9 
and TLR9 binding had been shown to be vital for the immune effects of CpG DNA as 
TLR9 deficient mice showed a refractory response to CpG DNA (Hemmi et al., 2000). 
Transfection of either murine or human TLR9 gene also enabled previously non-
responder cells to respond to CpG ODN (Bauer et al., 2001). The optimal CpG motif 
for murine TLR9 was GACGTT while that for human TLR9 was GTCGTT.(Bauer et 
al., 2001) 
 
Plasmid DNA had been shown to stimulate the activation of TLR-9 positive pDCs or 
conventional dendritic cells (cDC) and induced cytokine production and upregulation 
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of co-stimulatory molecules. pDC and cDC interaction elicited the production of IL-
12 in response to TLR9 stimulation. TLR9 had been found to stimulate production of 
IL-15 as well as expression of CD40 on cDC, the IL-15 elicited stimulated the 
expression of CD40L on pDC. CD40-CD40L ligation between cDC and pDC elicited 
the production of IL-12 from cDC (Kuwajima et al., 2006). However, there were also 
studies reported by other groups that casted doubt on the importance of TLR9 (Spies 
et al., 2003). The role of TLR9 remained unclear as in vivo, plasmid DNA vaccination 
of TLR9 or MyD88 deficient mice still could result in clonal expansion of 
SIINFEKL-specific CD8+ T cells and priming of OVA-specific cytotoxic T 
lymphocyte (Spies et al., 2003). Another group also reported similar findings whereby 
they found that DNA immunization elicited similar levels of antigen-specific antibody 
and stimulation of antigen specific IFN-γ secreting cells in TLR9-/- as well as in 
TLR9+/+ mice (Babiuk et al., 2004). However involvement of TLR9 had been shown 
in a study whereby TLR9 inhibitory sequences had been found to result in the 
impediment of TLR9 mediated activation in human and mouse cells (Duramad et al., 
2005). 
 
Recently CpG ODN had been shown to be able to induce IL-33 via TLR9 engagement 
(Shimosato et al.). It had been proposed that CpG ODN, via the induction of IL-33, 
could result in an inhibition of ST2/IL-33 activation, hence IL-33 could be able to 
counteract the effects of proinflammatory cytokines such as the IL-1 family 
(Shimosato et al.). Besides binding to CpG ODN, TLR9 was also vital in the defense 
against bacterial and viral infection such as Streptococcus pneumonia (Lee et al., 2007) 
and herpes simplex virus type I (Krug et al., 2004; Lee et al., 2007), resulting in the 
production of IFN-α by pDC. The phosphodiester 2’ deoxyribose backbone was also 
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found to be able to determine TLR9 activation (Haas et al., 2008). Besides, sequence 
specificity had been found to be exclusive when phosphorothiorate ODN were used, 
this specificity was not observed when the ODN was changed to a phosphodiester 
backbone (Roberts et al., 2005). In contrast, another study demonstrated that TLR9 
bound to phosphorothiorate DNA devoid of CpG motifs (Vollmer et al., 2004). 
Surprisingly, TLR9 had been found to be able to bind to non-CpG as well as CpG 
ODN, however binding of CpG ODN skewed immune responses to that of a Th1 
while non-CpG ODN skewed immune responses to that of a Th2 (Vollmer et al., 
2004). It was proposed that dependant on the type of stimulus (CpG or non-CpG 
ODN), Th1 or Th2 effects could be mediated by TLR9 (Vollmer et al., 2004). 
 
The regulatory network that underlied CpG dependent gene expression in vivo was 
investigated by microarray analysis of mRNA expression level in the spleen of mice 
that had been injected intraperitoneally with immunostimulatory CpG DNA (Klaschik 
et al., 2009). After stimulation, gene expression changes were first detected at 30min , 
peaked at 3h and declined after that, major inducers were found to be TNF, IL1B, 
IL1A and IFNG while minor inducers included IL6, NFKB1, IL15, TNFSF10, IL18 
and MYC (Klaschik et al., 2009). TNF, IL1B, IL1A and the minor inducers triggered 
a fast but short-lived upregulation of genes which was in stark contrast to IFNG that 
activated a long-lived network of genes at 3h post CpG stimulation (Klaschik et al., 
2009). The major inducers activated genes that elicited a proinflammatory response 
(Klinman et al., 1996). Suppressors such as IL10, MYC, NF-kB light chain gene 
enhancer in B cells inhibitor, α(NFKBIA), suppressor of cytokine signaling I(SOCS1), 
SOCS3, IL1RN and FOS were found to target at inducers , resulting in the decrease in 




1.5.5 TLR9 independent pathways 
Recognition of host DNA might not be totally dependent on TLR as it had been 
reported that DNA-specific TLR signaling was not essential for IFN production 
(Okabe et al., 2005). In the past decade, evidence had hinted at the presence of DNA 
sensors besides TLR9 that played a role in innate immune responses. Infection of cells 
lacking TLR9 with herpes simplex virus I or Listeria monocytogenes did not affect 
induction of type I IFN (Lund et al., 2003; Stetson and Medzhitov, 2006). In addition, 
type I IFN production was also not affected when TLR9 deficient cells were 
transfected with synthetic double stranded DNA (Stetson and Medzhitov, 2006). A 
growing body of evidence had suggested the presence of an innate immune activation 
pathway that was induced by DNA, yet independent of TLR (Ishii and Akira, 2005) as 
it had been shown that a TLR9 independent pathway mediated the increased 
expression of co-stimulatory molecules as well as induction of interferon-inducible 
genes by double stranded DNA (Li et al., 2005; Yasuda et al., 2005). In addition to 
that, it had also been proven that double stranded right handed helical form of DNA 
resulted in type I IFN and chemokines production via activation of mouse and human 
stromal and dendritic cells (Ishii et al., 2006).  
 
Recently, DNA mediated signalling pathways had been identified and they included 
stimulator of interferon genes (STING) pathway, RNA polymerase III/ retinoid-
inducible gene 1 (RIG-1)/ IFN-β promoter stimulator 1 (IPS-1) dependent pathway 
and nucleotide oligomerization domain (NOD)-like receptor pathway. STING was an 
endoplasmic reticulum associated molecule found to be crucial for the induction of 
type I interferons via cytosolic DNA stimulation in macrophages and dendritic cells 
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(Ishikawa and Barber, 2008; Ishikawa et al., 2009; Jin et al., 2008; Sun et al., 2009b; 
Zhong et al., 2008). Interestingly, single stranded DNA failed to induce robust type I 
interferon production via the STING pathway, implying that double stranded DNA 
structure was essential in activating the STING pathway. In addition, STING was 
involved in the induction of type I interferon but not IL-1β production in response to 
DNA stimulation, IL-1β production was dependent instead on absent in melanoma 2 
(AIM2) (Ishikawa et al., 2009). In pDCs, STING pathway as well as DEAH/RNA 
helicase A existed as DNA sensors (Ishikawa et al., 2009). However, STING did not 
appear to bind DNA, instead other molecules such as DNA dependent activator of 
interferon (DAI), also known as Z DNA binding protein 1 (ZBP-1), IFI16 (PYHIN 
protein) functioned as cytosolic DNA receptors (Takaoka et al., 2007; Unterholzner et 
al., 2010). Besides that, high mobility group box proteins had also been implicated in 
regulating DNA mediated innate immune signalling and were speculated to be 
essential in mediating the complete activation of the TLR, AIM-2 and STING 
pathways (Yanai et al., 2009).  
 
B-DNA was discovered to activate Tank binding kinase 1 (TBK1)-dependent 
pathways, subsequently activating NF-κB dependent pathway as well as induction of 
type I interferon production (Ishii et al., 2008; Miyahira et al., 2009). Upstream of 
TBK1 existed STING hence STING was essential for the regulation of TBK1 activity 
in response to DNA. When MyD88 and TRIF deficient mouse embryonic fibroblasts 
(MEFs) were transfected with B-DNA, there was still upregulation of expression of 
Ifnb , Cxcl10 and Ccl2 mRNA expression, which was similar to that induced in wild 
type MEF. This demonstrated that TLR signalling did not constitute to the induction 
of type I interferons and chemokines (Ishii et al., 2006) Similarly, MEFs lacking 
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RIG–I also upregulated Ifnb, Cxcl10 and Ccl2 mRNA expression, this suggested that 
RIG-I was not involved in the innate immune recognition of B-DNA (Ishii et al., 
2006). Microarray analysis of B-DNA stimulated cells revealed that B-DNA 
upregulated interferon-inducible antiviral genes that were TBK1-dependent such as 
gene encoding Vig-1(Rsad2), Mx1 and Mx2 genes encoding chemokines (Cxcl11 and 
Cxcl10), GTPases, RNA helicases (D11Lgple and Ifih1), TLR3, genes encoding Z-
DNA binding proteins (Zbp1 and Adar) and Irf7 (Ishii et al., 2006). Expression of 
interferon-inducible genes by immune and non immune cells was found to be induced 
by double stranded DNA and double stranded synthetic polynucleotides. Single 
stranded DNA on the other hand was unable to elicit such effects (Ishii et al., 2001; 
Suzuki et al., 1999).  
 
As mentioned earlier, IL-1β production in response to DNA was found to be AIM-2 
dependent and involved caspase I mediated production of proinflammatory cytokines 
like IL-1β. This production of IL-1β proceeded via the activation of the NOD-like 
receptor pathway and subsequent inflammasome mediated signalling (Yanai et al., 
2009). AIM-2, a cytoplasmic dsDNA sensor belonged to the PYD/HIN-200 (PYHIN) 
family which also consisted of other members like IFIX, IFI16 and MNDA 
(Burckstummer et al., 2009; Fernandes-Alnemri et al., 2009; Hornung et al., 2009; 
Roberts et al., 2009). Besides the STING pathway that triggered type I interferon 
production and the AIM-2 inflammasome/ Nod-like receptor pathway that mediated 
proinflammatory cytokine production, there was also a DNA mediated RNA 
polymerase III/ RIG-1/IPS-1 signalling pathway which was activated by AT rich 




1.6 Dendritic cells 
Innate immunity encompassed a variety of cells such as DCs, NK cells, γδ T cells, 
basophils, eosinophils, mast cells and neutrophils of which the most competent 
antigen presenting cells are the DCs which played a vital role in the regulation of 
adaptive immunity (Pulendran et al., 2010; Steinman and Nussenzweig, 2002). 
Dendritic cells are complex cell populations that are diverse in their antigen 
recognition, anatomic location, migratory capacity and processing machinery. 
Dendritic cells were involved in T cell differentiation and activation by taking up 
exogenous antigens, transmiting the signals to immune system by moving to draining 
lymph nodes and lastly presenting the processed antigens to T cells, inducing their 
proliferation and effector functions. Dendritic cells played essential roles in 
modulating innate and adaptive immune responses to infections as well as in the 
maintainenance of immune tolerance to self tissue (Banchereau and Steinman, 1998). 
Dendritic cells could be characterized based on their maturation status, immature DC 
were very efficient at capturing antigen but yet were inefficient at stimulating T cells, 
besides that, surface expression of costimulatory molecules and intracellular MHC 
class II was low. Immature DCs were speculated to promote tolerogenic responses 
due to inefficient T cell priming as well as expansion of regulatory T cells (Hawiger 
et al., 2001; Jonuleit et al., 2000; Mahnke et al., 2003). In contrast, mature DC were 
inefficient at capturing antigen but yet were very efficient at stimulating T cells and 
promoting immunogenic responses, in addition surface expression of costimulatory 
molecules and MHC class II were high (Daro et al., 2002). Dendritic cells as 
mentioned earlier also played a vital role in cross priming and in the generation of 




A variety of DC subsets existed both in mice and humans and they could be 
characterized by their phenotypic characteristics, functions and localizations 
(Pulendran et al., 2008). Steady state DCs were those present before infection such as 
type I interferon-producing pDC, cDC in lymphoid tissue and ‘migratory’ dendritic 
cells like the Langerhans cells (Shortman and Naik, 2007). Dendritic cells such as 
monocyte-derived ‘inflammatory DCs’, tumor necrosis factor producing and 
inducible nitric oxide synthase expressing DCs were those that developed after 
infection or inflammation (Geissmann et al., 1998; Naik et al., 2006; Randolph et al., 
1999b; Serbina et al., 2003; Wu and Liu, 2007). Conventional DC possessed dendritic 
form and functioned in the steady state while pre-DC such as plasmacytoid pre-DC 
required further activation and development. Plasmacytoid pre-DC had spherical 
shapes with the absence of dendrites, low expression of co-stimulatory molecules and 
inefficient T cell priming. Once activated, plasmacytoid pre-DC assumed dendritic 
cell form with dendrites and high expression levels of co-stimulatory molecules. In 
addition they were major producers of type I interferons and were able to present 
antigens as well as cross-present (Asselin-Paturel et al., 2001; Grouard et al., 1997; 
Irla et al., 2010; Naik et al., 2005a; Sapoznikov et al., 2007). Importantly, the type I 
interferons produced by pDC could also activate cDC. However pDCs were not very 
capable in the priming of naïve CD4+T cells but it could bring about the induction of 
secondary responses by increasing the number of memory CD4+ T cells. In addition, 
priming and survival of antigen-specific CD8+T cells could also be facilitated by 
pDCs (Di Pucchio et al., 2008; Swiecki et al., 2010). Involvement of pDC in 
differentiation of Th1, Th2, Th17, Th22 and Treg cells had been reported in some 
studies, with supporting evidence of the Tregulatory role of pDC being highlighted in 
another study whereby elevated levels of inducible T cell co-stimulator (ICOS) ligand 
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had been found on non-activated human pDCs and this interacted with a subset of 
ICOS expressing Foxp3+T reg cells, hence inducing its proliferation and IL-10 
production (Colonna et al., 2004; Ito et al., 2008).  
 
Besides TLR, DCs possessed a wide range of receptors such as RIG-I like receptors, 
NOD-like receptors and C-type lectins , which upon binding to microbial structures, 
triggered the activation of DCs (Iwasaki and Medzhitov, 2010; Kawai and Akira, 
2009). Besides TLR9, another MYD88 dependent DNA sensor had been identified to 
be cytosolic DExD/H-box helicases (Kim et al., 2010). In order to obtain sufficient 
number of dendritic cells for studies, in vitro generation was necessary as the number 
of DCs in vivo was low. Common methods to derive dendritic cells in vitro included 
using GMCSF or Flt3 ligand to derive dendritic cells from bone marrow (Boonstra et 
al., 2003; Brasel et al., 2000; Naik et al., 2005b). Bone marrow derived DCs using 
GMCSF and Flt3 ligand were representations of different DC subsets in vivo, such as 
Flt3 ligand when cocultured with bone marrow generated three distinct subsets, as 
pDC, CD8+ cDC and CD8- cDC that were similar to steady state DCs in vivo in terms 
of function and phenotype (Naik et al., 2005b). 
 
1.7 IL-35 
IL-35 was a heterodimeric cytokine from the IL-12 family that had been found to 
have potent T regulatory activity. IL-35 was composed of Epstein-Barr-virus-induced 
gene 3 (Ebi3) and interleukin-12 alpha which had been found to be expressed at high 
levels in mouse Foxp3+  Treg cells but not in resting or activated CD4+ cells (Collison 
et al., 2007b). Ebi3 was first identified in Epstein-Barr virus infected  B cells more 
than a decade ago (Devergne et al., 1996). Interleukin-12 alpha (IL-12p35) had a 
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constitutive expression unlike IL12p40 that had a inducible expression. In addition, 
IL-35 had also been found to be an inhibitor of Th17 cell differentiation in vitro and 
this finding was confirmed in a mouse model of collagen induced arthritis where IL-
17 production was found to be suppressed with the simultaneous upregulation of IFN-
γ synthesis (Niedbala et al., 2007). IL-17 was the signature cytokine produced by 
Th17 cells along with IL-17F and IL-22 and the Th17 lineage determining factor was 
RORγt. The inhibitor role of IL-35 in Th17 differentiation had been further 
exemplified in this study whereby Ebi3-/- splenocytes were reported to express 
increased levels of IL-17 and IL-22 upon antigen stimulation and the mRNA 
expression level of RORγt was upregulated (Yang et al., 2008a). Besides playing a 
role in attenuating established collagen-induced arthritis in mice, IL-35 had also been 
reported to play an immunosuppressive role in inflammatory bowel disease murine 
model whereby wild type Treg cell recipients recovered from disease, had weight gain 
and decreased histopathology (Niedbala et al., 2007). In contrast, Ebi3-/- or IL12α-/- T 
reg cells recipients continued to lose weight and had an increased mortality rate 
(Niedbala et al., 2007). Treg cells were also reported to constitutively express IL-35 
and in the presence of wild type Treg cells, the proliferation of  Teff cells was 
markedly decreased in a lymphopenic, recombination activating gene1 (Rag1)-/- 
environment. However this reduction in the proliferation of Teff cells was abolished in 
the presence of either Ebi3-/- or IL12α-/- T reg cells (Collison et al., 2007b). IL-35 had 
also been reported to have a suppressive effect on CD4+CD25- effector cells in vitro 
by another group (Niedbala et al., 2007). This immunosuppressive or 
immunomodulator effect of IL-35 may be linked to its high expression in placental 
trophoblasts so as to prevent rejection of the fetus (Devergne et al., 1997; Niedbala et 
al., 2007). The suppressive effect of IL-35 had been shown to be mediated by IL-35 
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induced Treg cells, IL-35 producing inducible costimulator positive Treg cells or IL-
10 producing CD39+CD4+ T cells upon IL-35 treatment (Collison et al., 2010; 
Kochetkova et al., 2010; Whitehead et al., 2011). 
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When the vaccine was 
administered intranasally, 
protective effect was 
induced that protected 
70% of mice against 
infection. A Th1 response 
was induced with 
upregulation in IgG2a and 
IFN-γ producing T cells. 
In contrast, oral 
administration of the 
vaccine failed to protect 
the mice. 
 
1.8 Rationales and specific aims of the study 
1.8.1 Rationales of study 
Allergic asthma was one of the most common and serious health problems worldwide. 
The prevalence of allergy had shown an increase in the past years with house dust 
mite allergy being the major triggering factor. Approximately 30% of the Singapore’s 
population had dust mite sensitization, out of which about 10-15% of schooling 
children suffered from allergic asthma and/or rhinitis; about 80% of them were 
triggered by dust mite allergy (Holt and Thomas, 2005). Blomia tropicalis was a 
clinically important mite species that played an important role in densely populated 
tropical and subtropical areas and about half of total mite allergy globally were caused 
by Blo t (Holt and Thomas, 2005). In addition in the tropics, the most vital major 
allergen was Blo t 5; with as many as 80% of asthmatic/rhinitis children in Singapore 
being sensitized by Blo t 5 allergen (Arruda et al., 1997; Kuo et al., 2003; Kuo et al., 
1999). Hence Blo t5 was the chosen allergen to work with in this study. 
 
Concept of DNA vaccines surfaced in early nineties (Ulmer et al., 1993). DNA 
vaccines consisted of a plasmid DNA backbone that could encode antigens from 
46 
 
allergens, pathogens and tumors. DNA vaccines were a promising therapeutic tool as 
it conferred many advantages over other vaccine approaches. DNA vaccines were 
inexpensive and easier to purify in large amounts, in addition, there was sustained 
antigen expression, a cold chain was not required and it was relatively safe. However 
although DNA vaccines had elicited strong immune responses in rodent disease 
models, most DNA vaccines exhibited low potency in non-human primates and 
humans (Ulmer et al., 2006). The safety and tolerability of vaccines had been tested in 
humans via clinical trials and it proved to be very safe, hence the next issue to address 
was the enhancement of potency of DNA vaccines. 
 
CpG-containing DNA motifs in the plasmid backbone of DNA vaccines played the 
role of molecular adjuvants that could activate the TLR9 pathway. In addition, the 
immunogenicity of DNA vaccines could also be mediated by a TLR-independent 
pathway involving the signalling molecule, TBK1 (Ishii et al., 2008). Hence in this 
study, multiple copies of optimized species-specific CpG motifs suitable for human 
use would be inserted into the plasmid backbone of DNA vaccines to enhance the 
priming of the immune responses induced by DNA vaccines by targeting at the innate 
arm of immunity. In addition to the insertion of additional CpG motifs, LAMP-1 
targeting strategy was also employed to improve the efficiency of antigen processing 
and presentation, hence promoting the priming of Th1-skewed cellular responses. 
LAMP-1 targeting sequence linked to antigen gene sequences had been reported to be 
an effective way to target newly synthesized antigens in vivo  to vacuolar 
lysosomal/endosomal compartments that contained MHC class II (HuangFu et al., 
2006; Lu et al., 2003; Marques et al., 2003; Tan et al., 2006). It had also been 
demonstrated that the potential risk of allergen sensitization had been reduced by 
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targeting the allergen to lysosomal/endosomal compartments, hence preventing the 
systemic distribution of conformationally intact allergen (Tan et al., 2006). 
 
Besides allergen gene delivery, cytokine gene delivery was also a promising option to 
alleviate allergic diseases as shown by cytokines such as IL-12, IL-10, TGF-β, type I 
and II IFNs (Fu et al., 2006; Hansen et al., 2000; Hogan et al., 1998; Huang et al., 
2001; Oh et al., 2002; Urban et al., 1993).  Regulatory T cells were vital in the 
maintenance of immune homeostasis, in recent years, increasing attention had been 
placed on the reciprocal regulation of effector and regulatory T cell subsets so as to 
come up with novel approaches to treat inflammatory diseases. Studies had shown 
that TGF-β and IL-10 contribute to the suppressive effects of Treg cells (Bettini and 
Vignali, 2009). However biological effects of these cytokines had been found to be 
highly pleiotropic in vivo, hence it might not be advisable to administer such 
therapeutic cytokines systematically as the potential pleiotropic effects of such 
cytokines might result in toxicities in vivo. Recombinant IL-10 when delivered 
systemically had little success in a number of small clinical trials (Herfarth and 
Scholmerich, 2002; Tilg et al., 2002). TGF-β could induce the differentiation of 
proinflammatory Th17 cells in synergy with IL-6 (McGeachy et al., 2007). Hence 
although IL-10 and TGF-β were both cytokines produced by Treg cells, they were not 
ideal therapeutic tools. Recent studies had revealed the novel cytokine IL-35 that was 
produced by Foxp3+ Treg cells also had suppressive functions (Collison et al., 2007a). 
IL-35 had also been found to be an inhibitor of Th17 cell differentiation in vitro and 
this finding was confirmed in an mouse model of collagen induced arthritis where IL-
17 production was found to be suppressed with the simultaneous upregulation of IFN-
γ synthesis (Niedbala et al., 2007). Although IL-35 had been shown to exert an 
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immunosuppressive effect on naïve CD4+ T cells, it was still unknown if IL-35 could 
also exert immunosuppressive effects on other cell populations such as Th2 cells that 
cause allergic diseases. The therapeutic role of IL-35 in Th2 mediated disease, for 
example, allergic asthma, had not been evaluated. Hence in this study we explored the 
use of IL-35 as a cytokine gene therapy approach. 
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1.8.2 Specific aims of the study 
 
1) To evaluate the immunogenicity and efficacy of DNA vaccines with the 
incorporation of CpG motifs into the plasmid backbone 
I) In vitro analyses of the stimulatory effects of CpG motifs modified plasmid 
DNA using different murine dendritic cells subsets and splenocytes 
II) In vivo analyses of the efficacies of CpG motifs modified plasmid DNA in a 
murine allergy model 
III) In vitro analyses of the stimulatory effects of CpG motifs modified plasmid 
DNA using human peripheral blood mononuclear cells 
IV) In vivo analyses of the immunogenicity of CpG motifs modified plasmid 
DNA in non-human primates 
 
2) To explore the use of cytokine gene delivery against airway inflammation and 
allergic responses 
I) Effects of IL-35 in the Blo t 5 specific Th2 cells induced airway 
inflammatory murine model 




Chapter 2 Materials and Methods 
 
2.1 Construction of pVAXBlot5 
The Blo t5target construct was generated by fusing the sslamp to the 5’end of Blo t 5 
and the targeting sequence to the 3’end of Blo t 5 by using the forward primer for 
sslamp and the reverse primer for the targeting sequence. The leader sequence 
(sslamp) was first fused to the 5’ end of  Blo t5 construct by PCR using forward 
primer for sslamp (5’-TGGAGGATCCACAAATGAAGTTCGCCATCGTTCTTATT 
G-3’) and reverse primer for Blo t5 (5’-TGGATCTAGATTATTGGGTTTGAATAT 
CCTTCACTTTT-3’) on a template DNA obtained from the lab. The lamp targeting 
sequence was then fused to sslamp-Blot5 construct by using the forward primer (5’-
TGGAGGATCCACAAATGAAGTTCGCCATCGTTCTTATTG-3’) and the reverse 
primer (5’-CCCTTCTAGACTAGATGGTCTGATAGCCGGCGTG-3’). The lamp 
targeting sequence template was obtained from the lab. The Blo t5target construct was 
generated by cloning cDNA coding for the mature Blo t5 into a construct of pVAX1 
using the restriction enzyme BamHI and XbaI. Amplifications were performed using 
high fidelity DNA polymerase (Roche Molecular Biochemicals, Mannheim, Germany) 
in a DNA thermal cycler (Perkin-Elmer Gene Amp PCR system 9700). Polymerase 
chain reaction (PCR) parameters were 2 min at 94°C, 40 cycles of 30 s at 94°C, 1 min 
at 55°C, 2 min at 68° C and a final extension of 7 min at 68°C. pVAXBlot5 and 
pVAXBlot5-DTKT were used for studies done in murine models and on mouse cells. 
 
2.2 Construction of pVAXhBlot5 
The humanized Blo t5target construct was generated by fusing the human tissue 
plasminogen activator (htpa) to the 5’end of Blo t5 and the human lamp targeting 
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sequence to the 3’end of Blo t5 by using the forward primer for htpa and the reverse 
primer for the targeting sequence. Human tissue plasminogen activator sequence, 
humanized Blo t 5, human lamp targeting sequence were amplified from DNA 
templates in the lab by the forward primer for htpa (htpa-F 5’-
AAAAGGATCCGCCACCATGGATGCAATGAAGAGAGGGCTCTGC-3’), 
reverse primer for htpa (htpa-R 5’ TTGGGCTTGTGCTCCTGGAGGGGCGGGACA 
CAGGGGTCCTG-3’), forward primer for humanized Blo t 5 (hBlot5-F 5’-
GGACCCCTGT GTCCCGCCCCTCCAGGAGCACAAGCCCAAGAAGGACG-3’), 
reverse primer for humanized Blo t 5 (hBlot5-R 5’-ACAGCGATGGGGATCAGCTG 
GGTCTGAATGTCCTTCACTTTCTGC-3’), forward primer for human lamp 
targeting (LampT-F 5’-GGAC ATTCAGACCCAGCTGATCCCCATCGCTGTGGG 
TGGTGCC-3’) and reverse primer for human lamp targeting (LampT-R 5’-
AAAATCTAGACTAGATAGTCTGGTAGCCTG CGTGACTCC-3’). Human tissue 
plasminogen sequence was then fused to humanized Blot5 construct by using the 
forward primer for htpa (htpa-F 5’-AAAAGGATCCGCCACCATGGATGCAATGA 
AGAGAGGGCTCTGC-3’), and reverse primer for humanized Blo t 5 (hBlot5-R 5’-
ACAGCGATGGGGATCAGCTGGGTCTGAATGTCCTTCACTTTCTGC-3’). 
Humanized lamp targeting sequence was then fused with the htpa-hblot5 construct by 
using the forward primer for htpa (htpa-F 5’-AAAAGGATCCGCCACCATGGATGC 
AATGAAGAGAGGGCTCTGC-3’) and reverse primer for human lamp targeting 
(LampT-R 5’-AAAATCTAGACTAGATAGTCTGGTAGCCTGCGTGACTCC-3’). 
The humanized Blo t5target construct was generated by cloning cDNA coding for the 
mature Blo t5 into a construct of pVAX1 using the restriction enzyme BamHI and 
XbaI. Amplifications were performed using high fidelity DNA polymerase (Roche 
Molecular Biochemicals, Mannheim, Germany) in a DNA thermal cycler (Perkin-
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Elmer Gene Amp PCR system 9700). PCR parameters were 2 min at 94°C, 40 cycles 
of 30 s at 94°C, 1 min at 55°C, 2 min at 68°C and a final extension of 7 min at 68°C. 
pVAXhBlot5 and pVAXhBlot5-DTKT were used for studies done in non-human 
primates and on human cells. 
 
2.3 Incoporation of K type CpG oligonucleotide into the pVAX backbone 
The DNA plasmid encoding Blo t5 was digested with PMII (New England Biolabs, 
MA) and incubated at 37°C for 4 hours. It was then treated with calf intestinal 
alkaline phosphatase (Promega, Madison, Wisconsin, USA) and incubated at 37° C 
for 15min. Nucleotide removal kit (Qiagen, Duesseldorf, Germany) was then used to 
remove excess nucleotides according to the manufacturer’s instructions. All primers 
and oligonucleotides were synthesized commercially (Sigma, St Louis). KT1 (5’-
ATCGACTCTCGAGCGTTGTTCTTCGTTCGTTCTC-3’) and KT2 (5’-GAGAACG 
AACGAAGAACAACGCTCGAGAGTCGAT-3’) were incubated at 95° C for 5 mins 
to allow annealing to form double stranded KT. Double stranded KT was then 
digested with PMII (New England Biolabs, MA) and incubated at 37°C. Excess 
nucleotides were removed using nucleotide removal kit. Digested double stranded KT 
was then incubated with linearized DNA plasmid together with DNA ligase (Promega, 
Madison, Wisconsin, USA) overnight at 16°C. The mixture was transformed into E 
coli strain DH5α. The clones were then selected and amplified using the primer PMII-
F (5’-CTAAATACATTCAAATATGTATCCGC-3’) and BGH-R. PCR 
amplifications were performed using high fidelity DNA polymerase (Roche 
Molecular Biochemicals, Mannheim, Germany) in a DNA thermal cycler (Perkin-
Elmer Gene Amp PCR system 9700). PCR parameters were 2 min at 94°C, 40 cycles 
of 30 s at 94°C, 30s at 50°C, 2 min at 72°C and a final extension of 7 min at 72°C. 
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The PCR products were then run under electrophoresis in a 1% agarose gel. Plasmids 
of suspected clones containing KT were digested with PMII and another restriction 
enzyme NheI (Promega, Madison, Wisconsin, USA) to confirm the presence of the 
insert KT. 
 
2.4 Incoporation of D type CpG oligonucleotide into pVAX backbone 
The DNA plasmid encoding Blo t5 with KT were digested with MIuI (Promega, 
Madison, Wisconsin, USA) and incubated at 37° C for 4 hours. It was then treated 
with klenow polymerase (Promega, Madison, Wisconsin, USA) to create blunt ends. 
After that, it was further treated with calf intestinal alkaline phosphatase (Promega, 
Madison, Wisconsin, USA) and incubated at 37° C for 15min. Nucleotide removal kit 
was then used to remove excess nucleotides according to the manufacturer’s 
instructions. DT1 (5’-GGTGCATCGATGCAGCATCGAGGCAGGTGCATCGATA 
CAGGGG-3’) and DT2 (3’-CCCCTGTATCGATGCACCTGCCTCGATGCTGCAT 
CGATGCACC-3’) were incubated at 95°C for 5 mins to allow annealing to form 
double stranded DT. Double stranded DT was then digested with MIuI (Promega, 
Madison, Wisconsin, USA) and incubated at 37°C. Excess nucleotides were removed 
using nucleotide removal kit. Digested double stranded DT was then incubated with 
linearized DNA plasmid together with DNA ligase (Promega, Madison, Wisconsin, 
USA) overnight at 16°C. The mixture was transformed into E coli strain DH5α. 
Plasmids of suspected clones containing DT was digested with MluI and another 
restriction enzyme XhoI (Promega, Madison, Wisconsin, USA) to confirm the 
presence of the insert DT. The clones were then selected and sequenced using the 





2.5 DNA sequencing 
DNA sequencing was used to verify the sequence of the reading frame of the 
recombinant constructs. To set up the PCR reaction, 200 ng of recombinant construct 
was added to 8 μl of ABI-prism Big Dye termination reaction mix (PE applied 
biosystems) and 10 pmol of either the forward or reverse primer. The PCR mixture 
was topped up to a final volume of 20 μl with ddH2O. PCR parameters were 1 min at 
96°C, 25 cycles of 10s at 95°C, 15s at 50°C and 4 min at 60°C. After amplification, 
precipation of the PCR mixture was carried out by the addition of 2 μl of 3 M NaOAc 
and 2 μl of 0.5 M EDTA, 60 μl of 100% ethanol and incubated on ice for 10 mins. 
The mixture was then centrifuged at 14000 rpm for 20min, the supernatant was 
discarded and the precipitate washed with 250 μl of 70% ethanol. It was centrifuged at 
14000 rpm for 5min, the supernatant was discarded and the precipitate left to air dry. 
The precipitate was then sent to an external company for sequencing. 
 
2.6 Preparation of single cell suspension of splenocytes 
Spleens were excised from mice and placed in 10 ml of 1x HBSS (Sigma, St Louis) in 
petri dishes. Spleens of mice were meshed and grinded using slides and red blood 
cells were lysed with 1.5 ml of RBC lysis buffer (10 mM Tris, 0.83% NH4Cl, pH 8.2-
8.4) for 90 seconds. The cells were then washed three times with large volumes of 1 x 
HBSS and resuspended in RPMI-1640 (Thermo fisher scientific, Waltham, 
Massachusetts, USA) supplemented with 10% heat-inactivated bovine calf serum 
(StemCell Technologies, Vancouver, BC, Canada), 1 mM sodium pyruvate (HyClone, 
South Logan, UT, USA), 2 mM L-glutamine, antibiotics (100 U/ml penicillin and 100 
μg/ml streptomycin), 5.5 x 10-2 mM β-mercapthoethanol (Gibco BRL, life 
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technologies, Paisley, UK) after which cell count was determined using 
hematocytometer under the light microscope. 
 
2.7 In vitro coculture of CpG-modified plasmids with splenocytes 
A total of 3 x 106  splenocytes were cocultured with 10 nM ,33 nM, 66 nM and 100 
nM of CpG-modified plasmid DNA per well in a 24 well plate (Greiner bio-one, 
Frickenhausen, Germany) for 24 hours. Plasmid DNA were tested to be endotoxin 
free. The culture supernatant was collected after 4 hours and 24 hours and the 
cytokines assayed via Milliplex. 
 
2.8 Cytokine ELISA 
50 μl of purified rat anti-mouse IFN-γ (Pharmingen, San Diego CA), TNF-α (R&D 
systems, Minneapolis, MN), IL-6 (Pharmingen, San Diego CA), IL-10 (R & D 
systems, Minneapolis, MN), IL-12 (Pharmingen, San Diego CA) antibodies were 
diluted in coating buffer (0.1 M NaHCO3, pH 8.3) to a concentration of 2 μg/ml, 0.8 
μg/ml, 1 μg/ml , 4 μg/ml and 2 μg/ml respectively and coated onto 96 well high 
binding plate (Costar). The plate was incubated at 4°C overnight and then washed 
with 0.05%Tween/TBS. 100 μl of blocking buffer (1% BSA 
(Sigma)/0.05%Tween/TBS) was added to each well and incubated at room 
temperature for 1 hour, after which the plate was washed again. 50 μl of culture 
supernatant was added and incubated at 4°C overnight. Standard curves were prepared 
and added to plate using 50 μl of recombinant mouse IFN-γ, TNF-α, IL-6, IL-10, IL-
12 of starting concentration 20 ng/ml, 2.5 ng/ml,10 ng/ml, 5 ng/ml and 10ng/ml 
respectively with two fold serial dilution in blocking buffer. This allowed the levels of 
cytokines in the culture supernatant to be quantified. After the overnight incubation, 
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the plate was washed and 50 μl of biotinylated anti-mouse IFN-γ (2 μg/ml), TNF-α 
(300 ng/ml), IL-6 (500 ng/ml), IL-10 (0.4 μg/ml), IL-12 (200 ng/ml) diluted in 
blocking buffer was added to each well. The plate was incubated for 1 hour at room 
temperature and washed. After which, 50 μl of ExtraAvidin®-alkaline phosphatase 
(Sigma, St Louis) (1:2000) diluted in blocking buffer was added and incubated at 
room temperature for 1 hour. The plate was washed after an hour of incubation and 50 
μl of phosphatase substrate p-nitrophenyl phosphate was added (Sigma, St Louis). 
The plates were read in a BioTek Synergy 2 reader at a wavelength of 405nm. Type I 
interferons (IFN-α and IFN-β) were assayed using ELISA kits (PBL biomedical 
laboratories, NJ) according to the manufacturer’s instructions. 
 
2.9 Deriving dendritic cells from bone marrow 
Bone marrow cells from C57BL/6 mice were isolated by flushing femurs with 5 ml of 
RPMI 1640 (Thermo fisher scientific, Waltham, Massachusetts, USA ) supplemented 
with 10% heat-inactivated bovine calf serum (StemCell Technologies, Vancouver, BC, 
Canada), 1 mM sodium pyruvate (HyClone, South Logan, UT, USA), 2 mM L-
glutamine, antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin), 5.5 x 10-2 
mM β-mercapthoethanol (Gibco BRL, life technologies, Paisley, UK) The bone 
marrow cells were centrifuged once and then resuspended in tris-ammonium chloride 
for 90 seconds to lyse red blood cells. The cells were centrifuged again and then 
strained through a 70-µm filter before being resuspended in RPMI 1640. For FMS-
like tyrosine kinase 3 ligand (Flt3L)-DCs, bone marrow cells were resuspended at 2 x 
106/ml in medium containing 200 ng/ml murine recombinant Flt3L (Peprotech, Rocky 
hill, NJ), plated at 5 ml/well in 6 well plates and cultured for 8 days without 
disturbing. For granulocyte macrophage colony stimulating factor (GMCSF)-DCs, 
57 
 
bone marrow cells were seeded at 5 x 105/ml in medium containing 40 ng/ml GMCSF 
(Peprotech, Rocky hill, NJ), plated at 10ml per petri dish and cultured for 6 days. 
After 3 days, another 10ml of fresh medium containing 40 ng/ml GMCSF was added. 
All cells were incubated at 37ºC with 10% CO2. 
 
2.10 In vitro stimulation of dendritic cells 
Flt3L-DCs were collected on day 8 and stained with APC-conjugated CD11c 
(Pharmingen, San Diego CA) in staining buffer (2%FCS/5mM EDTA/PBS/pH7.4) for 
20 mins at 4ºC. The stained cells were then washed twice with staining buffer and 
resuspended at a density of 2.5 x 107 cells/ml and sorted based on surface markers. 
The CD11c+ Flt3L-DCs were collected after cell sorting. GMCSF-DCs were collected 
on day 6 and subjected to dendritic cell enrichment. Purity of dendritic cells was 
checked by flow cytometry and found to be more than 95%. GMCSF-DCs were 
plated at 1 x 106 per well in 24 well plate and cocultured with either 10 nM or 100 nM 
of plasmid DNA or CpG oligonucleotide. Flt3L-DCs were plated at 1 x 106 per well in 
24 well plate and cocultured with either 10 nM or 100 nM of plasmid DNA. Plasmid 
DNA were tested to be endotoxin free.  The supernatant was collected after 24 hours 
and was assayed for cytokines and chemokines by cytokine/chemokine multiplex 
assays (Millipore, Bedford, MA, USA). 
 
2.11 Cytokine/chemokine multiplex assay (Milliplex) 
Cytokine/chemokine multiplex assay was carried out according to the manufacturer’s 
instructions (Millipore, Bedford, MA, USA). Briefly, 25 μl of the samples and diluted 
standards were added into the wells, followed by the addition of 25 μl of premixed 
beads and 25 μl of assay buffer. The plate was incubated at 4°C overnight with 
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shaking. The fluid was then removed by vacuum, followed by washing with 200 μl of 
wash buffer per well twice. Next, 25 μl of detection antibodies was added and 
incubated for 1h at room temperature with shaking, followed by the addition of 25 μl 
of Streptavidin-Phycoerythrin. The plate was incubated for 30 mins at room 
temperature with shaking and the fluid was then removed by vacuum, followed by 
washing with 200 μl of wash buffer per well twice. Lastly, 150 μl of sheath fluid was 
added to all wells, followed by shaking for 15 mins and run on Luminex 100TM IS. 
 
2.12 Cytokine and chemokine array 
The cytokine and chemokine array was performed according to the manufacturer’s 
instructions (Raybio® mouse cytokine antibody array G series 1000 array III and IV, 
Raybio® human cytokine antibody array G series 2000, RayBiotech Inc). Briefly, the 
glass chip was first assembled into the incubation chamber and frame. 100 μl of 1x 
blocking buffer was added to the glass chip and incubated for 30 mins at room 
temperature. The blocking buffer was then removed from the glass slide after 30 mins 
and 100 μl of culture supernatant was added and incubated for 2 hours. The samples 
were then removed from the wells and washed 3 times with 150 μl of 1x wash buffer I 
in each well at room temperature. The glass chip with frame was then placed into a 
box with 1 x wash buffer I and washed for 20 mins with gentle shaking, the wash 
buffer I was then removed with the addition of 1 x wash buffer I and washed at room 
temperature twice for 5 mins with gentle shaking. After removal of the wash buffer II, 
70 μl of diluted biotin-conjugated antibodies was added to each well and incubated at 
room temperature for 2 hours. The glass slide with frame was then washed with wash 
buffer I and II as mentioned above. 70 μl of diluted fluorescent dye conjugated 
strepavidin was added and incubated for 2 hours, it was then washed with wash buffer 
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I twice and the slide’s signals were scanned and read with Axon GenePix 4000b 
scanner. 
 
2.13 Flow cytometric analysis of the stimulatory effect of modified plasmids on 
bone marrow derived dendritic cells using GMCSF 
Bone marrow derived cells were cultured with 40 ng/ml GMCSF (Peprotech, Rocky 
hill, NJ) for 6 days. The bone marrow derived dendritic cells were enriched by 
gradient separation on day 6 and co-cultured with 10 nM and 100 nM of modified or 
unmodified plasmids for 24 hours. Flow cytometry was conducted to examine the 
expression of dendritic cell marker CD11c as well as the surface expression of MHC 
class II and costimulatory molecules CD86, CD80, CD40 on plasmids activated 
dendritic cells. Briefly, the cells were stained with either APC- conjugated CD11c 
(Pharmingen, San Diego CA), PE-conjugated CD40 (eBioscience, San Diego CA) 
and FITC-conjugated CD80 (Southern Biotech, USA) or with APC- conjugated 
CD11c (Pharmingen, San Diego CA), PE-conjugated CD86 (Pharmingen, San Diego 
CA) and FITC-conjugated MHC class II (Pharmingen, San Diego CA) in staining 
buffer (1% BSA/PBS) for 20 mins at 4ºC. The stained cells were then washed twice 
with staining buffer and resuspended in 1% paraformaldehyde/PBS. Flow cytometry 
was performed using FACScalibur (Becton Dickson Immunocytometry Systems, San 
Jose, CA). 
 
2.14 Flow cytometric analysis of the stimulatory effect of CpG oligonucleotides 
on bone marrow derived myeloid dendritic cells  
Bone marrow derived cells were cultured with 40 ng/ml GMCSF (Peprotech, Rocky 
hill, NJ) for 6 days. The bone marrow derived dendritic cells were enriched by 
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gradient separation on day 6 and co-cultured with 10 nM and 100 nM of modified 
plasmids or CpG oligonucleotides for 24 hours. Flow cytometry was conducted to 
examine the expression of dendritic cell marker CD11c as well as the surface 
expression of MHC class II and costimulatory molecules CD86, CD80, CD40 on 
plasmids and CpG ODN activated dendritic cells. Briefly, the cells were stained with 
either APC-conjugated CD11c (Pharmingen, San Diego CA), PE-conjugated CD40 
(eBioscience, San Diego CA) and FITC-conjugated CD80 (Southern Biotech, USA) 
or with APC-conjugated CD11c (Pharmingen, San Diego CA), PE-conjugated CD86 
(Pharmingen, San Diego CA) and FITC-conjugated MHC class II(Pharmingen, San 
Diego CA) in staining buffer (1% BSA/PBS) for 20 mins at 4ºC .The stained cells 
were then washed twice with staining buffer (1% BSA/PBS) and resuspended in 1% 
paraformaldehyde/PBS. Flow cytometry was performed using FACScalibur (Becton 
Dickson Immunocytometry Systems, San Jose, CA). 
 
2.15 TLR 9 inhibition experiment 
Flt3L-DCs were collected on day 8 and stained with APC-conjugated CD11c 
(Pharmingen, San Diego CA) , biotin-conjugated B220 (Pharmingen, San Diego CA) 
and FITC-conjugated CD11b antibodies (Pharmingen, San Diego CA) in staining 
buffer (2%FCS/5mM EDTA/PBS/pH7.4) for 20 mins at 4ºC. The stained cells were 
then washed twice with staining buffer and stained with PE-conjugated strepavidin 
antibodies (Pharmingen, San Diego CA) for 20 mins at 4 ºC. The stained cells were 
then washed twice with staining buffer and resuspended at a density of 2.5 x 107 
cells/ml and cell sorted. The Flt3L-DCs were sorted for CD11c+B220+CD11b- 
fraction and CD11c+B220-CD11b+ fraction. Purity of the CD11c+B220+CD11b- and 
CD11c+B220-CD11b+ fractions were found to be more than 95%. These fractions 
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were then seeded at 1 x 105 cells per well in 96-well plates and cocultured with 100 
nM of plasmid DNA for 24 hours in the presence of 0.1 μM, 1 μM or 2 µM of TLR9 
inhibitory ODN. The most effective dose of TLR9 inhibitory ODN was selected to be 
2 µM and the experiment repeated with the addition of 2 μM of control ODN 
(described below). The culture supernatant was collected after 24 hours and assayed 
for IFN-α, IFN-β (PBL biomedical laboratories, NJ) and cytokines using 
cytokine/chemokine multiplex assays (Millipore, Bedford, MA, USA). 
 
2.16 TLR9 inhibitory and control oligonucleotides 
Toll-like receptor 9 inhibitory oligonucleotide sequences used were IRS 2088, 5’-
TCCTGGCGGGGAAGT-3’. Control oligonucleotide sequence was 5’-TCC 
TGCAGGTTAAGT-3’. Control ODN had the same length (15 mer) and base 
composition as TLR9 inhibitory ODN with no CpG motif and apparent activity. 
Uppercase letters represent phosphorothiorate linkages (Duramad et al., 2005). 
 
2.17 Coculture of plasmid DNA pulsed dendritic cells with Blot5- specific T 
cells 
Bone marrow cells from female C57BL/6 mice were isolated by flushing femurs with 
5 ml RPMI 1640 supplemented with 10% heat-inactivated bovine calf serum 
(StemCell Technologies, Vancouver, BC, Canada), 1 mM sodium pyruvate (HyClone, 
South Logan, UT, USA), 2 mM L-glutamine, antibiotics (100 U/ml penicillin and 100 
μg/ml streptomycin), 5.5 x 10-2 mM β-mercapthoethanol (Gibco BRL, life 
technologies, Paisley, UK). The bone marrow cells were centrifuged once and then 
resuspended in tris-ammonium chloride for 90 seconds to lyse red blood cells. The 
cells were centrifuged again and then strained through a 70-µm filter before being 
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resuspended in RPMI 1640. Bone marrow cells were resuspended at 2 x 106/ml in 
medium containing 200 ng/ml murine recombinant Flt3L (Peprotech, Rocky hill, NJ), 
plated at 5 ml/well in 6 well plates and cultured for 8 days without disturbing. Flt3L-
DCs were collected on day 8 and stained with APC conjugated CD11c (Pharmingen, 
San Diego CA), PE-conjugated B220 (Pharmingen, San Diego CA) and FITC-
conjugated CD11b antibodies (Pharmingen, San Diego CA). The 
CD11c+CD11b+B220- Flt3L-DCs were collected after cell sorting and pulsed with 100 
nM of plasmid DNA for 24 hours. Purity of CD11c+CD11b+B220- Flt3L-DCs was 
found to be more than 95%. After 24 hours, the dendritic cells were washed twice 
with HBSS and pulsed with purified CD4+T cells (described below) from spleen of 
female Blo t5 T cell receptor (TCR) transgenic mouse at a 1:2 ratio. After 24hours of 
coculturing dendritic cells with plasmid DNA, the cells were washed twice with 
HBSS and pulsed with CD4+ T cells from spleens of Blo t 5 T cell receptor transgenic 
mice at a 1:2 ratio. 72 hours later, fresh medium containing IL-2 was added. 7 days 
after the coculture of DCs and T cells, the T cells were washed and subjected to ficoll 
separation to remove the dead cells. After which the T cells were restimulated again 
with freshly prepared plasmid DNA pulsed dendritic cells. The culture supernatant 
was collected after 72 hours and assayed for IL-17 and IFN-γ using 
cytokine/chemokine multiplex assays (Millipore, Bedford, MA, USA). 
 
2.18 Purification of CD4+ T cells 
After the removal of dead cells from splenocytes obtained from Blo t 5 TCR 
transgenic mice, the cells were stained with biotinylated anti-CD4 mAb in staining 
buffer (0.5% BSA/2mM EDTA/PBS, pH7.2) for 10 mins at 4°C. The cells were then 
washed with staining buffer and streptavidin-microbeads were added and incubated at 
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4°C for another 10min. The stained cells were washed twice and and suspended in 
staining buffer. Cell separation was performed using AutoMACS (Miltenyi Biotec 
GmbH, Gladbach, Germany) by running the “double positive selection” program. The 
purity of the CD4+ T cells was checked by flow cytometry and showed more than 
95% purity. 
 
2.19 Coculture of human peripheral blood mononuclear cells with plasmid 
DNA and CpG oligonucleotides 
Whole blood was obtained from volunteers and diluted one time with HBSS (Sigma, 
St Louis). The diluted blood was layered gently on top of 5 ml of Ficoll-Hypaque (GE 
healthcare, UK) and subjected to density gradient separation. The PBMC obtained 
were washed three times with HBSS and cultured in Aim V medium (Gibco, 
Invitrogen, CA, USA) with 1 nM, 10 nM and 100 nM of plasmid DNA or CpG ODN 
for 5 hours and 24 hours. The culture supernatants were collected and assayed via 
cytokine/chemokine multiplex assays (Millipore, Bedford, MA, USA). 
 
2.20 Mice  
6-8 weeks female C57BL/6 mice from the Centre for Animal Resources, National 
University of Singapore were used in the experiments. All experiments were 
performed according to Institutional Guidelines for Animal Care and Handling 
(IACUC). Blo t 5 specific TCR transgenic mice were generated in the laboratory 
(manuscript in preparation). 
 
2.21 Immunization regimen 
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Female C57BL/6 Mice were immunized with 50 μg of plasmid DNA (pVAX, 
pVAXBlot5, pVAXBlot5-DTKT) in 50 μl of PBS into the quadriceps of mouse with 
electrophoration as described in (Wolfowicz et al., 2003)  on days 0 and 14. Briefly, 
the quadriceps of the anesthetized mice was shaved and plasmid DNA were injected 
using a 1 ml syringe and 27G needle in the anterior tibalis followed by 
electrophoration with an ECM 830 apparatus (BTX, Genetronics, San Diego, CA). 
Electrophoration was carried out with 0.5 cm 2-needle array inserted 2 mm deep into 
the muscle that delivered 4 pulses of 20 ms, 80V each with a 200 ms interval. To 
study the early priming response, primed mice were sacrificed on day 21 and spleens 
were harvested for in vitro culture study. 
 
For the allergy model, female C57BL/6 mice were intraperitoneally immunized with 
10 μg of rBlo t 5 protein adjuvanted with aluminium hydroxide (alum) on day 0. 
Three weeks later, mice were given another intraperitoneal immunization with 5 μg of 
rBlo t 5 protein adjuvanted with alum and they were sacrified one week later. Spleens 
were harvested for in vitro study. Mice were bled weekly and sera were analysed for 
Blo t 5 specific IgG1, IgG2c and IgE by ELISA. 
 
In another study, mice were immunized with 50 μg of plasmid DNA (pVAX, 
pVAXBlot5, pVAXBlot5-DTKT) in 50 μl of PBS per mouse with electrophoration on 
days 0 and 14. Mice were immunized intraperitoneally with 10 μg of Blo t 5 protein 
adjuvanted with alum and 5 μg of Blo t 5 protein adjuvanted with alum on days 21 
and 42 respectively. Mice were sacrificed on day 49 and spleens were harvested for in 
vitro culture study. Mice were bled weekly and the sera were analyzed for Blo t 5 




2.22 Splenic cell culture 
Splenocytes were cultured in complete RPMI-1640 medium and incubated at 37°C in 
the presence of 5% CO2. To determine the cytokine production of freshly isolated 
splenic cells, 100 μl of cells (4 x 106 cells/ml) were stimulated in the presence of 100 
μl of Blo t 5 protein (20 μg/ml) per well in a 96 well U bottomed plate. To establish 
the short term T cell culture, splenocytes were cultured in 24 well (4 x 106 cells/ml) or 
6 well (2 x 107 cells/well) plates in the presence of 10 μg/ml rBlo t 5 protein for 7 
days. On days 3 and 5, cells were supplemented with fresh medium containing 10 
U/ml of recombinant mouse IL-2 (R&D Systems, Minneapolis, MN, USA). To 
determine the cytokine profile of short term culture T cells, 50 μl of T cells (2 x 106 
cells/ml) collected after Ficoll-Pague centrifugation (described below) and 50 μl of 
APCs (6 x 106 cells/ml) were added to 96-well U bottomed plate, followed by 100 μl 
of rBlo t 5 protein (20 μg/ml). The supernatant were collected at various timepoints 
for cytokine and chemokine profiling via Milliplex or ELISA. 
 
2.23 Preparation of antigen presenting cells 
Mitomycin C treated splenocytes of naïve mice were used as antigen presenting cells. 
Mitomycin C (Roche Diagnostics GmbH, Mannheim, Germany) was dissolved in 
PBS to a final concentration of 0.5 mg/ml and sterile filtered with 0.22 μM filter. 
Spleens of mice were meshed and grinded using slides and washed twice with 1x 
HBSS, after which, splenocytes were suspended in PBS at a concentration of 5 x 107 
cells/ml. Mitomycin C was added to a final concentration of 50 μg/ml and the tube 
was wrapped in aluminium foil and incubated for 20 mins in a 37°C water bath. After 
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the 20 mins incubation, the cells were washed 3 times with 30 ml of 1x HBSS and 
suspended in RPMI-1640 medium. 
 
2.24 Separation of dead cells from short term cultured splenocytes by Ficoll-
Paque centrifugation 
Cells were collected and suspended in 5 ml of 1x HBSS in 15 ml tube after 7 days of 
primary cell culture with antigen. Three milliliters of Ficoll-Paque (Amersham 
Biosciences Corp. Piscataway, NJ) was added to the bottom of the tube without 
interfering with the interface of the two layers, followed by centrifugation of the cells 
at 800x g. The live cells were then carefully collected from the interface, washed 3 
times with 1x HBSS and suspended in RPMI 1640. 
 
2.25 Construction of pVAX-IL-35 
The pVAX vector (Invitrogen Corporation) was used for the expression of murine IL-
35. The Epstein-Barr virus induced gene 3 (EBI3) was amplified from the first strand 
cDNA prepared from lipopolysaccharide activated bone marrow derived dendritic 
cells. EBI3 sense: 5′-AAAAGGATCCATCCAAGGAACAGAGCCACAGAGCATG 
TCC-3′ and EBI3 antisense: 5′-AGAACCACCACCAAGCTTGGGCTTATGGGGTG 
CAC-3′. BamHI and HindIII sites were introduced into EBI3 sense primer and 
antisense primer respectively. The p35 subunit of IL-12 (IL-12p35) was amplified 
from the first strand cDNA prepared from splenocytes. IL-12p35 sense: 5′-
GGTGGTGGTTCTGAATTCAGGGTCATTCCAGTCTCTGGACCTG-3′ and IL-
12p35 antisense: 5′-A AAAGCTAGCTCAGGCGGAGCTCAGATAGCCCATCACC 
CTGTT G-3′. EcoRI and NheI sites were introduced into IL-12p35 sense primer and 
antisense primer respectively. Two complementary oligonucleotides encoding for 4 
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repeats of GGGS linker were designed and annealed. Linker sense: 5′-A 
ACCAAGCTTGGTGGTGGTTCTGGTGGTGGTTCTGGTGGTGGTTCTGGTGGT
GGTTCTGGATCCGGTT-3′ and linker antisense: 5′-AACCGAATTCAGAACCAC 
CACCAGAACCACCACCAGAACCACCACCAGAACCACCACCAAGCTTGGTT
-3′. HindIII and EcoRI sites were included in the linker sense and linker antisense 
primers. Amplified EBI3, IL-12p35 and the double stranded linker were digested with 
respective restriction enzymes and ligated into BamHI and NheI sites of pVAX. The 
recombinant single-chain IL-35 in the pVAX vector (pVAX-IL-35) was verified by 
DNA sequencing. 
 
2.26 Intratracheal instillation of pVAX-IL-35 on the suppression of Blo t 5 
specific Th2 cell line induced airway inflammation 
Long-term cultured Blo t 5-specific Th2 cells were routinely harvested 7 days after re-
stimulation with rBlo t 5 protein and washed with sterile PBS. Six to 8 week-old 
female C57BL/6 mice were intratracheally administered with 400 µg of either pVAX 
or pVAX-IL-35 plasmid DNA on day 0. One day later, mice were received the 
transfer of 2 × 106 of Blo t 5 specific Th2 cells intravenously. A daily dose of 50 µg 
of rBlo t 5 protein was given intranasally to mice on days 2, 3 and 4. Mice were 
euthanized by carbon dioxide and the BALF was collected on day 5. Cellular 
infiltrates were assessed by differential cell count of 500 cells based on standard 
hematological characteristics of macrophages, lymphocytes, neutrophils and 
eosinophils. Cytokines/chemokines in the BALF were assessed by the 




2.27 Intramuscular injection of pVAX-IL-35 on the suppression of Blo t 5 
specific Th2 cell line induced humoral responses 
Six to 8 week-old female C57BL/6 mice were intramuscularly injected with 50 µg of 
either pVAX or pVAX-IL-35 plasmid DNA in 50 μl of PBS into the quadriceps of 
mouse with electrophoration as described (Wolfowicz et al., 2003) on days 0 and 14. 
Briefly, the quadriceps of the anesthetized mice were shaved and plasmid DNA was 
injected using a 1 ml syringe and 27G needle in the anterior tibalis followed by 
electrophoration with an ECM 830 apparatus (BTX, Genetronics, San Diego, CA). 
Electrophoration was carried out with 0.5 cm 2-needle array inserted 2 mm deep into 
the muscle that delivered 4 pulses of 20 ms, 80V each with a 200 ms interval. The 
mice received intravenous transfer of 2 × 10 6 of Blo t 5 specific Th2 cells on day 17 
and then given the first course of intranasal instillation of 50 µg of Blo t 5 protein 
daily on days 18, 19 and 20. The second course of intranasal instillation of 50 µg of 
rBlo t 5 protein was given daily on days 77, 78 and 79. Sera were collected on days 30, 
37, 44, 51, 84 and 91 for the assay of Blo t 5 specific IgE and IgG1 by ELISA. 
Concentrations of total IgG1, IgG2c, IgM, IgA and IgE were also determined from 
sera by ELISA. 
 
2.28 Intramuscular injection of pVAX-IL-35 on the suppression of Th2 
cytokines 
Six to 8 week-old female C57BL/6 mice were intramuscularly injected with 50 µg of 
either pVAX or pVAX-IL-35 plasmid DNA with electroporation in 50 μl of PBS into 
the quadriceps of mouse with electrophoration as described (Wolfowicz et al., 2003) 
on days 0 and 14. Briefly, the quadriceps of the anesthetized mice were shaved and 
plasmid DNA was injected using a 1ml syringe and 27G needle in the anterior tibalis 
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followed by electrophoration with an ECM 830 apparatus (BTX, Genetronics, San 
Diego, CA). Electrophoration was carried out with 0.5 cm 2-needle array inserted 2 
mm deep into the muscle that delivered 4 pulses of 20 ms, 80V each with a 200 ms 
interval. The mice received intravenous transfer of 2 × 106 of Blo t 5 specific Th2 
cells on day 17 and then given the first course of intranasal instillation of 50 µg of 
rBlo t 5 protein daily on days 18, 19 and 20. 1 week after the intranasal instillation, 
the mice were sacrificed and spleens were excised. For intracellular staining, one 
milliliter of cell suspension (2 x 106 /ml) was added to each well and stimulated in 
vitro with PMA (10 ng/ml) and ionomycin (1 μg/ml) for 4 hours after which 3 μM of 
monesin (Sigma-Aldrich, St Louis, MO) was added and further cultured for 8 hours. 
After staining with FITC-conjugated anti-Vβ3 TCR (Pharmingen, San Diego CA) and 
PerCP-conjugated anti-CD4 (Pharmingen, San Diego CA), the cells were fixed and 
permeabilized with Cytofix/Cytoperm™ solution and further stained with PE-
conjugated anti-IL-4 (Pharmingen, San Diego CA)  
 
2.29 Intratracheal instillation of pVAX-IL-35 on the suppression of airway 
inflammation in Blo t 5 TCR transgenic mice 
Six to eight week-old female Blo t 5 TCR transgenic mice were intratracheally 
administered with 400 µg of either pVAX or pVAX-IL-35 plasmid DNA on day 0. A 
daily dose of 50 µg of rBlo t 5 protein was given intranasally to mice on days 1, 2 and 
3. Mice were euthanized by carbon dioxide and the BALF was collected on day 4. 
Cellular infiltrates were assessed by differential cell count of 500 cells based on 
standard hematological characteristics of macrophages, lymphocytes, neutrophils and 
eosinophils. Cytokines / chemokines in the BALF were assessed by the cytokine / 




2.30 Detection of antigen-specific mouse immunoglobulin responses 
The levels of antigen specific IgG1 and IgE were determined by ELISA. rBlo t 5 
protein was diluted in coating buffer (0.1 M NaHCO3, pH 8.3) to a concentration of 5 
μg/ml, 50 μl of rBlo t 5 protein (5 μg/ml) was used to coat each sample well of 96-
well ELISA plate (Sigma, St Louis) while Ig κ light chain antibody (BD Pharmingen, 
USA) was used to coat the standard wells and incubated at 4°C overnight. After the 
overnight incubation, the plates were washed with 0.05%Tween/TBS and blocked 
with 100 μl of blocking buffer (1% BSA (Sigma) /0.05%Tween/TBS) for 1 hour. The 
plate was washed, sera was added and incubated at 4°C overnight. Standard curves 
were prepared and added to plates using 50 ng/ml of IgG1 and IgE (BD Pharmingen, 
USA), subjected to two fold serial dilution. After the incubation ,plates were washed 
and incubated with biotin-conjugated monoclonal rat anti-mouse IgE (LO-ME-3) or 
IgG1(LO-MG1-2)(Serotec Ltd, Oxford, England) for 1hour, after which the plate was 
washed and 50 μl of ExtrAvidin-alkaline phosphatase (Sigma, St Louis, MO, USA) 
was added. After the 1 hour incubation, the plates were washed 6 times and 50 μl of 
phosphatase substrate p-nitrophenyl phosphate (Sigma, St Louis) were added to the 
plates. The plates were measured at 405nm on BioTek Synergy 2 reader. Anti-mouse 
Igκ light chain antibody (187.1) and commercial standards of purified IgG1 (107.3) 
and IgE (38.2) (BD PharMingen, San Diego, CA, USA) were used to generate the 
standard curves. For IgG2c detection, ELISA kit (Bethyl laboratories, Montgomery, 
TX, USA) was used according to the manufacturer’s instructions. ELISA unit was 
defined as the OD405nm reading corresponding to the signal generated with 1 pg/ml 




2.31 Detection of total mouse immunoglobulin responses 
The levels of total antibodies were determined by ELISA. IgE, IgG1, IgA and IgM 
capture antibody (IgE antibody clone no: R35-72, IgG1 clone no: A85-3, IgA 
antibody clone CC10-3 BD Pharmingen, USA, IgM antibody clone no LO-MM3, 
Serotec) were diluted in coating buffer (0.1 M NaHCO3, pH 8.3) to a concentration of 
2 μg/ml and 50 μl used to coat each well of 96-well ELISA plates (Sigma, St Louis) 
and incubated  at 4°C overnight. After the overnight incubation, the plates were 
washed with 0.05%Tween/TBS and blocked with 100 μl of blocking buffer (1% BSA 
(Sigma)/0.05%Tween/TBS) for 1 hour. The plate was washed, sera was added and 
incubated at 4°C overnight. Standard curves were prepared and added to plates using 
50 ng/ml of IgG1 and IgE, 200ng/ml of IgA (BD Pharmingen, USA), 250ng/ml of 
IgM (Serotec), subjected to two fold serial dilution. After the incubation, plates were 
washed and incubated with biotin-conjugated monoclonal rat anti-mouse IgE , IgG1, 
IgA(BD Pharmingen, USA) or IgM (Serotec) antibodies for 1hour, after which the 
plate was washed and 50 μl of ExtrAvidin-alkaline phosphatase (Sigma, St Louis) was 
added. After the 1 hour incubation, the plates were washed 6 times and 50 μl of 
phosphatase substrate p-nitrophenyl phosphate (Sigma, St Louis) were added to the 
plates. For IgG2c detection, ELISA kit (Bethyl laboratories, Montgomery, TX, USA) 
was used according to the manufacturer’s instructions. The plates were read at a 
wavelength of 405 nm with BioTek Synergy 2 reader. 
 
2.32 Collection of bronchoalveolar lavage fluid and cytopsin preparation for 
differential cell count 
Mice were under deep anaesthesia by an intraperitoneal injection of a strong dose of a 
mixture containing 1.25 mg/ml midazolm, 2.5 mg/ml fluasione and 0.079 mg/ml 
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fentanyl citrate. Using a 20G cannula, the trachea was incised and cannulated by 
tracheotomy. The lung was then lavaged with 0.8ml of cold Hank’s balanced salt 
solution (HBSS) (Sigma, St Louis) without calcium and magnesium 3 times. The 
BALF collected was used for cytokine/chemokine multiplex assays (Millipore, 
Bedford, MA, USA). The same process was repeated 2 more times. The cells were 
then centrifuged at 3000 rpm for 10 min, the supernatant discarded and the cells 
resuspended in HBSS. The cells were then centrifuged again at 3000 rpm for 10 min 
and the cells resuspended in RPMI 1640 (Hyclone, Thermo Scientific). The cells were 
counted under the light microscope and the absolute cell number determined. 
Cytospin was carried out by centrifugation of 1 x 105 cells in 100 μl at 600 rpm for 10 
mins using Cytospin 3 (Shandon Lipshaw) (Cytospin, Runcorn, Cheshire, U.K.). 
After centrifugation, the cells were stained with Liu stain (Liu, 1953). Differential cell 
counts based on standard hematological characteristics were carried out under the 
light microscope and cells were differentiated into lymphocytes, macrophages, 
neutrophils and eosinophils. 
 
2.33 Rhesus macaques and immunization regimen 
Fifteen 3 to 4 year old Chinese-origin rhesus monkeys, weighing 4-5 kg were bred 
and maintained in Shanghai Medical College, China. All animal studies were carried 
out in accordance with the standards set forth in the Guide for the Care and Use of 
Laboratory Animals (published by the National Academy of Science, National 
Academy Press, Washington, DC, USA). Rhesus monkeys were immunized with 2 
mg of plasmid DNA thrice at 4 weeks interval. 4 and 8 weeks after the last 
immunization, the rhesus monkeys were subcutaneously immunized with 500 μg rBlo 
t 5 protein adjuvanted with alum. Sera were collected from the rhesus macaques 
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regularly. Titers of Blo t 5 -specific total IgG, IgG1, IgG3 and IgE were determined 
by ELISA. 
 
2.34 Enzyme-linked immunospot assay 
The monkey IFN-γ and IL-4 ELISPOT kits (U-Cytech, Utrecht, Netherlands) were 
used according to the manufacturer's instructions. Plates were coated overnight with 
50 µl of anti IFN-γ coating antibodies or anti-IL-4 coating antibodies per well at 4°C. 
Blocking buffer (200 µl/well) was then added, and plates were incubated for 1hour at 
37 C. Rhesus monkey PBMC were plated at a density of 4 × 105 cells/well and 
stimulated for 48hours at 37°C in 5% CO2 with 1 μM of Blo t 5 peptide pools. After a 
1hour incubation at 37°C with 100 µl of biotinylated anti-IFN-γ detection antibodies 
or biotinylated anti-IL-4 detection antibodies, 50 µl of streptavidin-HRP was added to 
each well, and plates were incubated for 1hour at 37°C. After this incubation, 100 µl 
of AEC substrate solution was added to each well, and plates were incubated at room 
temperature in the dark. When clear spots developed, reactions were stopped by 
rinsing the wells with deionized water. The spots were counted using an immunospot 
image analyzer. 
 
2.35 Statistical analyses 
All experimental results were presented as either mean ± SD or mean  SEM and 
analyzed by either the student t test or the two-tailed Mann-Whitney U test. A value 
of p < 0.05 was considered significant. 
74 
 
Chapter 3 Evaluation of the Immunogenicity and Efficacy of DNA Vaccines 
with the Incorporation of CpG Motifs into the Plasmid Backbone 
 
3.1 Introduction 
DNA vaccines were promising tools that had been extensively researched on in the 
past decade. DNA vaccines conferred many advantages over conventional protein 
vaccines such as it can be customized with the antigen of interest and it could be 
produced easily in huge amounts. However the major fallback of DNA vaccines was 
its low immunogenicity in humans and primates than in mice especially in the 
induction of humoral responses, hence research efforts have been directed at 
enhancing the immunogenicity of DNA vaccines. 
 
CpG motifs were molecular adjuvants that target at Toll-like receptor 9. There were 
two main classes of CpG oligonucelotides (ODN), K (also referred to as B) and D 
(also referred to as A). Characteristics of  K type ODN were a phosphorothiorate 
TCGT or TCGA motif that induced the stimulation of B cells and proliferation of 
monocytes, resulting in the subsequent secretion of IgM and IL-6 (Coban et al., 2005). 
K types ODN also stimulated the activation and maturation of plasmacytoid dendritic 
cells (pDC) leading to production of TNF-α, IL-6, low levels of type I interferon and 
increased expression of MHC II, CD80 and CD86 (Kerkmann et al., 2003). D type 
ODN on the other hand, consisted of a central CpG flanked by a purine and 
pyrimidine on both sides (Coban et al., 2005). In addition, there were 3 to 4 
complementary bases on both sides of the CpG motif and a 3’ poly G tail (Coban et 
al., 2005; Verthelyi and Klinman, 2003). D type ODN induced the production of high 




In this study, both human K and D type CpG motifs were inserted into the plasmid 
backbone containing the Blo t 5 allergen gene.To study if the incorporation of human 
CpG motifs into the plasmid backbone could increase the activation of antigen 
presenting cells, in vitro coculture of CpG modified plasmid DNA with murine 
dendritic cells were carried out. To answer the question if additional human CpG 
motifs confer increased immunogenicity, immune responses of CpG modified plasmid 
DNA immunized mice were evaluated. To further evaluate if human CpG modified 
plasmid DNA have any possible applications in humans, in vitro coculture of plasmid 
DNA with human peripheral blood mononuclear cells and in vivo immunization of 





3.2.1 Construction of pVAXBlot5 and pVAXhBlot5 
The Blo t 5 construct was generated with the Blo t 5 leader sequence at the 5’ end of 
mature coding sequence of Blo t 5 and the LAMP-1 targeting sequence at the 3’ end. 
The Blo t 5 construct was then cloned into pVAX-1 at the BamHI and XbaI sites and 
designated pVAXBlot5 (Fig 3.1a). The humanized Blo t 5 construct was generated by 
fusing the leader sequence of human tissue plasminogen activator (htpa) to the 5’ end 
of mature coding sequence of human codon optimized Blo t 5 and the human LAMP-
1 targeting sequence at the 3’ end. The humanized Blo t 5 construct was then cloned 
into pVAX-1 at the BamHI and XbaI sites and designated pVAXhBlot5 (Fig 3.1b) 
pVAXBlot5 was used in murine models and on mouse cells while pVAXhBlot5 was 
used in non-human primates and on human cells. 
 
3.2.2 Insertion of D and K type CpG motifs into the plasmid backbone of 
pVAXBlot5 
Schematic diagrams of the CpG modified plasmids were shown in Fig 3.2. K type 
CpG motif (KT) was first inserted into the plasmid backbone at the PmlI site followed 
by insertion of D type CpG motif (DT) at the MluI site. To determine if D and K type 
CpG motifs had been inserted into the plasmid backbone of pVAXBlot5, restriction 
enzyme digestion and polymerase chain reactions were carried out. K type CpG motif 
was inserted into the PmlI site, successful insertion of K type CpG motif would give 1 
band (~3500bp) upon digestion with PmlI and NheI as PmlI site would not be cleaved 
upon insertion of K type CpG motif (Fig 3.3). D type CpG motif was inserted in MluI 
site. Polymerase chain reaction was carried out using the reverse primers BGH-R at 3’ 
untranslated region and specific forward primer DT-1, successful insertion of D type 
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CpG motif was represented by an amplified PCR product of approximately 1300bp 
(Fig 3.4). To further verify if D type CpG motif had been inserted at the MluI site, 
restriction enzyme digestion was carried out using MluI and XhoI. Insertion of D type 
CpG motif at the MluI site would render the site uncleavable hence successful 
insertion of D type CpG motif would give 1 band (~3500bp) upon digestion (Fig 3.5). 
 
3.2.3 pVAXBlot5 and pVAXBlot5-DTKT induced IL-6 and IFN-γ production 
from splenocytes in a dose dependent manner 
Various doses (10 nM, 33 nM, 66 nM, 100 nM) of pVAXBlot5 and pVAXBlot5-
DTKT were cocultured with murine splenocytes and found to induce the production 
of proinflammatory cytokines IL-6 and Th1 signature cytokine IFN-γ in a dose 
dependent manner (Fig 3.6), pVAXBlot5 induced the increased production of IFN-γ 
from 840 pg/ml to 2964 pg/ml after 24 hours of coculture when the dose of 
pVAXBlot5 increased from 10 nM to 100 nM (Fig 3.6a). Similarly, production of IL-
6 also increased from 1109 pg/ml to 2704 pg/ml as dose of pVAXBlot5 increased 
from 10 nM to 100 nM (Fig 3.6b). IFN-γ production from pVAXBlot5-DTKT 
stimulated splenocytes increased from 754 pg/ml to 2410 pg/ml after 24 hours of 
coculture when the dose of pVAXBlot5-DTKT increased from 10 nM to 100 nM (Fig 
3.6a). Similarly, production of IL-6 also increased from 770 pg/ml to 1516 pg/ml as 
dose of pVAXBlot5 increased from 10 nM to 100 nM (Fig 3.6b). There was a trend of 
higher production of IFN-γ and IL-6 from pVAXBlot5 stimulated splenocytes than 
pVAXBlot5-DTKT stimulated splenocytes. Thus, pVAXBlot5 and pVAXBlot5-





3.2.4 Plasmid DNA induced higher cytokine and chemokine production from 
antigen presenting cells when compared to free CpG oligonucleotides. 
To determine the effect of plasmid DNA on antigen presenting cells, dendritic cells 
were generated from murine bone marrow using GMCSF and cocultured with either 
plasmid DNA or free CpG ODN for 24 hours. Coculture with dendritic cells derived 
from bone marrow using GMCSF (GMCSF-DC) showed that similar levels of 
cytokines were elicited with pVAXBlot5 or pVAXBlot5-DTKT coculture (Fig 3.7). 
Plasmid DNA induced significantly higher cytokines and chemokines production 
from GMCSF-DC as compared to free CpG ODN (Fig 3.7). pVAXBlot5-DTKT 
induced significantly higher IL-12p70 (110 ± 7.3 pg/ml vs 54 ± 1.2 pg/ml), IFN-γ (73 
± 1.8 pg/ml vs 16 ± 1.8 pg/ml), IL-6 (9194 ± 257 pg/ml vs 3411 ± 129 pg/ml), TNF-α 
(1003 ± 143 pg/ml vs 157 ± 15 pg/ml), MIP-1α (7616 ± 485 pg/ml vs 2574 ± 341 
pg/ml), MIP-2 (9160 ± 832 pg/ml vs 1685 ± 91 pg/ml) compared to DTKT ODN at 
100 nM (Fig3.7). A similar trend was seen at 10 nM. Thus, pVAXBlot5 and 
pVAXBlot5-DTKT induced comparable levels of cytokines and chemokines 
production from GMCSF-DC. Plasmid DNA elicited significantly elevated levels of 
cytokines and chemokines production from GMCSF-DC as compared to free CpG 
ODN. 
 
3.2.5 Modified and unmodified plasmid DNA induced comparable levels of 
upregulation of surface markers on antigen presenting cells 
To compare the potency of pVAXBlot5 and pVAXBlot5-DTKT on the upregulation 
of surface markers on antigen presenting cells, dendritic cells were first generated 
from bone marrow using GMCSF. Plasmid DNA was cocultured with GMCSF-DC 
for 24hours and pVAXBlot5-DTKT was found to elicit similar levels of upregulation 
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of surface markers CD80 (116.7 ± 12 MFI vs 110.1 ± 3 MFI), CD86 (1359 ± 50 MFI 
vs 1590 ± 102 MFI) and MHC class II (604 ± 40 MFI vs 506 ± 31 MFI) when 
compared to pVAXBlot5 at 10 nM (Fig 3.8b-d). A similar trend was observed at 100 
nM (Fig 3.8f-h). Higher upregulation of CD40 was observed for pVAXBlot5 
stimulated GMCSF-DC as compared to pVAXBlot5-DTKT stimulated GMCSF-DC 
at 10 nM (92.3 ± 2.7 MFI vs 60.3 ± 4.7 MFI) as well as at 100 nM (135.9 ± 6.8 MFI 
vs 91.8 ± 4.8 MFI) (Fig3.8a, e). Thus pVAXBlot5 and pVAXBlot5-DTKT elicited 
comparable upregulation of surface markers, CD80, CD86 and MHC class II on 
GMCSF-DC. 
 
3.2.6 CpG modified plasmid elicited higher upregulation of surface markers on 
bone marrow derived dendritic cells using GMCSF than free CpG 
oligonucleotides 
To compare the potency of CpG modified plasmid DNA and free CpG 
oligonucleotides (ODN) on upregulation of surface markers, both CpG modified 
plasmids and free CpG ODN were cocultured with bone marrow derived myeloid 
dendritic cells using GMCSF (GMCSF-DC). At a concentration of 10 nM, DTKT 
modified plasmids induced significantly higher upregulation of CD40 (60.3 ± 4.7 MFI 
vs 21.4 ± 3.2 MFI), CD80 (116.7 ± 12 MFI vs 69.4 ± 1.7 MFI), CD86 (1359 ± 49 MFI 
vs 302 ± 11 MFI) and MHC class II (604 ± 40 MFI vs 327 ± 14 MFI) on GMCSF-DC 
compared to the mixture of D type and K type CpG ODN (DTKT ODN) at 10 nM 
(Fig 3.9a-d). However, there was no difference in the upregulation of surface markers 
at 100 nM (Fig 3.9e-h). CpG modified plasmids were more potent than the free CpG 




3.2.7 pVAXBlot5 and pVAXBlot5-DTKT elicited proinflammatory cytokines 
and type I interferon production from bone marrow derived dendritic cells using 
Flt3 ligand (Flt3L-DC) 
Dendritic cells could be generated from bone marrow using either GMCSF or Flt3 
ligand. To evaluate the responses of Flt3L-DC to plasmid DNA stimulation, Flt3L-
DC were cocultured with plasmid DNA for 24 hours. Dose dependent increase in 
production of IL-6, TNF-α, IFN-α, IFN-β was observed when Flt3L-DC was 
stimulated with plasmid DNA (Fig 3.10). Production of TNF-α increased from 252 ± 
7.6 pg/ml to 293 ± 39.6 pg/ml, IL-6 increased from 1678 ± 9.8 pg/ml to 2302 ± 2.3 
pg/ml, IFN-α increased from 1043 ± 14 pg/ml to 1700 ± 140 pg/ml and IFN-β 
increased from 102 ± 1.5 pg/ml to 226 ± 4.7 pg/ml as the dose of pVAXBlot5-DTKT 
increased from 10 nM to 100 nM (Fig 3.10). A similar trend was observed for 
pVAXBlot5. There were no observable differences in cytokine and chemokine 
production between pVAXBlot5 and pVAXBlot5-DTKT stimulated Flt3L-DC. 
Plasmid DNA elicited cytokine and chemokine production from Flt3L-DC in a dose 
dependent manner. 
 
3.2.8 Cytokine and chemokine profiling of GMCSF-DC and Flt3L-DC when 
cocultured with CpG modified plasmid DNA 
To further evaluate the differences between GMCSF-DC and Flt3L-DC in response to 
CpG modified plasmid DNA stimulation, supernatants of GMCSF-DC and Flt3L-DC 
pulsed with pVAXBlot5-DTKT were assayed via a protein array whereby the 
supernatants were incubated on a glass chip with  mobilized capture antibodies. Biotin 
conjugated antibodies and strepavidin were added and the glass chip scanned. The 
scanned images were presented in Fig 3.11. Fold differences of cytokines and 
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chemokines between supernatants of stimulated Flt3L-DC and GMCSF-DC were 
represented in Fig 3.12 and 3.13. Flt3L-DC was found to be more responsive to 
pVAXBlot5-DTKT stimulation as it produced higher levels of G-CSF, IL-1α, KC, 
MCP-5, VCAM-1 , VEGF, MCP-1, PF-4, TCA-3 (Fig 3.14a, b) while GMCSF-DC 
produced elevated levels of MIP-1α (Fig 3.14c). Both GMCSF-DC and Flt3L-DC 
produced comparable levels of IL-12p40 (Fig 3.14c). Thus there was a difference in 
the cytokine and chemokine profile of GMCSF-DC and Flt3L-DC in response to 
pVAXBlot5-DTKT stimulation. 
 
3.2.9 Differential responses of subsets of Flt3L-DC to plasmid DNA and free 
CpG ODN stimulation 
Flt3L-DC was known to consist of two distinct subsets distinguished by differential 
expression of B220 and CD11b. To investigate the responsiveness of these different 
subsets of dendritic cells to plasmid DNA stimulation, Flt3L-DC was sorted based on 
the surface markers CD11c, CD11b and B220. CD11c+CD11b+B220- DCs were first 
cocultured with increasing doses (1 nM, 10 nM, 100 nM) of either plasmid DNA or 
free CpG ODN .There was a dose dependent increase in the production of cytokines 
and chemokines by CD11c+CD11b+B220- DCs when cocultured with plasmid DNA. 
Production of IFN-γ increased from 9 ± 0.3 pg/ml to 24 ± 1 pg/ml, IL-6 (1362 ± 112 
pg/ml to 5738 ± 45 pg/ml), TNF-α (27 ± 1.6 pg/ml to 127 ± 9.8 pg/ml), IL-12p40 
(183 ± 15 pg/ml to 673 ± 33 pg/ml), MIP-1α (304 ± 3.6 pg/ml to 1385 ± 109 pg/ml), 
MIP-1β (690 ± 52.5 pg/ml to 2634 ± 172 pg/ml), IP-10 (872 ± 105 pg/ml to 2491 ± 
307 pg/ml), KC (61 ± 8.7 pg/ml to 283 ± 6.1 pg/ml) and MIP-2 (118 ± 0.1 pg/ml to 
385 ± 8.7 pg/ml) when the dose of pVAXBlot5-DTKT increased from 1 nM to 100 
nM (Fig 3.15). pVAXBlot5 stimulated CD11c+CD11b+B220- DCs also showed a dose 
82 
 
dependent increase in production of cytokines and chemokines (Fig 3.15). There were 
no observable differences in the cytokine and chemokine production between 
unmodified and modified plasmid DNA. 
 
Similar to that noticed of CD11c+CD11b+B220- DCs, plasmid DNA also elicited a 
dose dependent production of IL-6, IP-10 and IL-12p40 from CD11c+CD11b-B220+ 
DCs. Production of IL-6 from CD11c+CD11b-B220+ DCs increased from 102 ± 10.7 
pg/ml to 214 ± 26 pg/ml, IL-12p40 (11 ± 1.2 pg/ml to 22.2 ± 1.4pg/ml), IP-10 (156 ± 
4.4 pg/ml to 421 ± 136 pg/ml) when the dose of pVAXBlot5-DTKT increased from 1 
nM to 100 nM (Fig 3.16). A similar trend was seen with pVAXBlot5 (Fig 3.16). The 
observable differences between the two dendritic cells subsets were that 
CD11c+CD11b+B220- DCs produced elevated amounts of IL-6 (5738 ± 45 pg/ml vs 
214 ± 26 pg/ml), IL-12p40 (673 ± 33 pg/ml vs 22.2 ± 1.4 pg/ml) and IP-10 (2491 ± 
307 pg/ml vs 421 ± 136 pg/ml) than CD11c+CD11b-B220+ DCs in response to 100 
nM of pVAXBlot5-DTKT (Fig 3.15b, 3.15d, 3.15g, 3.16a-c). A similar trend was 
seen at 1 nM and 10 nM of pVAXBlot5-DTKT coculture as well as with pVAXBlot5 
stimulation. Hence subsets of Flt3L-DC responded differentially to plasmid DNA 
stimulation with greater production of cytokines and chemokines by 
CD11c+CD11b+B220- DCs. 
 
3.2.10 TLR9 inhibition of dendritic cells attenuated the production of cytokines 
and chemokines 
DNA immunization had been found to elicit similar levels of antigen specific 
antibodies and interferon-γ secreting cells in TLR9-/- as well as in TLR9+/+ mice 
(Babiuk et al., 2004). To evaluate the involvement of TLR9, CD11c+CD11b-B220+ 
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DCs were cocultured with plasmid DNA in the presence of increasing doses (0.1 μM, 
1 μM and 2 μM) of a TLR9 inhibitory oligonucleotide. Production of IL-6, IL-12p40 
and IP-10 were almost completely abolished in the presence of TLR9 inhibitory 
oligonucleotides (Fig 3.17). The dose of TLR9 inhibitory oligonucleotide was fixed at 
2 μM and the experiment repeated with the addition of an oligonucleotide with an 
irrelevant sequence as a control. The addition of 2 μM of TLR9 inhibitory 
oligonucleotide sharply attenuated the production of IP-10 from CD11c+CD11b-
B220+ DCs (748 ± 327 pg/ml to 8 ± 3 pg/ml), IL-6 (381 ± 166 pg/ml to 1.8 ± 1.2 
pg/ml), IL-12p40 (30 ± 7.4 pg/ml to 1.4 ± 0.3 pg/ml), IFN-α (2352 ± 10 pg/ml to 10.4 
± 10.4 pg/ml) (Fig 3.18). However IFN-β production was not abolished. In 
comparison, the use of a control oligonucleotide did not abolish the cytokines and 
chemokine levels, IP-10, IL-6, IL-12p40, IFN-α remained high at 484 ± 353 pg/ml, 
375 ± 229 pg/ml, 25 ± 4.3 pg/ml and 1461 ± 9 pg/ml respectively (Fig 3.18). A 
similar trend was observed for pVAXBlot5.  
 
Similarly CD11c+CD11b+B220- DCs were cocultured with plasmid DNA in the 
presence of increasing doses (0.1 μM, 1 μM, 2 μM) of a TLR9 inhibitory 
oligonucleotide. TLR9 inhibitory oligonucleotide attenuated cytokines and 
chemokines production from CD11c+CD11b+B220- DCs in a dose dependent manner. 
Production of IL-6 from pVAXBlot5-DTKT stimulated CD11c+CD11b+B220- DCs 
decreased from 530 pg/ml to 6.3 pg/ml, IP-10 (1093 pg/ml to 104 pg/ml), IL-12p40 
(96 pg/ml to 2.1 pg/ml), KC (63 pg/ml to 5.7 pg/ml), MIP-1α (198 pg/ml to 6.5 pg/ml), 
MIP-1β (442 pg/ml to 12.2 pg/ml), TNF-α (8.1 pg/ml to 1.6 pg/ml) and MIP-2 (130 
pg/ml to 47.7 pg/ml) when the dose of TLR9 inhibitory oligonucleotide increased 
from 0.1 μM to 2 μM (Fig 3.19). The addition of 2 μM of TLR9 inhibitory 
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oligonucleotide sharply attenuated the production of TNF-α from pVAXBlot5-DTKT 
stimulated CD11c+CD11b+B220- DCs (245 ± 118 pg/ml to 5.4 ± 3.8 pg/ml), IL-6 
(8473 ± 2735 pg/ml to 10.8 ± 4.6 pg/ml), IL-12p40 (1079 ± 550 pg/ml to 4 ± 2 pg/ml), 
IP-10 (3317 ± 826 pg/ml to 125 ± 21 pg/ml), KC (289 ± 5.7 pg/ml to 6.5 ± 0.8 pg/ml), 
MIP-1α (3472 ± 2087 pg/ml to 15.7 ± 9.2 pg/ml), MIP-1β (4854 ± 2220 pg/ml to 9.6 
± 2.6pg/ml), IFN-α (146.4 ± 14.4 pg/ml to 38.3 ± 0.7 pg/ml) and MIP-2 (332 ± 53 
pg/ml to 74.4 ± 26.7 pg/ml) (Fig 3.20).. However IFN-β production was not abolished.  
This inhibition was TLR9 specific as the use of a control oligonucleotide did not 
abolish the cytokines and chemokines TNF-α (164 ± 74 pg/ml), IL-6 (6961 ± 1460 
pg/ml), IL-12p40 (1026 ± 429 pg/ml), IP-10 (2634 ± 702 pg/ml), KC (262 ± 1.5 
pg/ml), MIP-1α (2336 ± 1247 pg/ml), MIP-1β (4616 ± 1618 pg/ml), MIP-2 (237 ± 
48.6 pg/ml) and IFN-α (60.8 ± 5.9 pg/ml) (Fig 3.20). A similar trend was observed for 
pVAXBlot5 stimulated CD11c+CD11b+B220- DCs. Hence TLR9 was involved in the 
activation of dendritic cells by plasmid DNA as inhibition of TLR9 attenuated sharply 
the cytokines and chemokines production. 
 
3.2.11 Plasmid DNA pulsed dendritic cells presented antigen to Blo t 5 specific 
CD4+ T cells and polarized them to a similar T helper phenotype that produced 
IL-17 and IFN-γ 
To evaluate if there was any difference in the phenotype of antigen specific T cells 
primed by modified and unmodified plasmid DNA pulsed dendritic cells, Blo t 5 
specific CD4+ T cells were activated first round with plasmid DNA stimulated 
dendritic cells in the presence of recombinant Blo t 5 protein for 7 days, after which it 
was restimulated with freshly prepared plasmid DNA stimulated dendritic cells in the 
presence of recombinant Blo t 5 protein. It was observed that Blo t 5 specific CD4+ T 
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cells activated by pVAXBlot5-DTKT pulsed dendritic cells produced lesser IFN-γ 
compared to the cells activated by pVAXBlot5 pulsed dendritic cells (5463 ± 783 
pg/ml vs 8557 ± 898 pg/ml) (Fig 3.21a). In addition, there was a trend of attenuation 
of IL-17 produced by Blo t 5 specific CD4+ T cells activated with pVAXBlot5-DTKT 
pulsed dendritic cells as compared to those cells activated by pVAXBlot5 pulsed 
dendritic cells (677 ± 121 pg/ml vs 1054 ± 506 pg/ml) (Fig 3.21b). Production of 
IFN-γ and IL-17 was via interaction between plasmid DNA pulsed dendritic cells and 
Blo t 5 specific CD4+ T cells as plasmid DNA pulsed dendritic cells and Blo t 5 
specific CD4+ T cells did not secrete much IFN-γ and IL-17 when they were cultured 
alone (Fig 3.21). Plasmid DNA pulsed dendritic cells presented antigen to Blo t 5 
specific CD4+ T cells and polarized them to a similar T helper phenotype that 
produced IL-17 and IFN-γ. There was a trend of attenuation of IL-17 and IFN-γ 
production by pVAXBlot5-DTKT pulsed dendritic cells activated Blo t 5 specific T 
cells when compared to pVAXBlot5 pulsed dendritic cells activated Blo t 5 specific T 
cells. 
 
3.2.12 pVAXBlot5-DTKT immunized mice produced the highest magnitude of 
Blo t 5 specific immune responses. 
To determine the magnitude of Blo t 5 specific immune responses elicited by 
pVAXBlot5 and pVAXBlot5-DTKT immunization, C57BL/6 mice were 
intramuscularly immunized with plasmid DNA and the levels of T cell cytokines were 
measured to compare the immunogenicity of modified and unmodified plasmid DNA 
(Fig 3.22a). pVAXBlot5-DTKT immunized group responded with a trend of higher 
levels of Blo t 5 specific IFN-γ (538 ± 89 pg/ml vs 379 ± 101 pg/ml), IL-6 (73 ± 13.4 
pg/ml vs 64.5 ± 13.2 pg/ml), IP-10 (420 ± 73.4 pg/ml vs 290 ± 70.4 pg/ml), IL-17 
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(21.3 ± 8.1 pg/ml vs 16.9 ± 9.7 pg/ml), MIG (302 ± 41.8 pg/ml vs 171 ± 75.4 pg/ml) 
and GMCSF production (233 ± 52.5 pg/ml vs 130 ± 27 pg/ml) when compared to 
pVAXBlot5 immunized group (Fig 3.23). In addition, pVAXBlot5-DTKT immunized 
group also produced significantly higher levels of IL-6 (73 ± 13.4 pg/ml vs 30.2 ± 4.1 
pg/ml), IP-10 (420 ± 73.4 pg/ml vs 207 ± 20 pg/ml), MIG (302 ± 41.8 pg/ml vs 134 ± 
28.3 pg/ml) and  a trend of elevated levels of IFN-γ (538 ± 89 pg/ml vs 406±101 
pg/ml), IL-17 (21.3 ± 8.1 pg/ml vs 9.3 ± 3 pg/ml), GMCSF (233 ± 52.5 pg/ml vs 115 
± 17.8 pg/ml) when compared to pVAX-1 vector immunized group (Fig 3.23). 
Overall, pVAXBlot5-DTKT immunized groups produced the highest magnitude of 
Blo t 5 specific immune responses. 
 
3.2.13 Mixed cytokine profile in mice immunized with Blo t 5 protein 
adjuvanted with aluminium hydroxide (Allergy model) 
Naïve C57BL/6 mice receiving two intraperitoneal injections of 10 μg and 5 μg of 
rBlo t 5 protein adjuvanted with aluminum hydroxide (alum) respectively at 3 weeks 
apart (Fig 3.22b) showed a mixed T cell cytokine profile in a secondary culture in 
vitro and produced significantly higher Blo t 5 specific  IFN-γ (2288 ± 286 pg/ml vs 
395 ± 258 pg/ml), IL-17 (934 ± 220 pg/ml vs 42.5 ± 35.6 pg/ml), IL-5 (353 ± 53.9 
pg/ml vs 38.2 ± 24.5 pg/ml), IL-13 (168 ± 30 pg/ml vs 16.3 ± 7.7 pg/ml), IL-6 (519 ± 
104 pg/ml vs 103 ± 49.5 pg/ml), MCP-1 (1732 ± 279 pg/ml vs 499 ± 219 pg/ml) and a 
trend of higher MIG production (1165 ± 361 pg/ml vs 186 ± 72 pg/ml) than mice 
immunized with PBS adjuvanted with alum indicating that Th1, Th2 and Th17 
phenotypes were induced in mice immunized with rBlo t 5 protein adjuvanted with 
alum (Fig 3.24). Allergen adjuvanted with alum would induce Th1, Th2 and Th17 
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phenotypes in immunized mice. Such a strategy was previously used to prime Th2 
dominant immune responses. 
 
3.2.14 IL-17 and IFN-γ producing cells were distinct subsets in Blo t 5 specific T 
cells 
To evaluate if the IL-17 and IFN-γ produced in the T cell cultures of mice immunized 
with rBlo t 5 protein adjuvanted with alum were from the same cell, intracellular 
staining was carried out on Blo t 5 specific T cells. It was found out that IL-17 and 
IFN-γ were produced from distinct cell populations (Fig 3.25) and CD4+ T cells 
produced slightly higher levels of IFN-γ compared to IL-17 (5.9 ± 2.4% vs 3.3 ± 0.8%) 
(Fig 3.25c)while CD8+ T cells produced much elevated levels of IFN-γ compared to 
IL-17 (47.7 ± 1.6% vs 8.1 ± 2.1%) (Fig 3.25d). Hence the majority of IFN-γ produced 
could possibly be from Blo t 5 specific CD8+ T cells. IL-17 and IFN-γ producing cells 
were distinct subsets in Blo t 5 specific T cells from Blo t 5 protein adjuvanted with 
alum immunized mice. 
 
3.2.15 Blo t 5 specific antibody responses in mice immunized with Blo t 5 protein 
adjuvanted with aluminium hydroxide (Allergy model) 
Mice immunized with Blo t 5 protein adjuvanted with alum showed significantly 
higher Blo t 5 specific IgE levels than the control group (1876 ± 450 ELISA unit vs 
ND on day 14, 1521 ± 40 ELISA unit vs 261 ± 58 ELISA unit on day 28, p < 0.05) 
(Fig 3.26c). In addition, higher Blo t 5 specific IgG1 levels were also produced by 
mice immunized with Blo t 5 protein adjuvanted with alum compared to control mice 
from days 14 to 28 (p < 0.05) (Fig 3.26a) Mice immunized with Blo t 5 protein 
adjuvanted with alum also produced elevated levels of Blo t 5 specific IgG2c when 
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compared to control mice (Fig 3.26b). Mice immunized with Blo t 5 protein 
adjuvanted with aluminium hydroxide produced Blo t 5 specific IgG1, IgG2c and IgE. 
 
3.2.16 Allergen gene immunization effectively suppressed T effector cytokines 
induced by Blo t 5 protein adjuvanted with alum immunization 
This study had shown that naïve mice immunized twice intraperitoneally with rBlo t 5 
protein adjuvanted with alum develop a mixed T cell cytokine profile (Fig 3.24). To 
determine if DNA vaccination had any prophylactic suppressive effect on this mixed 
T cell cytokine profile, C57BL/6 mice were immunized with allergen gene DNA 
constructs (pVAXBlot5, pVAXBlot5-DTKT) and then challenged by intraperitoneal 
immunizations with rBlo t 5 protein adjuvanted with alum (Fig 3.22c). Control mice 
were not immunized with DNA constructs and they were only given the 
intraperitoneal immunization of rBlo t 5 protein adjuvanted with alum. Splenocytes 
from pVAXBlot5 immunized mice showed a 20 fold and 136 fold increase in IFN-γ 
production (137 ± 47 pg/ml) as compared to pVAX-1 immunized mice and control 
mice respectively at 72 hours (p < 0.05) (Fig 3.27a). In comparison, cells from 
pVAXBlot5-DTKT immunized mice showed a greater increase in IFN-γ production 
(210 ± 70 pg/ml), about 30 fold and 209 fold increase as compared to pVAX-1 
immunized mice and control mice respectively at 72 hours (Fig 3.27a). Cells from 
pVAXBlot5 and pVAXBlot5-DTKT immunized mice continued to show a significant 
increase in IFN-γ production when compared to pVAX-1 immunized mice and 
control mice at 96 hours (Fig 3.27a). Low levels of IL-13, IL-17, IL-5 and IL-6 were 
also produced by mice in all the groups at 72 hours and 96 hours (Fig 3.27). Besides 
cytokine production, DNA immunization also induced chemokine production. pVAX-
1, pVAXBlot5, pVAXBlot5-DTKT immunized mice also showed a 4.8, 5.3 and 6.2 
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fold increase in MCP-1 production compared to control mice at 96 hours (p < 0.05) 
(Fig 3.27f). Cells from pVAXBlot5 and pVAXBlot5-DTKT immunized mice 
produced significantly higher levels of MIG when compared to pVAX-1 and control 
mice at 72hours. There was a trend of higher production of IFN-γ, IL-6 and MCP-1 
elicited by pVAXBlot5-DTKT immunized mice when compared to pVAXBlot5 
immunized mice in the primary culture. 
 
Upon secondary stimulation with rBlo t 5 protein, plasmid DNA immunized mice 
showed a significant attenuation in Blo t 5 specific IFN-γ (Fig 3.28a) and IL-17 (Fig 
3.28b) when compared to control mice. It was interesting to note that pVAXBlot5 and 
pVAXBlot5-DTKT immunized group showed a greater attenuation in IL-17 
compared to pVAX immunized group (p < 0.05) (Fig 3.28b). In addition, the 
pVAXBlot5 and pVAXBlot5-DTKT immunized groups showed significant reduction 
in production of Blo t 5 specific IL-5, IL-13, IL-6 (Fig 3.28c, 3.28d, 3.28e), when 
compared to both pVAX-1 immunized group and control group (p < 0.05). 
pVAXBlot5-DTKT immunized group showed a greater suppression in IL-5, IL-6, IL-
13 and IL-17 when compared to pVAXBlot5 group out of which suppression in IL-13 
was statistically significant (p < 0.05) (Fig 3.28). Notably, pVAX immunized group 
failed to show suppression in Blo t 5 specific IL-5, IL-13 and IL-6 when compared to 
the control mice. Besides attenuation in cytokine production, plasmid DNA 
immunized groups also showed a trend in reduction in MCP-1 and MIG (Fig 3.28f, 
3.28g) when compared to control mice, pVAXBlot5-DTKT immunized group in 
particular showed a significant reduction in MCP-1 (Fig 3.28f) level when compared 
to control mice (p < 0.05). Allergen gene immunized mice suppressed Blo t 5 specific 
IFN-γ, IL-17, IL-5, IL-13 and IL-6 induced by intraperitoneal immunization with rBlo 
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t5 protein adjuvanted with alum. pVAXBlot5-DTKT immunized mice showed a trend 
of greater suppression in Blo t 5 specific IL-5, IL-6, IL-13 and IL-17 when compared 
to pVAXBlot5 immunized mice. 
 
3.2.17 Allergen gene immunization effectively suppressed antigen specific IgE 
production induced by intraperitoneal immunization with allergen adjuvanted 
with alum 
To evaluate the modulatory effect of pVAXBlot5 and pVAXBlot5-DTKT on the 
humoral responses induced by rBlo t 5 protein adjuvanted with alum immunization, 
Blo t 5 specific IgG1, IgG2c and IgE were measured from the sera collected weekly. 
Control mice only received intraperitoneal immunizations with rBlo t 5 protein 
adjuvanted with alum. Mice immunized with pVAXBlot5-DTKT produced the 
highest titres of Blo t 5 specific Th1 signature antibody IgG2c subclass (Fig 3.29b) 
and IgG1 subclass (Fig 3.29a) among the groups. Notably, pVAXBlot5-DTKT 
induced significantly higher levels of Blo t 5 specific IgG1 than pVAXBlot5 (5028 ± 
835 (ELISA unit x103) vs 2208 ± 605 (ELISA unit x103) on day 28, 11148 ± 3830 
(ELISA unit x103) vs 2894 ± 534 (ELISA unit x103) on day 35, 18319 ± 2904 (ELISA 
unit x103) vs 6528 ± 1483 (ELISA unit x103) on day 49, p < 0.05) (Fig 3.29a). 
Allergen gene immunized mice (pVAXBlot5 and pVAXBlot5-DTKT groups) also 
persistently produced significantly higher levels of Blo t 5 specific IgG2c from days 
21-49 as compared to pVAX group (p < 0.05) (Fig 3.29b). Both pVAXBlot5 and 
pVAXBlot5-DTKT immunized groups showed an attenuation in Blo t 5 specific IgE 
antibody when compared to pVAX empty vector group on days 35 and 42 but only 
pVAXBlot5-DTKT group continued to show a significant suppression in Blo t 5 
specific IgE till day 49 (p < 0.05) (Fig 3.29c). pVAXBlot5-DTKT immunized mice 
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produced higher levels of Blo t 5 specific IgG1 and IgG2c when compared to 
pVAXBlot5 immunized mice. Mice immunized with Blo t 5 constructs effectively 
suppressed Blo t 5 specific IgE production induced by intraperitoneal immunization 
with rBlo t 5 protein adjuvanted with alum. 
 
3.2.18 CpG modified plasmid DNA induced higher proinflammatory cytokine 
and chemokine production from human peripheral mononuclear cells compared 
to unmodified plasmid DNA 
To evaluate the effect of pVAXhBlot5 and pVAXhBlot5-DTKT on human cells, 
various doses (1 nM, 10 nM, 100 nM) of pVAXhBlot5, pVAXhBlot5-DTKT and 
DTKT ODN were cocultured with human peripheral mononuclear cells (PBMC) for 5 
hours and 24 hours. Dose dependent secretion of proinflammatory cytokines, TNF-α, 
IL-6 and activation chemokines MIP-1α, MIP-1β were observed for plasmid DNA 
stimulated PBMC at both the 5 hour and 24 hour timepoints. At an early timpoint of 5 
hours, pVAXhBlot5-DTKT stimulated PBMC produced significantly higher levels of 
IL-6 (494 ± 46 pg/ml vs 76.9 ± 30.4 pg/ml), MIP-1α (1014 ± 74 pg/ml vs 324 ± 122 
pg/ml) and MIP-1β (577 ± 127 pg/ml vs 198 ± 32.7 pg/ml) when compared to 
pVAXhBlot5 stimulated PBMC at 100 nM (Fig 3.30).At a later timepoint of 24 hours, 
pVAXhBlot5-DTKT stimulated PBMC continued to produce a trend of higher 
production of TNF-α (54.2 ± 12.8 pg/ml vs 42.8 ± 7.8 pg/ml), IL-6 (478 ± 150 pg/ml 
vs 385 ± 172 pg/ml), MIP-1α (1275 ± 288 pg/ml vs 689 ± 110 pg/ml) and MIP-1β 
(881 ± 116 pg/ml vs 511 ± 125 pg/ml) when compared to pVAXhBlot5 stimulated 
PBMC (Fig 3.31). Thus pVAXhBlot5-DTKT induced higher production of cytokines 
and chemokines from human PBMC than pVAXhBlot5. These distinct differences 




3.2.19 Protein array analysis of differentially expressed regulatory cytokines and 
chemokines profile of plasmid DNA stimulated human peripheral mononuclear 
cells 
To extensively study the differences in cytokine and chemokine production among 
pVAXhBlot5-DTKT, pVAXhBlot5 and DTKT ODN stimulated human peripheral 
mononuclear cells, supernatants of pVAXhBlot5-DTKT, pVAXhBlot5 and DTKT 
ODN stimulated human peripheral blood mononuclear cells were analysed via protein 
array and it was found that there was differential regulation of different proteins at 
different timepoints. At an early timepoint of 5 hours, pVAXhBlot5-DTKT induced 
significant upregulation of PDGF-AA, GRO-α, NT-4, IL-1β, osteoprotegerin, VEGF-
D, GMCSF, MCP-1 and ENA-78 (Fig 3.32a) and downregulation of ErbB3, IP-10, 
angiogenin, IGFBP-2 and MCP-2 (Fig 3.32b) compared to pVAXhBlot5 (p<0.05). At 
a later timepoint of 24 hours, pVAXhBlot5-DTKT induced significant upregulation of 
angiogenin, Flt3 ligand, I-309, IL-10, MCP-1, MCP-4, MIP-3α, PARC, TARC and 
TECK (Fig 3.33a) with downregulation of IL-12p40 as compared to pVAXhBlot5 (p 
< 0.05) (Fig 3.33b). When compared to DTKT ODN at an early timepoint of 5 hours, 
pVAXhBlot5-DTKT induced significant upregulation of ENA-78, Flt3 ligand, 
GMCSF, IL-1β, IL-6, MIP-3α, PDGF-BB, GRO-α, MIP-1α, NT-4 and 
osteoprotegerin (Fig 3.34a) with the downregulation of leptin R, IP-10 and angiogenin 
(Fig 3.34b) (p < 0.05). At a later timepoint of 24 hours, GCP-2, MCP-3, MCP-4, 
MDC, MIP-3α, PARC, TNF-α, ENA-78, IL12p40, IL-8, oncostatin M, TIMP-1, 
uPAR, Siglec-5, GMCSF, sTNFRII, I-309, IL-10, IL-1β, IL-6, GRO-α, MIP-1α, 
MMP-9 and Activin A were upregulated in the pVAXhBlot5-DTKT group when 
compared to DTKT ODN (p < 0.05) (Fig 3.35a, 3.35b). PDGF-AA and angiogenin 
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were downregulated (p < 0.05) (Fig 3.35c). Interestingly, pVAXBlot5-DTKT induced 
higher upregulation of IL-1β when compared to both pVAXhBlot5 (4 fold) (Fig 3.32a) 
and DTKT ODN (30 fold) (Fig 3.33a) at 5 hrs. Hence pVAXhBlot5-DTKT 
upregulated higher cytokines and chemokines production from human PBMC as 
compared to pVAXhBlot5 and DTKT ODN. There was a dynamic change in the 
upregulation profile of cytokines and chemokines profile at early (5 hours) and later 
(24 hours) timepoints. 
 
3.2.20 Evaluation of immunogenicity of Blo t 5 encoded plasmid DNA by 
production of Blo t 5 specific antibodies in non human primates 
To evaluate if CpG modified pVAXhBlot5-DTKT had any enhanced immunogenic 
effect in vivo, non-human primates were immunized with pVAX-1, pVAXhBlot5 and 
pVAXhBlot5-DTKT and subsequently received subcutaneous immunizations with 
rBlo t 5 protein adjuvanted with alum (Fig 3.22d). Sera was collected monthly and 
assayed for allergen specific antibodies. Production of Blo t 5 specific total IgG and 
IgG1 in non-human primates vaccinated with plasmid encoding allergen gene 
(pVAXBlot5 and pVAXBlot5-DTKT) were earlier than the group vaccinated with 
pVAX-1. At week 14, pVAXhBlot5 and pVAXhBlot5-DTKT immunized groups 
produced significantly higher levels of Blo t 5 specific total IgG when compared to 
pVAX-1 group (p < 0.05) (Fig 3.36a). Blo t 5 specific IgG1 production also showed 
similar kinetics as Blo t 5 specific total IgG. pVAXhBlot5-DTKT was found to induce 
significantly higher levels of Blo t 5 specific IgG1 than pVAX-1 (89 ± 43 (OD x DF) 
vs 3 ± 2 (OD x DF) at week 14, 230 ± 33 (OD x DF)   vs 56 ± 31 (OD x DF) at week 
18, p < 0.05) (Fig 3.36b). There was a trend of higher production of Blo t 5 specific 
total IgG and IgG1 in pVAXhBlot5-DTKT group as compared to pVAXhBlot5 group 
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at week 18 (Fig 3.36a, b). All three groups elicited comparable levels and kinetics of 
Blo t 5 specific IgG3 production (Fig 3.36c). Both pVAXhBlot5 and pVAXhBlot5-
DTKT immunized groups showed an attenuation in Blo t5 specific IgE compared to 
pVAX-1 immunized group at week 18 (Fig 3.36d). Immunogenicity of allergen gene 
constructs was demonstrated by faster kinetics and levels of Blo t 5 specific IgG 
production. 
 
3.2.21 Blo t 5 specific IFN-γ and IL-4 producing cells in plasmid DNA 
immunized non-human primates 
To evaluate the cellular responses induced by plasmid DNA immunization, Blo t 5 
specific IFN-γ and IL-4 producing cells were examined by ELISPOT. Monkeys’ 
PBMC were stimulated with three Blo t 5 peptide pools. There was a trend of higher 
numbers of IFN-γ producing cells elicited in allergen gene vaccinated groups in 
response to all three Blo t 5 peptide pools when compared to pVAX-1 immunized 
group (Fig 3.37). pVAXhBlot5-DTKT immunized monkeys produced higher number 
of IFN-γ producing cells per million PBMC upon stimulation with Blo t 5 peptide 
pool 1 when compared to pVAXhBlot5 and pVAX groups (Median of 4.2 spots vs 2.5 
spots and 0.83 spots respectively) (Fig 3.37a). Higher number of IFN-γ producing 
cells per million PBMC was also produced from pVAXhBlot5-DTKT immunized 
group in response to Blo t 5 peptide pool 2 stimulation when compared to 
pVAXhBlot5 and pVAX groups (Median of 3 spots vs 2.5 and 0 spots respectively) 
(Fig 3.37b). pVAXhBlot5-DTKT and pVAXhBlot5 immunized groups also 
attenuated the number of IL-4 producing cells per million PBMC upon stimulation 
with Blo t 5 peptide pool 2 and 3 when compared to pVAX group (Fig 3.38b, 3.38c). 
Notably, 3 out of 5 non-human primates immunized with pVAXhBlot5-DTKT did not 
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induce any IL-4 producing cells in response to Blo t 5 peptide pool 2 stimulation (Fig 
3.38b). Thus pVAXhBlot5-DTKT immunized group yielded the highest number of 
IFN-γ producing cells and lowest number of IL-4 producing cells in response to Blo t 
























Figure 3.1: Construction of pVAXBlot5 and pVAXhBlot5 
The mature coding sequence of Blo t 5 was cloned into the pVAX vector containing 
Blo t 5 leader sequence ( LS ) and LAMP-1 targeting region and designated as 
pVAXBlot5 construct (a) The human codon optimized Blo t 5 gene ( hBlot5 ) was 
cloned into pVAX vector containing human tissue plasminogen activator leader 
sequence ( HTPA LS ) and human LAMP-1 targeting region and designated as 
pVAXhBlot5 construct (b). The sequence was verified by sequencing and these 





CMV promoter : Bases 137-724 
T7 promoter/priming site : Bases 664-683 
Multiple cloning site : Bases 696-811 
BGH reverse priming site : Bases 823-840 
BGH polyadenylation signal : Bases 829-1053 
Kanamycin resistance gene : Bases 1226-2020 

























Figure 3.2: Schematic diagram of the CpG modified plasmid DNA constructs 
D type and K type CpG motifs were inserted into the MluI and PmlI sites sequentially 
in the plasmid backbone of pVAXBlot5 and pVAXhBlot5, giving rise to double 
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Lane 1: 1 kb DNA ladder 
Lane 2-5: Clones 1 to 4 







Figure 3.3: Incoporation of K type CpG oligonucleotide (KT) into the PmlI site in 
the plasmid pVAXBlot5 
To confirm the presence of KT in the selected clones, plasmids of selected clones 
were extracted and digested with PmlI and NheI. Presence of the insert KT will result 
in only 1 band (~3500bp) after digestion. Negative control consists of 3 bands. Clones 
1 to 4 all contain the insert KT. These positive clones containing the insert KT were 
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Lane 1: 1kb DNA ladder 
Lane 2: 100bp DNA ladder 








Figure 3.4: Incoporation of D type CpG oligonucleotide into MIuI site of pVAX-
Blo t5 
After PCR amplification with the primers BGH-R and  DT1, 10 μl of the PCR 
products were run in a 1% agarose gel at 100V for 1 hr. Clones 1 and 6 are suspected 







       1           2         3            4          5           6 
Lane 1: 1 kb DNA ladder 
Lane 2, 6:100 bp DNA ladder 
Lane 3: negative control 
Lane 4: clone 1 








Figure 3.5: Restriction enzyme digest to confirm the presence of D type CpG 
oligonucleotide (DT) in the suspected clones 1 and 6 
To confirm the presence of DT in clones 1 and 6 ,the plasmids of the clones were 
extracted and digested with MIuI and XhoI. Presence of insert DT will result in 1 band 
(~3500bp) after digestion. Both clones 1 and 6 contain the insert DT. Sequences of 


























Figure 3.6: Response of mouse splenocytes to plasmid DNA and free CpG 
oligonucleotides 
Mouse splenocytes were incubated with 10 nM, 33 nM, 66 nM and 100 nM of pVAX-
Blot5, pVAXBlot5-DTKT and DTKT ODN. IFN-γ and IL-6 in culture supernatant 





















































Figure 3.7: Response of dendritic cells (GMCSF-DC) to plasmid DNA and free 
CpG oligonucleotides stimulation 
Bone marrow derived dendritic cells using GM-CSF (GMCSF-DC) were cocultured 
with 10 nM and 100 nM of plasmid DNA or free CpG ODN for 24 hours. The culture 
supernatant collected after 24hours was assayed for IL-12p70, IFN-γ, IL-6, TNF-α, 
MIP-1α and MIP-2. Data illustrated was the mean±SEM of two independent 
experiments. * stands for statistically significant differences when compared to DTKT 


















































































































Figure 3.8: Modified and unmodified plasmid DNA elicited similar levels of 
upregulation of surface markers on bone marrow derived dendritic cells using 
GMCSF 
Bone marrow derived dendritic cells using GMCSF were incubated with 10 nM(a-d) 
and 100 nM(e-d) of the modified plasmid, pVAXBlot5-DTKT (blue line) and the 
unmodified plasmid, pVAXBlot5 (red line). Grey areas represent dendritic cells 
without stimulation. Cells were harvested at 24hours and stained with mAb against 
CD11c, CD86, CD80, CD40 and MHC class II. Data analyzed was gated on CD11c+ 
cells. The geometric mean of fluorescent intensity of surface markers on bone marrow 
derived dendritic cells using GMCSF when stimulated with pVAXBlot5-DTKT and 
pVAXBlot5 was indicated in black and red respectively. Figure shown was the 
representative of a triplicate in an experiment. Numbers were the mean ± SD of 
triplicates of a representative experiment. Data shown was representative of two 
independent experiments. Student t test was used, p < 0.05 
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Figure 3.9: Modified plasmid elicit higher upregulation of activation surface 
markers compared to the corresponding free CpG oligonucleotides 
Bone marrow derived dendritic cells using GMCSF were incubated with 10 nM (a-d) 
and 100 nM (e-h) of the modified plasmid, pVAXBlot5-DTKT (blue line) and the free 
CpG oligonucleotide, DTKT ODN (green line). Grey areas represent dendritic cells 
without stimulation. Cells were harvested at 24hr and stained with mAb against 
CD11c, CD86, CD80, CD40 and MHC class II. Data analyzed was gated on CD11c+ 
cells. The geometric mean of fluorescent intensity of surface markers on bone marrow 
derived dendritic cells using GMCSF when stimulated with pVAXBlot5-DTKT and 
DTKT ODN was indicated in black and red respectively. Figure shown was the 
representative of a triplicate in an experiment. Numbers are the mean ± SD of 
triplicates of a representative experiment. Data shown was representative of two 
independent experiments. Student t test was used. * p < 0.05, ** p <0.005 
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60.3±4.7  116.7±12 1359±49 604±40
91.8±4.8  146.8±4.3 2024±76 620.3±68 
21.4±3.2  69.4±1.7  302±11 327±14 
64.7±3.6  130.6±5.6 1456±210 678±111
CD40  CD80  CD86  MHC class II 
























Figure 3.10: Response of dendritic cells (Flt3L-DC) to plasmid DNA stimulation 
Bone marrow derived dendritic cells using Flt3L was cocultured with 10 nM and 100 
nM of plasmid DNA for 24 hours. The culture supernatant collected after 24hours was 
assayed for IL-6, TNF-α, IFN-α and IFN-β. Data illustrated was the mean ± SEM of 
















































































Figure 3.11: Image of protein array 
Both GMCSF-DCs and Flt3L-DCs were plated at 1 x 106 per well in 24 well plate and 
cocultured with 100 nM of plasmid DNA. The supernatant collected after 24 hours 
was assayed for cytokines and chemokines by the protein array. 
 




























Figure 3.12: Cytokine and chemokine profiling of stimulated Flt3L-DC and 
GMCSF-DC 
Both GMCSF-DCs and Flt3L-DCs were plated at 1 x 106 per well in 24 well plate and 
cocultured with 100 nM of plasmid DNA. The supernatant collected after 24 hours 


























Figure 3.13: Cytokine and chemokine profiling of stimulated Flt3L-DC and 
GMCSF-DC 
Both GMCSF-DCs and Flt3L-DCs were plated at 1 x 106 per well in 24 well plate and 
cocultured with 100 nM of plasmid DNA. The supernatant collected after 24 hours 







































































































Figure 3.14: Differential protein expressions between Flt3L-DC and GMCSF-DC 
Both GMCSF-DCs and Flt3L-DCs were plated at 1 x 106 per well in 24 well plate and 
cocultured with 100 nM of pVAXBlot5-DTKT. The supernatant collected after 24 







































































































































































Figure 3.15: Response of CD11c+ CD11b+B220- DCs to plasmid DNA and free 
CpG oligonucleotides stimulation 
CD11c+ CD11b+B220- DCs were cocultured with 1 nM, 10 nM and 100 nM of 
plasmid DNA or free CpG ODN for 24 hours. The culture supernatant collected after 
24hours was assayed for IFN-γ, IL-6, TNF-α, IL-12p40, MIP-1α, MIP-1β, IP-10, KC 
and MIP-2. Results shown were the mean ± SEM of duplicates of an experiment. Data 








































Figure 3.16: Response of CD11c+ CD11b-B220+ dendritic cells to plasmid DNA 
and free CpG oligonucleotides stimulation 
Bone marrow derived dendritic cells using Flt3 L (CD11c+B220+ pDCs) were 
cocultured with 100nM of plasmid DNA or free CpG ODN for 24 hours. The culture 
supernatant collected after 24hours was assayed for IL-6, IL-12p40 and IP-10. Results 
shown were the mean ± SEM of duplicates of an experiment. Data shown were the 

































































Figure 3.17: Dose dependent TLR9 inhibition of CD11c+ CD11b-B220+ dendritic 
cells 
CD11c+CD11b-B220+ DCs were seeded at 1 x 105 cells in 96 well plate and 
cocultured with 100 nM of plasmid DNA for 24 hours in the presence of titrated doses 
of TLR9 inhibitory ODN. The culture supernatant was collected after 24 hours and 






























































Figure 3.18: TLR9 blocking of CD11c+ CD11b-B220+ dendritic cells 
CD11c+CD11b-B220+ DCs were seeded at 1 x 105 cells in 96 well plate and 
cocultured with 100 nM of plasmid DNA for 24 hours in the presence of either 2 µM 
of TLR9 inhibitory ODN or control ODN. The culture supernatant was collected after 
24 hours and assayed for IP-10, IL-6, IL-12p40, IFN-α and IFN-β. Results were the 























































































Figure 3.19: Dose dependent TLR9 inhibition of CD11c+ CD11b+B220- dendritic 
cells 
CD11c+CD11b+B220- DCs were seeded at 1 x 105  cells in 96 well plate and 
cocultured with 100 nM of plasmid DNA for 24 hours in the presence of titrated doses 
of TLR9 inhibitory ODN.The culture supernatant was collected after 24 hours and 

















































































































































































Figure 3.20: TLR9 inhibition of CD11c+ CD11b+B220- dendritic cells 
CD11c+CD11b+B220- DC were seeded at 1 x 105  cells in 96 well plate and cocultured 
with 100 nM of plasmid DNA for 24 hours in the presence of either 2 µM of TLR9 
inhibitory ODN or control ODN. The culture supernatant was collected after 24 hours 
and assayed for TNF-α, IL-6, IL-12p40, IP-10, KC, MIP-1α, MIP-1β, MIP-2, IFN-α 





















Figure 3.21: Coculture of plasmid DNA pulsed dendritic cells with Blo t 5 
specific T cells 
Flt3L-DCs were collected on day 8 and stained with antibodies against CD11c, 
CD11b and B220. The CD11c+CD11b+B220- DCs were collected after cell sorting 
and pulsed with 100 nM of plasmid DNA for 24hours. After 24hours, the dendritic 
cells were washed twice with HBSS and pulsed with CD4+ Tcells from spleen of Blo t 
5 TCR transgenic mouse at a 1:2 ratio. 72hours later, fresh medium containing IL-2 
was added. 7 days after the coculture of DC and T cell, the T cells were washed and 
subjected to ficoll separation to remove the dead cells. After which the T cells was 
restimulated again with plasmid DNA pulsed dendritic cells. The culture supernatant 
was collected after 72hours and assayed for IFN-γ and IL-17. Results were the mean 























































Figure 3.22: Schematic diagrams on the experimental regimens 
C57BL/6 mice were immunized via intramuscular route with pVAX, pVAXBlot5, 
pVAXBlot5-DTKT on days 0 and 14.The mice were sacrified on day 21 for 
splenocyte culture (a). C57/BL6 mice were immunized via intraperitoneal route with 
rBlo t 5 protein adjuvanted with aluminium hydroxide on days 0 and 21. Control mice 
were immunized with PBS adjuvanted with aluminium hydroxide, the mice were bled 
weekly and sacrified on day 28 for splenocyte culture (b). C57/BL6 mice were 
immunized via intramuscular route with pVAX, pVAXBlot5, pVAXBlot5-DTKT on 
days 0 and 14.The mice were then intraperitoneally immunized with rBlo t 5 protein 
adjuvanted with aluminium hydroxide on days 21 and 42 and they were sacrified on 
day 49 for splenocyte culture. Mice were bled weekly. (c) Rhesus macaques were 
immunized via the intramuscular route with pVAX, pVAXhBlot5, pVAXhBlot5-
DTKT on weeks 0, 4, 8 and subcutaneously immunized with rBlo t 5 protein 
adjuvanted with aluminium hydroxide on weeks 12 and 16. ELISPOT analysis was 
carried out on week 18. Rhesus macaques were bled monthly (d). All sera collected 




















































Figure 3.23: Cytokine profile of splenocytes in mice immunized with plasmid 
DNA 
Mice were immunized with 50 μg of plasmid DNA with electrophoration on day 0 
and 14. The mice were sacrificed one week after the second intramuscular 
immunization. Splenocytes of mice were stimulated with 10 μg/ml rBlo t 5 protein 
and culture supernatant collected after 72 hours. Culture supernatant was assayed for 
IFN-γ, IL-6, IP-10, IL-17, MIG and GMCSF by milliplex. Data were presented as 
mean ± SEM (n = 4-5) * statistical significance when compared with pVAX vector 












































































































































































































Figure 3.24: Cytokine profile of cultured T cells of mice intraperitoneally 
injected with Blo t 5 protein (allergy mode) 
Mice were immunized intraperitoneally at 3 weeks apart with rBlo t 5 protein 
adjuvanted with aluminium hydroxide. Control mice were intraperitoneally 
immunized with PBS adjuvanted with alum only. Mice were sacrified one week after 
the second intraperitoneal immunization. Splenocytes of treated and control mice 
were stimulated with rBlo t 5 protein for 7 days in vitro. Viable cells were 
restimulated with Blo t 5 in the presence of antigen-presenting cells for 72 hours. 
Culture supernatant was collected and analyzed for IFN-γ, IL-17, IL-5, IL-13, IL-6, 
MCP-1 and MIG by milliplex. Data were presented as mean ± SEM (n=4-7) * 






















Figure 3.25: Intracellular cytokine staining of mice intraperitoneally immunized 
with rBlo t 5 recombinant protein adjuvanted with alum. 
Mice were intraperitoneally immunized with rBlo t 5 protein adjuvanted with alum 
twice at three weeks apart. One week after the second intraperitoneal injection, the 
mice were sacrificed. Splenocytes of treated and control mice were stimulated with 
Blo t 5 protein for 7 days in vitro. Viable cells were restimulated with anti-CD3 and 
CD28 antibodies and cells were stained with anti-CD4, anti-CD8, anti IFN-gamma, 
anti IL-17A antibodies and analysed via flow cytometry. Data analysed was based on 












































































































Figure 3.26: Allergen specific antibody responses of mice intraperitoneally 
injected with rBlo t 5 protein (allergy model) 
Mice were immunized intraperitoneally at 3 weeks apart with rBlo t 5 protein 
adjuvanted with aluminium hydroxide. Control mice were intraperitoneally 
immunized with PBS adjuvanted with alum only. Sera were collected weekly. Titers 
of Blo t 5 -specific IgG1, IgG2c and IgE were determined by ELISA. Data were 

















































































































































































Figure 3.27: Cytokine and chemokine profile of splenocytes in mice immunized with 
plasmid DNA and intraperitoneally injected with rBlo t 5 protein 
Mice were immunized with 50 μg of plasmid DNA with electrophoration at day 0 and 
14. 1 and 4 weeks after the second immunization, the mice were intraperitoneally 
injected with rBlo t 5 protein adjuvanted with alum. The mice were sacrificed one 
week after the second intraperitoneal injection. Splenocytes were stimulated with 10 
μg/ml rBlo t 5 protein. Seventy-two and ninety-six hours later, supernatants were 
collected and analyzed for IFN-γ, IL-17, IL-5, IL-13, IL-6, MCP-1, MIG, TGF-β and 
IL-10 by milliplex. Control mice were not immunized with plasmid DNA. Data were 
presented as mean ± SEM (n = 7-8) # compared with control group, *compared with 
































































































































































Figure 3.28: Cytokine and chemokine profile of cultured T cells of mice 
immunized with plasmid DNA and intraperitoneally injected with rBlo t 5 
protein 
Splenocytes of treated and control mice were stimulated with rBlo t 5 protein for 7 
days in vitro. Viable cells were restimulated with rBlo t 5 protein in the presence of 
antigen-presenting cells for 72 hours. Culture supernatant were collected and analyzed 
for IFN-γ, IL-17, IL-5, IL-13, IL-6, MCP-1, MIG, TGF-β and IL-10. Control mice 
were not immunized with plasmid DNA. Data were presented as mean ± SEM (n = 7-
8) # compared with control mice, * compared with pVAX vector group, ^ compared 



































































Figure 3.29: Allergen specific antibody responses in mice immunized with 
plasmid DNA and intraperitoneally injected with rBlo t 5 protein 
Mice were immunized with 50 μg of plasmid DNA with electrophoration at day 0 and 
14. 1 and 4 weeks after the second immunization, the mice were intraperitoneally 
injected with rBlo t 5 protein. The mice were sacrificed one week after the second 
intraperitoneal injection. Sera were collected weekly. Titers of Blo t 5 -specific IgG1, 
IgG2c and IgE were determined by ELISA. * stands for statistical significance 
between pVAXBlot5 and pVAX; # stands for statistical significance between 
pVAXBlot5-DTKT and pVAX, ^ stands for statistical difference between 
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Figure 3.30: Differential response of human PBMC to plasmid DNA or free CpG 
oligonucleotides at 5 hours 
Human PBMCs were cocultured with various doses (1 nM, 10 nM, 100 nM) of 
plasmid DNA or free CpG ODN and the culture supernatants were collected at 5 
hours. The culture supernatants were assayed for TNF-α, IL-6, MIP-1α and MIP-1β 
via milliplex. Data illustrated were the mean ± SEM from three donors. # stands for 
statistical significance compared to DTKT ODN. * stands for statistical significance 









































































Figure 3.31: Differential response of human PBMC to plasmid DNA or free CpG 
oligonucleotides at 24 hours 
Human PBMCs were cocultured with various doses (1 nM, 10 nM, 100 nM) of 
plasmid DNA or free CpG ODN and the culture supernatant was collected at 24 hours. 
The culture supernatants were assayed for TNF-α, IL-6, MIP-1α and MIP-1β via 
milliplex. Data illustrated were the mean ± SEM from three donors. # stands for 
statistical significance compared to DTKT ODN. * stands for statistical significance 















































































Figure 3.32: Differential regulatory protein expression of human PBMC to 
plasmid DNA at 5 hours 
Human PBMCs were cocultured with 100 nM of plasmid DNA, pVAXhBlot5 (hBT5) 
and pVAXhBlot5-DTKT (hBT5-DTKT). Culture supernatants were collected at 5 
hours and assayed for cytokines and chemokines via the protein array. Data was 




























Figure 3.33: Differential regulatory protein expression of human PBMC to 
plasmid DNA at 24 hours 
Human PBMCs were cocultured with 100 nM of pVAXhBlot5 (hBT5) and 
pVAXhBlot5-DTKT (hBT5-DTKT). Culture supernatant was collected at 24 hours 
and assayed for cytokines and chemokines via the protein array. Data was presented 
















































Figure 3.34: Differential regulatory protein expression of human PBMC to 
plasmid DNA or free CpG oligonucleotides at 5 hours 
Human PBMCs were cocultured with 100 nM of pVAXhBlot5-DTKT (hBT5-DTKT) 
and free CpG ODN (DTKT ODN). Culture supernatants were collected at 5 hours and 
assayed for cytokines and chemokines via the protein array. Data was presented as 






















































Figure 3.35: Differential regulatory protein expression of human PBMC to 
plasmid DNA or free CpG oligonucleotides at 24 hours 
Human PBMCs were cocultured with 100 nM of pVAXhBlot5-DTKT (hBT5-DTKT) 
and free CpG ODN (DTKT ODN). Culture supernatant was collected at 24 hours and 
assayed for cytokines and chemokines via the protein array. Data was presented as 


































































































Figure 3.36: Allergen specific antibody responses in rhesus macaques 
intramuscularly immunized with plasmid DNA and subcutaneously immunized 
with Blo t 5 protein 
Rhesus macaques were immunized with 2 mg of plasmid DNA thrice at 4 weeks 
interval. 4 and 8 weeks after the last immunization, the rhesus macaques were 
subcutaneously immunized with 500 μg rBlo t 5 protein adjuvanted with alum. Sera 
were collected from the rhesus macaques regularly. Titers of Blo t 5 -specific total 
IgG, IgG1, IgG3 and IgE were determined by ELISA. * stands for statistical 
significance between pVAX and pVAXhBlot5 groups, # stands for statistical 






































































































































Figure 3.37: IFN-γ producing cells in rhesus macaques intramuscularly 
immunized with plasmid DNA and subcutaneously immunized with rBlo t 5 
protein 
Rhesus macaques were immunized with 2 mg of plasmid DNA thrice at 4 weeks 
interval. 4 and 8 weeks after the last immunization, the rhesus macaques were 
subcutaneously immunized with 500 μg rBlo t 5 protein adjuvanted with alum. Blood 
was collected from the rhesus macaques 2 weeks after the second subcutaneous 
immunization and IFN-γ forming spots of peripheral blood mononuclear cells in 


































Figure 3.38: IL-4 producing cells in rhesus macaques intramuscularly 
immunized with plasmid DNA and subcutaneously immunized with rBlo t 5 
protein 
Rhesus macaques were immunized with 2 mg of plasmid DNA thrice at 4 weeks 
interval. 4 and 8 weeks after the last immunization, the rhesus macaques were 
subcutaneously immunized with 500 μg rBlo t 5 protein adjuvanted with alum. Blood 
was collected from the rhesus macaques 2 weeks after the second subcutaneous 
immunization and IL-4 producing spots of peripheral blood mononuclear cells in 











DNA vaccine was an attractive modality for the treatment of allergic disease as it 
could be engineered to incorporate the gene of interest as well as molecular adjuvants. 
In addition, DNA vaccines were cheap, easy to produce and did not require cold 
storage. DNA vaccines could provide a long term source of antigen. However the 
main disadvantage of DNA vaccine was its low immunogenicity. Hence, in this study, 
multiple approaches were employed to increase the immunogenicity of the DNA 
vaccine. In this study, Blo t 5 allergen gene together with a signal peptide and a 
lysosome-targeting signal, LAMP-1 targeting sequence, was cloned into pVAX vector 
with the insertion of human CpG motifs into the backbone. Previous reports had 
shown that robust antigen specific Th1 responses could be induced by the use of 
LAMP-1 in HIV gag DNA vaccines (de Arruda et al., 2004; Marques et al., 2003). 
Electrophoration was also employed to increase the efficiency of plasmid DNA 
uptake (Babiuk et al., 2002; Mir et al., 1999; Uno-Furuta et al., 2001). This study had 
evaluated if the insertion of additional CpG motifs into the plasmid backbone 
provided an adjuvant effect by enhancing the immunogenicity. 
 
To evaluate if CpG modified plasmid DNA enhanced the antigen presenting 
properties of antigen presenting cells, both pVAX-Blot5 and pVAXBlot5DTKT were 
used to stimulate either GMCSF or Flt3 ligand derived dendritic cells from mouse 
bone marrow in vitro as it was difficult to isolate dendritic cells in sufficient numbers 
in vivo. Antigen presenting properties of antigen presenting cells were assessed via 
upregulation of surface markers and cytokine production. This study had showed that 
modified and unmodified plasmid DNA elicited similar effects on bone marrow 
derived dendritic cells in terms of surface marker upregulation and cytokine 
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production. This could be due to the presence of alternate DNA sensor pathways such 
as the STING pathway that triggered type I interferon production, the AIM-2 
inflammasome pathway/NOD-like receptor pathway that mediated proinflammatory 
cytokine production and the DNA mediated RNA polymerase III/RIG-1/IPS-1 
pathway. Double stranded DNA structure was shown to be efficient in the activation 
of the STING pathway as single stranded DNA did not induce robust type I 
interferons. As both activation of the DNA sensor pathways and activation of TLR9 
via CpG motifs converged at the downstream activation of NF-κB hence it was 
possible that the effect of additional CpG motifs was not observed due to the robust 
activation of the DNA sensor pathways. Besides that, TLR9 could interact with the 
phosphodiester 2’ deoxyribose backbone of plasmid DNA and activate the 
intracellular signaling cascade (Haas et al., 2008). Furthermore, additional human 
CpG motifs inserted into the plasmid backbone may not be optimal for murine cells 
hence the adjuvant effect of CpG motifs was not profound.The enhanced 
immunogenic effect of human CpG motifs was reflected by using human cells as CpG 
modified plasmid DNA induced more robust production of proinflammatory 
cytokines from human peripheral blood mononuclear cells as compared to unmodified 
plasmid DNA. Plasmid DNA induced robust activation of the DNA sensor pathways 
may overwhelm the effect of activation of TLR9 by CpG motifs.  
 
Dendritic cells were potent antigen presenting cells that could direct the 
differentiation of CD4+ T cells. The combined effect of antigen dose, maturation 
status of dendritic cells and stimulation of dendritic cells with pathogenic-derived 
products affected the subsequent development of either a Th1 or Th2 response 
(Boonstra et al., 2003). High antigen doses had been suggested to promote Th1 cell 
141 
 
development while low antigen dose tended to favour Th2 cell development  
(Boonstra et al., 2003). Level of TLR9 expression varied in different dendritic cell 
subsets. In mice, bone marrow derived dendritic cells using GMCSF (GMCSF-DC) 
were myeloid dendritic cells that had low expression of TLR9 but high expression of 
TLR4 (Boonstra et al., 2003). In contrast, bone marrow derived dendritic cells using 
Flt3L (Flt3L-DC) were mainly plasmacytoid dendritic cells that have high expression 
of TLR9 and TLR7 but low expression of TLR2, TLR3 and TLR4 (Okada et al., 
2003). Hence differential cytokine and chemokine production by bone marrow 
derived dendritic cells using GMCSF or Flt3 ligand may be due to the difference in 
TLR9 content. Flt3L-DC were known to be made up of 50% of CD11c+CD11b- 
dendritic cells and another 50% of CD11c+CD11b+ dendritic cells while GMCSF-DC 
were reported to consist of a single population of CD11c+CD11b+B220- dendritic cells 
which were similar in phenotype to CD11c+CD11b+B220- dendritic cells induced by 
Flt3L (Gilliet et al., 2002). CD11c+CD11b- subset from Flt3L-DC had been 
demonstrated to express the typical markers of mouse plasmacytoid DC precursors 
such as high levels of B220, CD45RB, Ly6c, GR-1, low levels of MHC class II  and 
undetectable CD80 , CD86 levels (Asselin-Paturel et al., 2001; Nakano et al., 2001). 
In contrast, lower levels of CD45RB, Ly6c, GR-1, higher levels of CD80, CD86, 
MHC class II and undetectable levels of B220 were observed on CD11c+CD11b+ 
subset from Flt3L-DC and this phenotype was similar to that of splenic myeloid DC 
subsets (Moser and Murphy, 2000; Pulendran et al., 2001; Shortman, 2000). In this 
study, GMCSF-DC was found to produce higher levels of IL-6 and TNF-α as 
compared to Flt3L-DC upon stimulation with plasmid DNA. A possible reason could 
be that since Flt3L-DC consisted of 50% of CD11c+CD11b+B220- cells cells that 
resembled GMCSF-DC, only about 50% of DC were capable of producing IL-6 and 
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TNF-α in response to plasmid DNA stimulation while over 90% of GMCSF-DC 
could produce IL-6 and TNF-α. IL-6 was known to be the prototypic cytokine of 
conventional DC. (Yasuda et al., 2006) Besides that, CD11c+CD11b+B220- fraction of 
Flt3L-DC also showed a similar cytokine profile as GMCSF-DC with higher IL-6 and 
TNF-α than the CD11c+CD11b-B220+ fraction which is in agreement with another 
published study (Gilliet et al., 2002). Hence CD11c+CD11b+B220- dendritic cells 
were more responsive to plasmid DNA stimulation and produced higher levels of 
cytokines and chemokines than CD11c+CD11b-B220+  dendritic cells. 
 
Development of immune responses could be affected by the CpG content in the 
plasmid backbone of DNA vaccines, hence a way to enhance the immune responses is 
to increase the number of CpG motifs (Coban et al., 2005; Kojima et al., 2002; 
Pontarollo et al., 2002). Synthetic CpG ODN had been used in many studies as they 
had proven to have potent adjuvant properties (Conforti et al., 2008; Sur et al., 1999; 
Weiner et al., 1997). CpG ODN had been demonstrated to induce robust upregulation 
of CD40, CD86 as well as IL-12p40, IL-12p70, IL-6 and TNF-α from GMCSF-DC 
(Dearman et al., 2009). In this study, CpG modified plasmid DNA was found to be 
more potent activators of dendritic cells in terms of upregulation of surface markers 
MHC class II, CD80, CD86, CD40 and production of proinflammatory cytokines such 
as IL-6, TNF-α when compared to free CpG ODN. Possible reason for the 
enhancement of antigen presenting functions of dendritic cells by CpG modified 
plasmid DNA could be that in addition to activating TLR9, the DNA plasmid 




This study had established an experimental allergy model in which an allergen Blo t 5 
when adjuvanted with alum was capable of triggering mixed Th1, Th2 and Th17 
immune responses. In addition, mixed humoral responses were also induced in such 
an experimental model with the production of IgG1, IgG2c (Th1 signature antibody) 
and IgE (Th2 signature antibody). This model provided a more accurate 
representation of the actual situation as allergic inflammation was now known to be 
not only a Th2 type mediated process, Th1 and Th17 type responses also played a role 
at enhancing Th2 immune responses (Randolph et al., 1999a; Sugimoto et al., 2004; 
Wakashin et al., 2008). This study showed that allergen gene vaccination could 
suppress production of Th1 cytokine IFN-γ, Th17 cytokine IL-17, Th2 cytokines IL-5, 
IL-13 and proinflammatory cytokine IL-6 from Blo t 5 specific T cells. Possible 
mechanisms could be via the induction of Treg cells with the subsequent production 
of immunosuppressive IL-10 or mediated by the effect of IFN-γ. The role of Treg in 
suppressing Th1, Th2, Th17 cells was highlighted in a study whereby Treg cells were 
ablated using human diphtheria toxin in ‘knock in’ mice with the insertion of the 
coding region of the toxin receptor at the 3’ untranslated region of Foxp3 (Kim et al., 
2007). Ablation of Treg cells resulted in inflammation at multiple organs and 
increased mortality which could be due to the increased activation of Foxp3-CD4+ T 
cells (Kim et al., 2007). Supporting evidence was apparent in another study which 
demonstrated that transfer of effector Foxp3- T cells into Rag2-/- recipient mice 
upregulated production of Th1, Th2, Th17 cytokines and inflammation in many 
organs (Chaudhry et al., 2011). In addition other studies reported that nTregs could 
suppress lung allergic responses through IL-10 and TGF-β production (Joetham et al., 
2007; Presser et al., 2008). Allergen gene vaccination increased the production of 
immune suppressive cytokines such as IL-10 by splenocytes in response to rBlo t 5 
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protein when compared to pVAX vector group (Figure 3.27). Hence, it was possible 
that the suppression in Blo t 5 specific Th1, Th2 and Th17 cytokines was mediated 
through IL-10 producing Treg cells in vivo. Phospholipase A specific T cells from 
PBMC had been reported to produce IL-10 in response to phospholipase A with the 
subsequent induction of an anergic state in peripheral T cells (Akdis et al., 1998). 
Treg cells bear IL-10R and signalling via IL-10R was essential to suppress Th17 
responses (Chaudhry et al., 2011). In addition STAT3, a transcription factor that 
drove the differentiation of Th17 had been found to bind to IL-10 locus in Treg cells 
and IL10R deficient Treg cells failed to produce IL-10 (Chaudhry et al., 2011). Given 
that Th1, Th2 and Th17 cells were also competent in producing IL-10, it would be 
reasonable to deduce that IL-10 produced by these cells could act in a feedback loop 
by acting on IL-10R on Treg cells and activating STAT3 with the subsequent 
production of more immunosuppressive IL-10 (Chaudhry et al., 2011). This IL-10 
produced might control or suppress the effector cells. Role of IL-10 as a negative 
regulator of Th17 responses had been demonstrated in another study whereby IL-10R 
deficient Treg cells failed to suppress IL-17 and IL-22 by CD4+Foxp3- T cells 
(Chaudhry et al., 2011). Besides that IL-10Rα had been found to be expressed on IL-
17A producing CD4+ T cells hence it may be probable that IL-10 could act directly 
and exert a suppressive effect on Th17 cells (Huber et al., 2011). IL-10 could be a 
possible mediator for the suppressive effect on antigen specific Th1, Th2, Th17 
cytokines observed in allergen gene vaccinated mice.  
 
Interestingly, splenocytes from allergen gene immunized groups produced 
significantly higher levels of IFN-γ than the pVAX vector group as well as the group 
that had been immunized intraperitoneally with rBlo t 5 protein adjuvanted with alum. 
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The immune regulatory role of IFN-γ had been previously reported and it had been 
shown that IFN-γ was capable of suppressing Th2 cytokines, IL-5, IL-13 as well as 
Th1 and Th17 type cytokines in the lung (Nakagome et al., 2009). It was hence 
possible that the suppression in the Th1, Th17 and Th2 cytokines seen in the allergen 
gene vaccinated group could be a result of the high levels of IFN-γ produced. Another 
possibility is that TH1 TR cells that develop in Th1 biased conditions could be induced. 
This antigen specific CD4+ regulatory T cells were found to produce both IFN-γ and 
IL-10 and were capable of inhibiting effector T cell responses such as Th2 responses 
(Stock et al., 2004). TGF-β, also a regulatory cytokine produced by Treg cells, could 
also be a possible mediator but no difference was observed in this study. Hence it was 
speculated that IFN- γ could possibly play a role in the suppressive effect on antigen 
specific Th1, Th2, Th17 cytokines observed in allergen gene vaccinated mice.  
 
pVAX vector vaccination group also showed suppression in IFN-γ and IL-17 
production by Blo t 5 specific T cells. A probable reason was that the DNA plasmid 
backbone itself could activate different DNA sensor pathways as mentioned earlier. 
There were a number of DNA-sensing pattern recognition receptors such as the 
cytosolic sensor DAI (DNA dependent activator of IRF also known as ZBP1 and 
DLM-1), IFI16, absent in melanoma 2 (AIM-2) and TLR-9. Double stranded DNA 
was reported to bind to DAI with the subsequent phosphorylation of TANK-binding 
kinase-1 (TBK1) and activation of IRF3 (IFN regulatory factor 3), resulting in the 
expression of type 1 IFNs and proinflammatory cytokines (Takaoka et al., 2007; 
Wang et al., 2008). Importance of TBK1 was highlighted in another study where it 
was demonstrated that TBK1-dependent signalling was needed for DNA vaccine 
induced humoral and cellular immune responses in vivo (Ishii et al., 2008). The 
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binding of DNA to DAI could also activate another pathway, receptor interacting 
protein-1 kinase could also bind to DAI with subsequent activation of NFκB pathway 
(Kaiser et al., 2008). In addition, the phosphodiester 2’ deoxyribose backbone of 
DNA also had been reported to activate TLR9 (Haas et al., 2008). It was observed in 
this study that Flt3L-DC produced type I interferons in response to plasmid DNA 
stimulation in vitro. Hence it was probable that type I interferon production stimulated 
by the DNA sensors pathways could be the suppressive factor for the attenuation of 
allergen specifc IL-17 and IFN-γ (Moschen et al., 2008). 
 
Notably, pVAXBlot5-DTKT immunized group showed greater suppression in Th2 
cytokines, IL-5 and IL-13, when compared to pVAXBlot5 immunized mice that had 
been immunized intraperitoneally with rBlo t 5 protein adjuvanted with alum (Figure 
3.28). In addition, pVAXBlot5-DTKT activated dendritic cells also showed attenuated 
IL-17 and IFN-γ production in in vitro priming of Blo t 5 specific T cells as compared 
to pVAXBlot5 (Figure 3.21). A possible mediator of the suppressive effect could be 
GMCSF, as splenocytes from pVAXBlot5-DTKT immunized mice produced the 
highest levels of GMCSF (Figure 3.23). GMCSF has been implicated in the expansion 
of Treg cells, hence suppressive effect observed in pVAXBlot5-DTKT immunized 
mice could be attributed to GMCSF expansion of Treg cells (Sheng et al., 2008). 
 
The importance and involvement of TLR9 had been a topic of interest after some 
studies revealed that TLR9 deficient mice elicited similar immune responses to DNA 
vaccination (Babiuk et al., 2004; Spies et al., 2003). However recently other studies 
had demonstrated that TLR9 was still involved in the activation by CpG DNA as it 
was shown that CpG DNA but not non CpG DNA bound to TLR9 hence inducing a 
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conformational change and activation of TLR9 via in vivo single molecule 
experiments (Chen et al., 2011). In addition, dendritic cells activation by plasmid 
DNA and subsequent priming of antigen specific CD8+ T cell responses was found to 
be dependent on TLR9 in vitro and in vivo (Rottembourg et al., 2010). Expression 
levels of TLR9 in primary human cells were found to correlate with the 
responsiveness to CpG-DNA stimulation and the highest expression of TLR9 was 
found in pDCs and B cells (Bauer et al., 2001; Hornung et al., 2002). In mouse, TLR9 
was expressed in pDCs, cDCs and B cells. Upon activation of TLR9, IL-15 was 
secreted by cDCs that in turn induced pDCs to express CD40L. In addition, CD40 
expression on cDCs was also induced by TLR9 signalling. This CD40-CD40L 
ligation subsequently induced conventional dendritic cells to produce IL-12 that 
activate NK cells to produce IFN-γ (Kuwajima et al., 2006). Hence the increased 
levels of IFN-γ observed in the splenocyte cultures of pVAXBlot5-DTKT mice could 
also be due to the activation of NK cells brought about by the crosstalk between 
plasmacytoid dendritic cells and conventional dendritic cells upon TLR9 engagement 
by CpG motifs. In this study, the involvement of TLR9 was also verified via TLR9 
inhibition experiments whereby inhibition of TLR9 attenuated sharply the production 
of IL-6, TNF-α, IL-12p40, IP-10, KC, MIP-1α, MIP-1β, MIP-2 and IFN-α from 
CD11c+CD11b+B220- DCs and IFN-α, IL-6, IP-10, IL-12p40 from CD11c+CD11b-
B220+ DCs. Hence TLR9 might be involved in the enhanced levels of IFN-γ observed 
in pVAXBlot5-DTKT immunized mice. 
 
It was demonstrated in the allergy model that intraperitoneal immunization with Blo t 
5 adjuvanted with alum induced distinct subsets of IL-17 and IFN-γ producing cells. 
The flexibility of Th17 phenotype had been demonstrated by the conversion of Th17 
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cells into Th1/Th17 cells in the presence of IFN-γ in vivo (Annunziato and 
Romagnani, 2010; Kurschus et al., 2010; Lexberg et al., 2010). Given that allergen 
gene vaccination had been shown to induce the production of considerable levels of 
IFN-γ by splenocytes, it is probable that Th17 cells can be converted to Th1 cells 
under the IFN-γ rich microenvironment. Another piece of supporting evidence came 
from a recent study in which a Th17 reporter mouse line had been used to show the 
plasticity of both in vitro and in vivo generated Th17 cells as these cells can change 
their phenotype into Th17/Th1 as well as Th1 cells (Kurschus et al., 2010). 
Allergen/alum immunization induced IL-17 producing cells could either be 
suppressed by IFN-γ or switched to other T helper phenotypes. 
 
One of the major limitations of DNA vaccines was its limited efficacy in humans 
especially in their induction of humoral responses (Calarota et al., 1998; Coban et al., 
2004; Epstein et al., 2002). In this study, by employing the use of molecular adjuvant, 
human CpG motifs, we proved by both in vitro and in vivo studies using murine 
model as well as human peripheral blood mononuclear cells and non-human primates 
of the enhanced immunogenic effect of CpG modified plasmid DNA. In this study we 
showed that pVAXhBlot5-DTKT induced human PBMC to secrete elevated levels of 
IL-6, MIP-1α and MIP-1β. This was in agreement with previous studies that reported 
that plasmid DNA with additional CpG motifs (either the D or K type) induced 
PBMC to produce IL-6 (Coban et al., 2005). Addition of human CpG motifs into the 
plasmid backbone showed enhanced stimulatory effect on human cells. Human CpG 
motifs were active in both mouse and humans while optimal CpG motifs for mice did 
not work in humans, as such human CpG motifs were employed so that its efficacy 
could be assessed by using both the murine and human system (Ishii et al., 2004). In 
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addition the use of humanized Blo t 5 gene sequence, humanized lamp targeting 
sequence and human CpG motifs made it more possible for this plasmid DNA to be 
applicable for human use. This study was one of the few studies that evaluated 
allergen gene vaccination in non-human primates. In this study, pVAXhBlot5-DTKT 
immunized macaques produced the highest level of Blo t 5-specific total IgG and 
IgG1, suggesting that incorporating CpG motifs into the plasmid backbone enhanced 
the immunogenicity of the DNA vaccine. Besides that, cellular responses were also 
improved in pVAXhBlot5-DTKT immunized non-human primates that elicited higher 
number of IFN-γ producing cells in response to stimulation with Blo t 5 peptide pools. 
Studies done by other groups had also reported that immune responses to hepatitis B 
vaccine and heat-killed leishmania vaccine had been strongly enhanced by the use of 
CpG ODN in non-human primates (Davis et al., 2000; Jones et al., 1999). However 
subsequent studies of DNA vaccines carried out in murine models should evaluate 
airway hyperresponsiveness and airway remodeling as these readouts serve as better 
indicators of the efficacy of DNA vaccines. However despite the success in using 
CpG ODN to improve the immunogenicity of vaccines, caution must be taken in the 
use of CpG ODN as it had been shown that coagulation serine proteases, plasminogen 
and thrombin production could be triggered by phosphorotioated oligonucleotides 
(Bokarewa et al., 2002). Hence the incorporation of CpG ODN into the plasmid 
backbone might be a safer way of boosting the immunogenicity of DNA vaccines by 




Chapter 4 Exploration on the Use of Cytokine Gene Delivery against Airway 
Inflammation and Allergic Responses 
 
4.1 Introduction 
Increased prevalence of allergic asthma had become a public health issue 
(Ozdoganoglu and Songu, 2011). Genetic vaccination was a promising alternative 
approach to treat allergic asthma compared to protein immunization as protein 
immunization was associated with potential anaphylactic side effects and synthesis of 
IgE. In addition, gene expression in the skeletal muscle had been reported to be 
detected for many months after injection due to the episomal existence of plasmids in 
muscle cells (Davis et al., 1996; Wolff et al., 1992). Besides allergen gene 
immunization, cytokine gene immunization was also extensively researched on as a 
modality to skew the underlying T helper type 2 immune responses to that of a T 
helper 1 response in allergy. As such, attention had been placed on pro Th1 cytokines 
such as IL-12, IL-18, IFN-γ and IL-10 in the past decade (Dow et al., 1999; Li et al., 
2008; Maecker et al., 2001; Nakagome et al., 2005). 
 
It had been demonstrated that vaccination with an OVA and IL-18 fusion plasmid 
DNA not only protected mice from airway hyperresponsiveness induction but also 
reduced allergen specific IgE production (Maecker et al., 2001). In addition, OVA and 
IL-18 fusion plasmid DNA could negate established airway hyperresponsiveness, 
decrease Th2 cytokine IL-4 and increase Th1 cytokine IFN-γ in vaccinated mice, this 
effect was not seen in groups vaccinated with OVA plasmid DNA only (Maecker et 
al., 2001). In another study, vaccination of mice with plasmids encoding IFN-γ and 
IL-12 induced strong Th1 responses hence protecting the mice against lung 
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inflammation, as well as IgE induction (Kumar et al., 2001). Besides IL-18 and IL-12, 
intravenous and intratracheal IFN-γ gene delivery also resulted in a significant 
attenuation of AHR and airway eosinophilia, in addition administration of IFN-γ via 
the intravenous route was also able to reduce serum IgE levels (Dow et al., 1999). 
However there were certain dangers with the use of these cytokine genes as they may 
result in overwhelming Th1 responses. 
 
As such, we aimed to determine the role of regulatory cytokines in allergic diseases. 
Regulatory cytokines were known to modulate the immune responses instead of 
skewing it in a particular direction. The novel regulatory cytokine, IL-35 is a 
heterodimeric cytokine from the IL-12 family that was composed of Epstein-Barr-
virus-induced gene 3 (Ebi3) and interleukin-12 alpha which had been found to be 
expressed at high levels in mouse Foxp3+  Treg cells but not in resting or activated 
CD4+ cells (Collison et al., 2007b). The immunosuppressive role of IL-35 had been 
demonstrated in murine models of collagen induced arthritis as well as inflammatory 
bowel disease (Collison et al., 2007a; Niedbala et al., 2007) but its role in Th2 
mediated disease, for example, allergic asthma had not been determined. Allergic 
asthma is a chronic inflammatory respiratory disease affecting atopic individuals 
globally. Asthma is a heterogenous and chronic inflammatory disease, its’ cellular 
inflammation profiles could either be characterized by eosinophilia or neutrophilia. 
The prevalence of allergy has been increasing steadily in recent years, even with the 
emergence of more potent drugs. Hence, more effective therapies are warranted. In 
this study, we aimed to evaluate the suppressive effect of IL-35 on the Th2 and 
Th1/Th17 mediated lung inflammation in two newly developed murine models. One 
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was induced by a Blo t 5-specific Th2 cell line and the other was induced by the direct 




4.2.1 Construction of pVAX-IL35 
The Epstein-Barr virus induced gene 3 (EBI3) was amplified from the first strand 
cDNA prepared from lipopolysaccharide activated bone marrow derived dendritic 
cells. Amplified EBI3 had a BamHI site at the 5’ site and a HindIII site at the 3’ end. 
The p35 subunit of IL-12 (IL-12p35) was amplified from the first strand cDNA 
prepared from splenocytes. Amplified IL-12p35 had EcoRI site at the 5’ end and a 
NheI site at the 3’ end. Two complementary oligonucleotides encoded for 4 repeats of 
GGGS linker were designed and annealed with the HindIII and EcoRI sites at the 
sense and antisense strands respectively. Amplified EBI3, IL-12p35 and the double 
stranded linker were digested with respective restriction enzymes and ligated into 
BamHI and NheI sites of pVAX. The amino acid sequence of IL-35 constructed by 
the fusion of EBI3, 4 repeats of GGGS linker and IL-12p35 was shown (Fig 4.1). 
 
4.2.2 Expression of EBI-3, IL-12p35 and IL-35 mRNA in lungs of mice treated 
with pVAX-IL-35 
To evaluate the expression of single chain IL-35, mice were administered 
intratracheally with pVAX-IL-35 and total RNA was extracted from the lungs. EBI-3, 
IL12p35 and IL-35 mRNA expression was determined by real time PCR. EBI-3, IL-
12p35 and single chain IL-35 mRNA expression was detected at cycle number 18, 23 
and 31 respectively (Fig 4.2). Since the expression of the fusion single chain IL-35 
transcript could be detected by PCR, that distinguished it from the endogenous EBI3 





4.2.3 IL-35 attenuated Blo t 5-specific Th2 cell line mediated allergic airway 
inflammation 
To assess if local delivery of the new regulatory cytokine IL-35 can attenuate the Blo 
t 5-specific Th2 cell line induced inflammation by transfer of Blo t 5-specific Th2 
cells and intranasal Blo t 5 protein challenge, a plasmid DNA encoding recombinant 
single-chain IL-35 was intratracheally delivered into the airway. Total cell infiltration 
in the BALF was reduced in mice that had been administered pVAX-IL-35 compared 
to those administered with pVAX (1.68 × 105 vs 3.35 × 105, p < 0.05) (Fig 4.3A). 
Intratracheal administration of pVAX-IL-35 also significantly reduced eosinophils, 
lymphocytes and neutrophils numbers in the BALF (Fig 4.3B). The reduction in 
eosinophils was most marked from 2.37 × 105 in pVAX treated mice to 7.0 × 104 in 
pVAX-IL35 treated mice (Fig 4.3B). In addition, Th2 effector cytokines, IL-5, IL-4 
and IL-13 were also significantly attenuated in the BALF of experimental pVAX-IL-
35 group compared to the control pVAX group (Fig 4.3C). Concomitantly with the 
suppressed Th2 cytokine concentrations in the BALF, CCL2/MCP-1, CXCL1/KC, 
CXCL5/LIX, CXCL9/MIG and CXCL10/IP-10 concentrations in the BALF were also 
attenuated in the BALF from mice of the experimental pVAX-IL-35 (Fig 4.3D). 
Hence, locally expressed IL-35 could suppress the Blo t 5-specific Th2 cell line 
mediated lung inflammation by reducing the Th2 effector cytokines and 
chemoattractant CC- and CXC- motif chemokines for the recruitment of polymorphic 
mononuclear cells and lymphocytes. 
 
4.2.4 IL-35 suppressed antigen-specific IgE, IgG1 and confered long term 
protection upon subsequent Blo t 5 challenge 
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To investigate whether systemic distribution of IL-35 can suppress Blo t 5-specific 
Th2 cells initiated Blo t 5-specific humoral responses, mice were intramuscularly 
injected with pVAX-IL-35 twice before the transfer of Blo t 5-specific Th2 cells. 
Mice were administered 2 courses of 3 consecutive days of intranasal Blo t 5 
challenges and Blo t 5-specific IgE and IgG1 were determined. Mice that received 
intramuscular immunization of pVAX-IL-35 produced lower titers of Blo t 5-specific 
IgE on days 30 (755 ELISA unit vs 321 ELISA unit), 37 (372 ELISA unit vs 94 
ELISA unit) and 84 (12865 ELISA unit vs 2838 ELISA unit ) as compared to that of 
pVAX injected mice (Fig 4.4B). Suppression of Blo t 5-specific IgG1 production was 
persistent for the whole experimental period up to day 91 in the pVAX-IL-35 treated 
mice (Fig 4.4C). Delivery of plasmid DNA encoding IL-35 not only provided the 
short-term suppression of Blo t 5 specific IgE production after the first course (days 
18-20) of intranasal Blo t 5 instillation but also the long term suppression of Blo t 5 
instillation as evidenced from the significant suppression in Blo t 5-specific IgE on 
day 84 and IgG1 on both days 84 and 91. 
 
4.2.5 IL-35 suppressed total IgE while levels of total IgM, IgA, IgG1 and IgG2c 
remained unchanged. 
In order to determine if systemic distribution of IL-35 has any effect on the 
production of different immunoglobulin isotype, total serum IgE, IgM, IgG1, IgG2c 
and IgA were assayed and compared from both groups of mice that received either 
pVAX or pVAX-IL-35. There was a significant suppression in total serum IgE on 
days 84 (52 x 103 ELISA unit vs 210 x 103 ELISA unit) and 91 (13 x 103 ELISA unit 
vs 42 x 103 ELISA unit) from pVAX-IL-35 treated mice that subsequently received 
the Blo t 5 specific Th2 cell transfer and intranasal Blo t 5 challenges when compared 
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to pVAX treated mice (Fig 4.5A). On contrary, total serum IgM, IgG1, IgG2c and 
IgA levels are similar between pVAX-IL-35 and pVAX treated groups for 3 months 
(Fig 4.5B-E). Thus IL-35 exerted a long lasting suppressive effect on the production 
of total serum IgE at the time points after the second course of Blo t 5 intranasal 
challenges. These results indicate that systemic IL-35 did not exert a pan 
immunosuppressive effect on antibody production. 
 
4.2.6 IL-35 suppressed IL-4 in the donor Th2 cells 
To examine if IL-35 exert a direct suppression on the production of IL-4 by Th2 cells, 
mice were first intramuscularly injected with pVAX-IL-35 twice before the transfer of 
Blo t 5-specific Th2 cells and administered 3 consecutive days of intranasal Blo t 5 
challenges (Fig 4.6A). Spleens were excised one week later. Splenocytes of both 
pVAX-IL-35 as well as pVAX treated mice that had been stimulated in vitro with 
PMA and ionomycin were stained intracellularly for IL-4. It was found that 
splenocytes from pVAX-IL-35 experimental group had a significant reduction in IL-4 
expressing CD4+ TCRβ+ cells (0.56 ± 0.14%) as compared to the pVAX-1 control 
group (0.73 ± 0.04%) (Fig 4.6B). In addition, IL-4 expressing CD4+ cells were also 
significantly reduced in the pVAX-IL-35 experimental group (1.31 ± 0.3 %) as 
compared to the pVAX control group (1.93 ± 0.16 %) (Fig 4.6B). These results 
suggested that IL-35 may suppress the Th2 cytokine production of donor Th2 cells in 
vivo. 
 
4.2.7 IL-35 reduced neutrophil infiltration, chemokines and proinflammatory 
cytokines in a neutrophilic airway inflammatory murine model 
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We next assessed if local delivery of pVAX-IL35 intratracheally can attenuate 
neutrophilia in Blo t 5 TCR transgenic mice. Intratracheal instillation of 400 μg of 
pVAX-IL-35 reduced the total cell infiltration in the BALF (1.17 × 106 vs 2.77 × 106) 
when compared to pVAX treated mice (Fig 4.7A). Concomitantly with the decreased 
cellular infiltration, lymphocytes (4.18 × 105 vs 1.23 × 106) and neutrophils (3.29 × 
105 vs 9.92 × 105) infiltration were also significantly attenuated in the BALF of 
pVAX-IL35 treated mice (Fig 4.7B). Proinflammatory cytokines such as IL-1α, IL-6, 
IL-17, IFN-γ and other cytokines that play a role in promoting the survival, 
proliferation and activation of neutrophils and other cell types such as G-CSF and LIF 
also showed a significant reduction in the BALF of pVAX-IL35 treated group (Fig 
4.7C). Chemokines that played a chemoattractant role for monocytes and activated T 
cells such as CCL3(MIP-1α), CCL4(MIP-1β), CCL5(RANTES), CXCL1(KC), 
CXCL-9(MIG) and CXCL-10(IP-10), were significantly attenuated in BALF of 
experimental pVAX-IL-35 group compared to the control pVAX group (Fig 4.7D). 
These results suggested that pVAX-IL-35 could suppress neutrophil chemoattractant 







     BamHI                         M  S  K  L  L  F  L  S  L  
gccctctgggccagccgctcccctggttacactgaaacagctctcgtggctctaagccag 
 A  L  W  A  S  R  S  P  G  Y  T  E  T  A  L  V  A  L  S  Q  
cccagagtgcaatgccatgcttctcggtatcccgtggccgtggactgctcctggactcct 
 P  R  V  Q  C  H  A  S  R  Y  P  V  A  V  D  C  S  W  T  P  
ctccaggctcccaactccaccagatccacgtccttcattgccacttacaggctcggtgtg 
 L  Q  A  P  N  S  T  R  S  T  S  F  I  A  T  Y  R  L  G  V  
gccacccagcagcagagccagccctgcctacaacggagcccccaggcctcccgatgcacc 
 A  T  Q  Q  Q  S  Q  P  C  L  Q  R  S  P  Q  A  S  R  C  T  
atccccgacgtgcacctgttctccacggtgccctacatgctaaatgtcactgcagtgcac 
 I  P  D  V  H  L  F  S  T  V  P  Y  M  L  N  V  T  A  V  H  
ccaggcggcgccagcagcagcctcctagcctttgtggctgagcgaatcatcaagccggac 
 P  G  G  A  S  S  S  L  L  A  F  V  A  E  R  I  I  K  P  D  
cctccggaaggcgtgcgcctgcgcacagcgggacagcgcctgcaggtgctctggcatccc 
 P  P  E  G  V  R  L  R  T  A  G  Q  R  L  Q  V  L  W  H  P  
cctgcttcctggcccttcccggacatcttctctctcaagtaccgactccgctaccggcgc 
 P  A  S  W  P  F  P  D  I  F  S  L  K  Y  R  L  R  Y  R  R  
cgaggagcctctcacttccgccaggtgggacccattgaagccacgactttcaccctcagg 
 R  G  A  S  H  F  R  Q  V  G  P  I  E  A  T  T  F  T  L  R  
aactcgaaaccccatgccaagtattgcatccaggtgtcagctcaggacctcacagattat 
 N  S  K  P  H  A  K  Y  C  I  Q  V  S  A  Q  D  L  T  D  Y  
gggaaaccaagtgactggagcctccctgggcaagtagaaagtgcaccccataagcccAAG 
 G  K  P  S  D  W  S  L  P  G  Q  V  E  S  A  P  H  K  P  K  
CTTggtggtggttctggtggtggttctggtggtggttctggtggtggttctGAATTCagg 
 L  G  G  G  S  G  G  G  S  G  G  G  S  G  G  G  S  E  F  R  
gtcattccagtctctggacctgccaggtgtcttagccagtcccgaaacctgctgaagacc 
 V  I  P  V  S  G  P  A  R  C  L  S  Q  S  R  N  L  L  K  T  
acagatgacatggtgaagacggccagagaaaaactgaaacattattcctgcactgctgaa 
 T  D  D  M  V  K  T  A  R  E  K  L  K  H  Y  S  C  T  A  E  
gacatcgatcatgaagacatcacacgggaccaaaccagcacattgaagacctgtttacca 
 D  I  D  H  E  D  I  T  R  D  Q  T  S  T  L  K  T  C  L  P  
ctggaactacacaagaacgagagttgcctggctactagagagacttcttccacaacaaga 
 L  E  L  H  K  N  E  S  C  L  A  T  R  E  T  S  S  T  T  R  
gggagctgcctgcccccacagaagacgtctttgatgatgaccctgtgccttggtagcatc 
 G  S  C  L  P  P  Q  K  T  S  L  M  M  T  L  C  L  G  S  I  
tatgaggacttgaagatgtaccagacagagttccaggccatcaacgcagcacttcagaat 
 Y  E  D  L  K  M  Y  Q  T  E  F  Q  A  I  N  A  A  L  Q  N  
cacaaccatcagcagatcattctagacaagggcatgctggtggccatcgatgagctgatg 
 H  N  H  Q  Q  I  I  L  D  K  G  M  L  V  A  I  D  E  L  M  
cagtctctgaatcataatggcgagactctgcgccagaaacctcctgtgggagaagcagac 
 Q  S  L  N  H  N  G  E  T  L  R  Q  K  P  P  V  G  E  A  D  
ccttacagagtgaaaatgaagctctgcatcctgcttcacgccttcagcacccgcgtcgtg 
 P  Y  R  V  K  M  K  L  C  I  L  L  H  A  F  S  T  R  V  V  
accatcaacagggtgatgggctatctgagctccgcctga 
 T  I  N  R  V  M  G  Y  L  S  S  A STOP 
 
 
Figure 4.1: Nucleotide and amino acid sequences of constructed single chain IL-
35 
Single chain IL-35 was constructed by the fusion of EBI3, linker of 4 x GGGS repeats 
and IL-12p35. Leader sequence of EBI3 is in italics and highlighted, linker sequence 
is underlined and highlighted. Restriction enzymes sites are in captital letters and 
underlined. Single chain IL-35 was cloned into the multiple cloning sites of pVAX-1 

















Figure 4.2: mRNA expression of EBI3, IL-12p35 and single chain IL-35 in the 
lungs 
Mice were given an intratracheal instillation of 400 µg of pVAX-IL-35 and they were 
sacrificed one day later. The lungs of mice were excised and total RNA extracted. RT-





















Figure 4.3: Effects of intratracheal instillation of pVAX-IL-35 on the suppression 
of Blo t 5-specific Th2 induced airway inflammation. 
The C57BL/6 mice were given an intratracheal instillation of 400 µg of either pVAX 
control or pVAX-IL-35 (IL-35) on day 0, followed by intravenous injection of 2 x 106 
Th2 cells on day 1 and intranasal instillation of 50 µg of Blo t 5 protein on days 2, 3, 
4. The mice were sacrificed on day 5 and the BALF was obtained (A) Total cell 
counts (n = 6-7) and (B) differential cell counts for macrophages, lymphocytes, 
neutrophils and eosinophils in the BALF were performed. (C) Soluble mediators in 
the BALF was assessed by Milliplex multi-analyte profiling for cytokines IL-4, IL-5 , 
IL-13 and chemokines CCL2 (MCP-1), CXCL1 (KC), CXCL5 (LIX), CXCL9 (MIG) 
and CXCL10 (IP10).Results are presented as mean ±SEM. Data are the representative 








































































































Figure 4.4: Effect of intramuscular injection of pVAX-IL-35 on humoral 
responses in vivo. 
(A) The schematic diagram shows the protocol of the animal experiment. Mice (n=7) 
were given intramuscular (i.m.) injection of 50 μg of pVAX or pVAX-IL-35 on days 
0 and 14. All mice were given the intravenous (i.v.) transfer of Blo t 5-specific Th2 
cells on days 17 and followed by 2 courses (1st and 2nd) of 3 consecutive days of 
intranasal (i.n.) Blo t 5 challenges at indicated days. The levels of Blo t 5-specific IgE 
(B), IgG1 (C) were assayed by sandwich ELISA. Results are presented as mean 
±SEM. Data are the representative of three separate experiments for results obtained 
within day 37 and two separate experiments for results obtained till day 91.*:p < 0.05. 
 



























































































Figure 4.5:  Total serum immunoglobulin from mice treated with pVAX and 
pVAX-IL-35.  
The experimental protocol was the same as in Figure 4.4a. Sera were collected on 
indicated days and analyzed by sandwich ELISA. Results were presented as mean ± 
SEM (n = 7). Data were the representative of three separate experiments for results 
obtained within day 37 and two separate experiments for results obtained till day 91. *: 
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Figure 4.6: Effect of intramuscular injection of pVAX-IL35 on IL-4 in donor 
Th2 cells 
A) The treatment timeline of mice. Mice (n = 7) were immunized with 50 µg of either 
pVAX empty vector or pVAX-IL35 twice at 2 weeks interval. The mice were then 
sensitized to Blot 5 by intravenous administration of 2 x 106 Blot 5 specific Th2 cells 
three days after the second immunization and then boosted with intranasal instillation 
of 50 µg of Blot 5 protein on 3 consecutive days. 1 week after the intranasal 
instillation, the mice were sacrificed and spleens were excised. B) Intracellular IL-4 
staining of CD4+TCRVβ3+ cells. Splenocytes of pVAX and pVAX-IL-35 treated 
mice were stimulated in vitro with PMA and ionomycin, in the presence of monesin 
for 8 hours. CD4+ cells expressing both TCRVβ3 and IL-4 were analysed by flow 
cytometry. Data was presented as the mean ± SEM of the CD4+TCRVβ3+ cells 
expressing IL-4 (n = 5-7). * statistical significance between pVAX-treated mice and 
pVAX-IL-35 treated mice, p < 0.05 
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1.2 ±  
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0.75 ± 




















Figure 4.7: Effects of intratracheal instillation of pVAX-IL-35 on the suppression 
of airway inflammation in Blo t 5 TCR transgenic mice 
The Blo t 5 TCR transgenic mice were given an intratracheal instillation of 400 µg of 
either pVAX control or pVAX-IL-35 (IL-35) on day 0, and intranasal instillation of 
50 µg of Blo t 5 protein on days 1, 2, 3. The mice were sacrificed on day 4 and the 
BALF was obtained. (A) Total cell count (n = 8-9) and (B) differential cell counts for 
macrophages, lymphocytes, neutrophils and eosinophils in the BALF were performed. 
(C) Soluble mediators in the BALF was assessed by Milliplex multi-analyte profiling 
for cytokines IL-1α, IL-6, IL-17, IFN-у, GCSF, LIF and chemokines CCL3 (MIP-1α), 
CCL4(MIP-1β), CCL5 (RANTES), CXCL1 (KC), CXCL9(MIG) and CXCL10 
(IP10).Results are presented as mean ± SEM. Data are the representative of two 
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One of the most common chronic diseases in the world is asthma with around 300 
million people of all ages and ethnic groups suffering from asthma (Masoli et al., 
2004). The prevalence rate of asthma had been reported to increase with the increased 
urbanization of communities (Masoli et al., 2004). Asthma remains a major problem 
as main therapies to treat asthma currently such as glucocorticoids do not provide a 
long term solution to control asthma. As such, attention had been shifted to find new 
potent therapies for asthma and T regulatory cells as well as cytokines produced by T 
regulatory cells are gaining importance in the field. Cytokine gene immunization 
might be a promising approach. The potent inhibitory effects of IL-35, a cytokine 
produced by T regulatory cells, could be harnassed through the use of DNA vaccines. 
 
Recent studies revealed that IL-35 was a novel cytokine that was constitutively 
expressed in murine CD4+CD25+ Treg cells and contributed to their suppressive 
function (Collison et al., 2007b). Other groups had shown in earlier studies that IL-35 
was an inhibitor of Th17 cell differentiation in vitro and in vivo where IL-17 
production was found to be suppressed with the simultaneous upregulation of IFN-γ 
synthesis in a mouse model of collagen induced arthritis (Niedbala et al., 2007). An 
immunosuppressive role of IL-35 in inflammatory bowel disease murine model also 
had been reported whereby wild type Treg cell recipients recovered from disease, had 
weight gain and decreased histopathology (Niedbala et al., 2007). IL-35 production by 
Treg cells had been found to be enhanced upon contact with conventional T cells, this 
suppression was dependent on IL-35 and IL-10, in addition maximal Treg cell 
suppression abilities was brought about by conventional T cell activation (Collison et 
al., 2009). However there had been no prior studies to determine the effect of IL-35 
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on allergic diseases. Allergic diseases conventionally had been thought to be only Th2 
mediated with the characteristic infiltration of increased numbers of eosinophils, Th2 
lymphocytes, activated mast cells and airway remodeling (Bousquet et al., 2000; 
Pascual and Peters, 2005). However, cellular infiltration profiles of asthma were not 
only characterized by eosinophilia, neutrophilia was also a characteristic feature of 
another subtype of asthma. Studies on neutrophilic asthma had shed light on the 
involvement of IL-17, the hallmark cytokine produced by Th17 cells (Hellings et al., 
2003). Hence in our study, we employed both the eosinophilic and neutrophilic 
murine models of airway inflammation. 
 
Studies on IL-35 had been hampered by the fact that production of recombinant IL-35 
was challenging due to the low expression level and the poor stability of the 
recombinant IL-35 protein. To circumvent problems associated with the production of 
the recombinant IL-35 protein, we adopted both local and systemic plasmid DNA 
encoding IL-35 gene delivery approaches. Administration of pVAX-IL-35 had been 
found to exert immunosuppressive effects on effector Th2 cells when introduced both 
locally and systemically. Th2 cells were reported to express Th2 cytokines such as IL-
5 and IL-13 which could augment the inflammation in allergic asthma (Hamid et al., 
1991; Kay et al., 1991). Administration of IL-35 encoded plasmid intratracheally 
suppressed cellular infiltration into the lungs, in particular eosinophil and lymphocyte 
infiltration. Th2 effector cytokines as well as CC- and CXC- motif chemokines that 
were chemoattractants for polymorphic mononuclear cells and lymphocytes were also 
attenuated in BALF from mice that received pVAX-IL-35. Th2 cytokines, IL-5, IL-4 
and IL-13  and chemokines such as CCL2 (MCP-1), CXCL1 (KC), CXCL5 (LIX), 
CXCL9(MIG) and CXCL10 (IP10) that played a chemoattractant role for neutrophils, 
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monocytes, macrophages and T cells were reduced in the  BALF from mice 
administered with pVAX-IL-35 compared to mice that received pVAX. 
 
IL-5 was the key cytokine that was involved in the recruitment, proliferation, 
differentiation and release of eosinophils from the bone marrow (Broide, 2002; Cho et 
al., 2004; Lopez et al., 1988; Rothenberg, 1998). Other Th2 cytokines like IL-4 and 
IL-13 facilitated the migration of eosinophils by increasing the expression of cell 
adhesion molecules in vascular endothelial cells (Meager, 1999). Another study had 
also demonstrated that IL-5 producing antigen-specific Th2 cells when adoptively 
transferred into unprimed mice can result in eosinophilic inflammation and this was 
IL-5 dependent as anti-IL-5 neutralizing antibody when administered abolished 
eosinophil infiltration (Kaminuma et al., 1997). In a separate study, it was 
demonstrated that the intranasal instillation of Th2 cell supernatant brought about 
eosinophilia and the production of specific chemokines, in addition IL-4 and IL-5 had 
been reported to stimulate higher production of MIP-2 and KC while IL-4 also 
induced higher MCP-1 production (Li et al., 1999). The association between IL-5 and 
eosinophilia had been demonstrated by the above mentioned studies. In our study, 
with the use of IL-35 encoding plasmid, the levels of IL-5, IL-13, IL-4, eosinophils 
and lymphocytes were significantly attenuated, which also implied at the alleviation 
of the inflammation seen in allergic asthma. Intracellular staining experiments also 
suggested that IL-35 suppressed IL-4 production by Th2 cells. Hence IL-35 might 
exert a suppressive effect in vivo by the attenuation of Th2 cytokines produced by the 
transferred Th2 cells, hence resulting in a decrease in the induction of production of 
chemoattractant chemokines, resulting in reduced eosinophilia and cellular infiltration. 
In addition, mice that received the pVAX-IL-35 treatment prior to the transfer of the 
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Blo t 5–specific Th2 memory cell line showed a long-term suppression of allergen-
specific IgE, IgG1 and total serum IgE production, without affecting concentrations of 
other immunoglobulin isotypes in sera. This was the first study to demonstrate that 
DNA vaccine encoding IL-35 could be a potent immunosuppressive vaccine that was 
capable of long term protection against allergic asthma. This could be partly due to 
the long lasting in vivo expression of IL-35 by the intramuscular DNA delivery (Chua 
et al., 2009). That provided the constitutive source of IL-35 and maintained the long 
term protection effect on the Blo t 5-specific IgE and total IgE production 2 months 
later upon the second course of Blo t 5 intranasal challenges. An alternative 
possibility was that the initial IL-35 expression might also expand CD4+CD25+ Treg 
cells or induce a new regulatory population of cells iTR35, that was responsible for 
conferring the long-term protection on the Blo t 5-specific IgE and total IgE 
production (Collison et al., 2010; Kochetkova et al., 2010; Niedbala et al., 2007). 
 
All B cells initially expressed surface IgM, B cells in the germinal center could be 
stimulated to undergo class switch recombination of Ig heavy chains via the cytokine 
stimulation. Class switching from IgM to IgE was mainly regulated by two combined 
signaling from Th2 cells. Cytokines like IL-4 and IL-13 together with CD40 could 
induce IgE isotype switch (de Vries et al., 1993; McKenzie et al., 1999; Poulsen and 
Hummelshoj, 2007). IL-4 also activated class switch recombination to IgG1 in mouse 
and IgG4 in humans (Hellman, 2007; Snapper et al., 1988). Total serum IgE was 
partly controlled by IL-13 as a strong association of single nucleotide polymorphisms 
in the IL-13 gene with the total serum IgE is well recognized in humans (Graves et al., 
2000; Maier et al., 2006). In addition,a functional single nucleotide polymorphism in 
the distal IL-13 promoter among variants linked to total serum IgE had been verified 
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that indicated the association of IL-13 level with the total serum IgE (Kiesler et al., 
2009). Long-lived IgE producing plasma cells were not easily exterminated by 
therapeutics as they did not undergo cell division and were often located in localized 
areas like the bone marrow (Shapiro-Shelef and Calame, 2005). IgE though present in 
much lower levels than IgG, played a vital role in the induction of inflammation as it 
was able to bind to and cross-link high affinity receptors on mast cells and basophils. 
Immense efforts had been spent on clinical studies on antibodies against the receptor-
binding region of human IgE (Nowak, 2006). However, this might not be the optimal 
solution due to its high cost as huge quantities of recombinant protein had to be 
administered to the patients (Buhl, 2005). Thus DNA vaccines encoding IL-35 might 
be a promising therapeutic tool as it had been shown to attenuate allergen specific and 
total IgE. The suppressive effects of IL-35 on Blo t 5-specific IgE and total serum IgE 
could be through the inhibition of Blo t 5-specific Th2 effector cytokines IL-4 and IL-
13 by IL-35 as these cytokine levels in the BALF were also reduced in pVAX-IL-35 
treated mice. 
 
Besides suppressing Th2 mediated eosinophilia, IL-35 also had a suppressive effect 
on neutrophilia. There was significant reduction in Blo t 5 challenges induced 
neutrophils as well as lymphocytes in the airway of Blo t 5 specific TCR transgenic 
mice. In addition, neutrophil chemoattractant and activation chemokines, IL-17, IFN-
γ as well as proinflammatory cytokines in the BALF were also significantly 
attenuated in the pVAX-IL-35 treated group. Allergen inhalation had been reported to 
increase IL-17 expression in airways of murine models (Hellings et al., 2003). The 
involvement of IL-17 in the bronchial neutrophilic influx had been confirmed via the 
use of anti-IL17 monoclonal antibody before allergen inhalation that attenuated 
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neutrophilia (Hellings et al., 2003). Neutrophil count had been reported to have a 
positive correlation with IL-17 mRNA expression in sputum of asthmatic patients 
(Bullens et al., 2006). In addition, severe asthmatics had also been found to have 
increased neutrophils in their airways (Jatakanon et al., 1999). Besides targeting at 
cytokine genes, IL-17 target genes also included neutrophil attracting chemokines as 
well as CC chemokines such as CCL2/MCP-1 (Dragon et al., 2007; Hata et al., 2002; 
Henness et al., 2004; Jones and Chan, 2002; Khader et al., 2007; Ruddy et al., 2004; 
Shen and Gaffen, 2008; Takaya et al., 2002; Witowski et al., 2000). All this evidence 
hinted that IL-17 played a major role in the recruitment and activation of neutrophils 
during an inflammatory response via the induction of chemokines and cytokines. In a 
recent study, inducible costimulator positive positive Treg cells produced IL-35 and 
this resulted in the suppression of IL-17 as well as the reversal of established IL-17 
dependent AHR in murine models (Whitehead et al., 2011).The suppressive effect of 
IL-35 on neutrophilia could be through the inhibition of IL-17. 
 
Another study had reported that the adoptive cell transfer of a TH17 polarized 
population into mice could convert to IFN-γ producers that can produce either both 
IFN-γ and IL-17 or IFN-γ only in the lung (Ashino et al.). This IFN-γ was found to be 
vital for the induction of airway hyperresponsiveness (Ashino et al.). IFN-γ could also 
enhance Th2 mediated immune responses (Bocek et al., 2004). In our study, we too 
had seen IFN-γ and IL-17 in the BALF of the mice that had neutrophilic inflammation 
in the lungs, importantly, IL-35 treated mice showed reduction in both IFN-γ and IL-
17 in the BALF compared to controls. This suggested that both cytokines IFN-γ and 
IL-17, responsible for neutrophilia and airway hyperesponsiveness had been 
suppressed by IL-35. Hence reduction of IL-17 thus seemed to be a promising 
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strategy to alleviate neutrophilic asthma compared to anti-inflammatory agents that 
may have non-specific mode of action. However, it had also been pointed out that the 
use of anti-IL-17 monoclonal antibody increased circulating IL-5 as well as IL-5 
levels in the BALF in anti-IL-17 antibody treated mice compared with controls 
(Hellings et al., 2003). In addition, anti-IL17 monoclonal antibody also elevated 
eosinophilia (Hellings et al., 2003). Thus anti-IL-17 antibodies might not be the best 
therapeutic tool. IL-35 may prove to be a better candidate given its robust suppressive 
effect on eosinophilia and neutrophilia, besides eosinophilia was not significantly 
upregulated with the use of DNA vaccine encoding IL-35. 
 
Besides the secretion of IL-35, T regulatory cells also secreted IL-10 and TGF-β. The 
pleiotropic cytokine, TGF-β, was mainly secreted by eosinophils while other cells 
such as mast cells, lymphocytes, macrophages, fibroblasts and epithelial cells also 
produced TGF-β (Leivonen et al., 2005; Samarakoon et al., 2005; Xu et al., 2003). 
Although TGF-β had been reported to suppress allergen-induced inflammation when 
delivered intratracheally (Joetham et al., 2007), it had also been demonstrated to be 
involved in the stimulation of mucus hypersecretion, globet cell proliferation as well 
as tissue remodeling (Makinde et al., 2007; McMillan et al., 2005). Airway 
remodeling, peribronchiolar extracellular matrix deposition, proliferation of airway 
smooth muscle cell and mucus production in the lung was attenuated upon 
neutralizing anti-TGF-β antibody administration to mice with established airway 
inflammation in a treatment model (McMillan et al., 2005). Another study reported 
that intratracheal instillation of recombinant TGF-β protein in mice brought about an 
increase in collagen deposition in the airways as well as increased mRNA expression 
of collagen I and III (Kenyon et al., 2003). In addition, in asthmatic patients, serum 
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TGF-β was significantly elevated compared to control patients (Manuyakorn et al., 
2008). In bronchoalveolar lavage fluid of asthmatic patients, TGF-β1 was also 
elevated and further increased when exposed to allergen (Redington et al., 1997). Due 
to the detrimental effects of TGF-β in asthma, TGF-β, though also a cytokine 
produced by T regulatory cells, was not considered as a candidate for DNA vaccine in 
our study. Mortality was significantly increased in mice with overexpression of IL-10 
in the lung when they were challenged intratracheally with P.aeruginosa bacteria 
compared to control mice (Sun et al., 2009a). Bacterial clearance was also hindered in 
mice that had overexpression of IL-10 in the lungs (Sun et al., 2009a). As such, IL-10 
was also not an ideal candidate for DNA vaccine. Hence with the possible detrimental 
effects of TGF-β and IL-10, they were not considered as therapeutic tools in our study 
although they were also produced by Treg cells. 
 
Initially, there had been some controversy to the presence of IL-35 in humans. In 
contrast to murine models, it had been demonstrated that human CD4+CD25+Foxp3+ 
T reg did not show a constitutive expression of IL-35, in addition neither EBI3 nor 
p35 mRNA was upregulated upon the induction of Foxp3 (Bardel et al., 2008). 
However recently, IL-35 was found to be expressed and needed by human T 
regulatory cells to exert the maximal suppressive effect (Chaturvedi et al., 2011).  In 
addition, IL-35 from human T regulatory cells also converted suppressed human T 
conventional cells into new regulatory population of cells iTR35 that also exerted 
suppressive effect via IL-35 (Chaturvedi et al., 2011). In another study, it had been 
demonstrated that human rhinovirus activated dendritic cell (R-DC) could induce 
CD4+ and CD8+ peripheral blood T cells to produce and release IL-35 through the 
inhibitory signals delivered from R-DC to T cells via B7-H1 and sialoadhesin. This 
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showed that human IL-35 producing T reg could be induced (Seyerl et al.). IL-35 had 
also been detected in the CD4+ T cells obtained from peripheral blood of chronic 
Hepatitis B patients but not from healthy subjects (Liu et al., 2011). All this suggested 
the presence of immunosuppressive effect of IL-35 in human immune system, hence 
the IL-35 gene delivery might be feasible for application in humans. 
 
IL-35 fusion protein was relatively unstable and may be technically difficult to 
produce and store. With the use of IL-35 encoding DNA vaccines, this problem is 
circumvented as DNA vaccines make use of the host machinery to produce the 
recombinant protein. In addition, the relative ease of production of DNA vaccines, 
low cost, stability and safety as well as no requirement for cold chain were more 
advantages of DNA vaccines. In conclusion, in this study we showed that IL-35 was a 
very promising therapeutic tool against effector T cells mediated airway inflammation 
as it exerted a potent suppressive effect on cellular infiltrates and 
cytokines/chemokines in the BALF, allergen specific IgE and IgG1 production as well 
as total IgE production. 
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Chapter 5 Conclusion and Perspectives 
5.1 Conclusions 
The first part of the study demonstrated an allergy model whereby intraperitoneal 
immunization of mice with rBlo t 5 protein adjuvanted with alum elicited a mixed T 
helper phenotype consisting of Th1, Th2 and Th17 immune responses. This mixed 
Th1, Th2 and Th17 immune responses could be suppressed by allergen gene 
vaccination. pVAXBlot5-DTKT immunized mice showed a trend of greater 
suppression in Blo t 5 specific IL-5, IL-6, IL-13 and IL-17 when compared to 
pVAXBlot5 immunized mice. In addition to the enhanced suppressive effect on T 
helper cytokine production, pVAXBlot5-DTKT immunized mice also elicited 
stronger humoral responses as evident from the higher levels of Blo t 5 specific IgG1 
and IgG2c when compared to pVAXBlot5 immunized mice. Mice immunized with 
Blo t 5 constructs effectively suppressed Blo t 5 specific IgE production induced by 
intraperitoneal immunization with rBlo t 5 protein adjuvanted with alum. CpG 
modified plasmid DNA immunized mice showed a greater suppression of Blo t 5 
specific T effector cytokines as well as enhanced Blo t 5 specific IgG2c production as 
compared to unmodified plasmid DNA immunized group. 
 
In vitro studies carried out using dendritic cells derived from bone marrow with either 
GMCSF or Flt3L demonstrated the differences of cytokine and chemokine profiles in 
response to pVAXBlot5 or pVAXBlot5-DTKT stimulation. Flt3L-DCs were found to 
be more responsive to pVAXBlot5-DTKT stimulation as it produced higher levels of 
G-CSF, IL-1α, KC, MCP-5, VCAM-1, VEGF, MCP-1, PF-4, TCA-3 while GMCSF-
DCs produced elevated levels of MIP-1α . In addition, subsets of Flt3L-DCs also 
responded differently to plasmid DNA stimulation. CD11c+CD11b+B220- DCs 
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produced elevated amounts of IL-6, IL-12p40 and IP-10 when compared to 
CD11c+CD11b-B220+ DCs in response to pVAXBlot5-DTKT stimulation. Both 
pVAXBlot5 as well as pVAXBlot5-DTKT elicited similar levels of cytokine 
production and upregulation of surface markers on dendritic cells. TLR9 was involved 
in the activation of dendritic cells by plasmid DNA as inhibition of TLR9 sharply 
attenuated the production of cytokines and chemokines. 
 
pVAXBlot5-DTKT elicited significantly higher production of IL-6, MIP-1α and MIP-
1β from human peripheral blood mononuclear cells than pVAXBlot5. This enhanced 
immunogenic effect of pVAXBlot5-DTKT was not observed in mouse cells. The 
protein array was used to explore the differences between pVAXBlot5-DTKT and 
pVAXBlot5 stimulated human peripheral blood mononuclear cells and a dynamic 
change in the upregulation profile of cytokines and chemokines at early (5 hours) and 
later (24 hours) timepoints was observed. At an early timepoint of 5 hours, 
pVAXhBlot5-DTKT induced significant upregulation of PDGF-AA, GRO-α, NT-4, 
IL-1β, osteoprotegerin, VEGF-D, GMCSF, MCP-1 and ENA-78 and downregulation 
of ErbB3, IP-10, angiogenin, IGFBP-2 and MCP-2 compared to pVAXhBlot5. At a 
later timepoint of 24 hours, pVAXhBlot5-DTKT induced significant upregulation of 
angiogenin, Flt3 ligand, I-309, IL-10, MCP-1, MCP-4, MIP-3α, PARC, TARC and 
TECK with downregulation of IL-12p40 as compared to pVAXhBlot5. In vivo 
analysis was carried out by the immunization of non-human primates with pVAX-1, 
pVAXhBlot5 and pVAXhBlot5-DTKT. These monkeys were subsequently received 
subcutaneous immunizations with rBlo t 5 protein adjuvanted with alum. 
Immunogenicity of allergen gene constructs was demonstrated by faster kinetics and 
levels of Blo t 5 specific IgG productions. In pVAXhBlot5-DTKT immunized group, 
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there was a trend of higher production of Blo t 5 specific total IgG and IgG1 as 
compared to pVAXhBlot5 group. Allergen gene immunized groups showed 
attenuation of Blo t 5 specific IgE as compared to pVAX-1 immunized group. 
Notably, pVAXhBlot5-DTKT immunized group yielded the highest number of IFN-γ 
producing cells and lowest number of IL-4 producing cells in response to stimulation 
with three Blo t 5 peptide pools. 
 
The second part of the study demonstrated the use of the immunoregulatory cytokine, 
IL-35, in the suppression of two airway inflammation models. The allergic airway 
inflammation model was induced by adoptive transfer of Blo t 5 specific Th2 cells 
followed with Blo t 5 challenges and the neutrophilic airway inflammation model was 
induced by intranasal instillations of Blo t 5 in Blo t 5 specific TCR transgenic mice. 
In the allergic airway inflammatory model, intratracheal administration of pVAX-IL-
35 significantly reduced total cellular infiltration, eosinophils, lymphocytes and 
neutrophils numbers in the BALF. In addition, CCL2/MCP-1, CXCL1/KC, 
CXCL5/LIX, CXCL9/MIG and CXCL10/IP-10 concentrations in the BALF were also 
attenuated in mice of the experimental pVAX-IL-35. Intramuscular immunization of 
mice with plasmid DNA encoding IL-35 prior to the transfer of Blo t 5-specific Th2 
cells provided both short term as well as long term suppression of Blo t 5 specific IgE 
production after intranasal Blo t 5 instillation. In addition to the suppression in Blo t 5 
specific IgE, IL-35 also exerted a long lasting suppressive effect on the production of 
total serum IgE and IL-35 did not exert a pan immunosuppressive effect on antibody 
production. A possible mechanism behind the suppressive effect of IL-35 might be 
the via suppressive effect on the Th2 cytokine production of donor Th2 cells as 
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pVAX-IL-35 treated mice was found to have reduced IL-4 expressing CD4+TCRVβ3+ 
cells. 
 
In the neutrophilic airway inflammatory model, intratracheal delivery of pVAX-IL35 
could also attenuate neutrophilia in Blo t 5 specific TCR transgenic mice. Total 
cellular infiltration and lymphocytes were also significantly reduced in pVAX-IL35 
treated mice. Proinflammatory cytokines and chemokines such as IL-1α, IL-6, IL-17, 
IFN-γ, G-CSF, LIF, CCL3(MIP-1α), CCL4(MIP-1β), CCL5(RANTES), CXCL1(KC), 
CXCL-9(MIG) and CXCL-10(IP-10) also showed a significant reduction in the BALF 
of pVAX-IL35 treated mice. pVAX-IL-35 treatment could suppress neutrophil 
chemoattractant and activation chemokines as well as proinflammatory cytokines and 
hence reduce neutrophilia. 
 
In summary, the results from the first part of the study had shed light on the probable 
regulatory effects of allergen gene vaccination. Allergen gene vaccinated groups 
produced higher levels of IFN-γ and IL-10, this may suggest the possible induction of 
T regulatory cells, TH1 TR cells, by allergen gene vaccination with the subsequent 
suppressive effect on the mixed T cell responses induced by intraperitoneal 
immunization with Blo t 5 protein adjuvanted with alum. In addition, CpG motif 
modified plasmid DNA was also found to have enhanced efficacy on human cells and 
in non-human primates. This will contribute valuable information to help in the 
development of more potent vaccines in prevention of allergic asthma. The use of IL-
35 as a cytokine gene in DNA vaccines had revealed the potent suppressive effect of 
IL-35 on eosinophilia as well as on neutrophilia. Hence IL-35 had great potential in 
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the control of airway inflammation and this may be useful in the development of 




5.2 Future Studies and Perspectives  
 
Future Studies: 
There are several aspects in this study that require further investigation.This study had 
shown that immunization with pVAXBlot5-DTKT resulted in a suppressive effect on 
the mixed Th1, Th2 and Th17 immune responses elicited by intraperitoneal 
immunization with rBlo t 5 protein adjuvanted with alum. To evaluate if the proposed 
mediators such as IFN-γ, IL-10 or GMCSF are involved, depletion studies using 
neutralizing antibodies can be carried out. An alternative way for evaluation of the 
possible mediators is to use knock out mice. This will enable us to evaluate the 
mechanism behind the mode of action of DNA vaccines. 
 
Protein array studies on plasmid DNA stimulated human peripheral mononuclear cells 
had revealed that pVAXBlot5-DTKT stimulated human PBMC had higher production 
of cytokines and chemokines as compared to pVAXBlot5 stimulation. These 
mediators may shed light on possible mechanisms or signalling cascades due to the 
effect of additional CpG motifs. 
 
pVAX-IL-35 had been demonstrated to play a suppressive role in this study, however 
it has yet to be evaluated if IL-35 could also control established airway inflammation. 
Hence to evaluate if pVAX-IL-35 could suppress established airway inflammation, 
mice could be first induced to develop airway inflammation via the transfer of Blo t 5 
specific Th2 cells and intranasal Blo t 5 challenges before the subsequent delivery of 
pVAX-IL-35. This will contribute knowledge to the efficacy of IL-35 as a therapeutic 




The suppressive effect of IL-35 had been shown to be mediated by IL-35 induced 
Treg cells, IL-35 producing inducible costimulator positive Treg cells or IL-10 
producing CD39+CD4+ T cells. However it has yet to be evaluated if IL-35 can 
directly exert the suppressive effect on effector T cells like Th2 cells and that deserves 




1) As CpG modified plasmid DNA showed enhanced immunogenicity on human 
cells and in non-human primates, this suggests that backbone modification is 
still a useful approach to improve the immunogenicity of DNA vaccines. 
 
2) Inhibition of TLR9 attenuated the cytokines and chemokines production from 
plasmid DNA stimulated dendritic cells hence it implied that TLR9 though 
non essential but it is still involved, hence strategies to target at TLR9 is still 
useful. 
 
3) DNA vaccines are a promising tool against allergic diseases as they have been 
shown to suppress a mixed T helper phenotype response. 
 
4) IL-35 had been shown to elicit suppressive effect in neutrophilic and 
eosinophilic airway inflammation murine models, hence the potent 
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